Unnamed: 0,NCT Number,DrugBank ID,SMILES,Title,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
0,NCT02179671,DB11689,CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",Completed,Has Results,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Drug: Gefitinib|Drug: AZD9291|Drug: Selumetinib+Docetaxel|Drug: Tremelimumab,Confirmed Complete Response (CR) Rate|Objective Response Rate (ORR)|Progression-free Survival|Duration of Response|Overall Survival,"AstraZeneca|Quintiles, Inc.",All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,32.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4191C00011,"July 25, 2014","June 11, 2016","June 11, 2016","July 2, 2014","August 2, 2019","August 2, 2019","Research Site, Goodyear, Arizona, United States|Research Site, Washington, District of Columbia, United States|Research Site, Augusta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Ashland, Kentucky, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT02179671
1,NCT02179671,DB00317,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",Completed,Has Results,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Drug: Gefitinib|Drug: AZD9291|Drug: Selumetinib+Docetaxel|Drug: Tremelimumab,Confirmed Complete Response (CR) Rate|Objective Response Rate (ORR)|Progression-free Survival|Duration of Response|Overall Survival,"AstraZeneca|Quintiles, Inc.",All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,32.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4191C00011,"July 25, 2014","June 11, 2016","June 11, 2016","July 2, 2014","August 2, 2019","August 2, 2019","Research Site, Goodyear, Arizona, United States|Research Site, Washington, District of Columbia, United States|Research Site, Augusta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Ashland, Kentucky, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT02179671
2,NCT02179671,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",Completed,Has Results,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Drug: Gefitinib|Drug: AZD9291|Drug: Selumetinib+Docetaxel|Drug: Tremelimumab,Confirmed Complete Response (CR) Rate|Objective Response Rate (ORR)|Progression-free Survival|Duration of Response|Overall Survival,"AstraZeneca|Quintiles, Inc.",All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,32.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D4191C00011,"July 25, 2014","June 11, 2016","June 11, 2016","July 2, 2014","August 2, 2019","August 2, 2019","Research Site, Goodyear, Arizona, United States|Research Site, Washington, District of Columbia, United States|Research Site, Augusta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Ashland, Kentucky, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT02179671
3,NCT02259114,DB15189,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NC1=CC=C(O)C=C1)N=C2C1=CC=C(Cl)C=C1,"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)",Completed,Has Results,NUT Midline Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation|Castrate-resistant Prostate Cancer|CRPC|Pancreatic Ductal Adenocarcinoma,Drug: Birabresib,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an AE|Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria|Observed Maximum Plasma Concentration (Cmax) of MK-8628|Time to Cmax (Tmax) of MK-8628|Area Under to Concentration-Time Curve From 0 to Infinity (AUC0-∞) of MK-8628|Volume of Distribution at Steady State (Vdss) of MK-8628|Terminal Half-Life (t1/2) of MK-8628|Total Plasma Clearance (CL) of MK-8628,Oncoethix GmbH,All,"18 Years and older   (Adult, Older Adult)",Phase 1,47.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8628-003|OTX015_108|2014-002680-15|MK-8628-003,"October 23, 2014","March 3, 2017","March 3, 2017","October 8, 2014","October 1, 2018","January 26, 2021",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02259114/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02259114/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02259114
4,NCT02395601,DB14581,COC1=C(CNC(=O)C2=C(C)N([C@H](C)C3CCN(CC(F)(F)F)CC3)C3=CC=CC=C23)C(=O)NC(C)=C1,A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,Completed,No Results Available,B-Cell Lymphoma,Drug: CPI-1205,"Frequency of Dose-limiting toxicities (DLTs)|Frequency of adverse events|Pharmacokinetic parameters of CPI-1205: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by EZH2 inhibition|Pharmacodynamic effects of CPI-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (H3K27me3)|Disease response assessment will be performed using the 2014 Lugano Response Criteria for Hodgkin and Non-Hodgkin Lymphoma",Constellation Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1205-01,March 2015,December 2018,December 2018,"March 23, 2015",,"September 6, 2019","Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02395601
5,NCT03157310,DB00317,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Bone Metastasis on the Survival of Gefitinib Effective Patients,Completed,No Results Available,"Overal Survival, Non-small Cell Lung Cancer",Drug: Gefitinib,Overal survival of patients|Survival of patients with both bone metastasis and brain metastasis,Qilu Hospital of Shandong University,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,265.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-QLH-11,"May 1, 2009","May 1, 2013","July 12, 2015","May 17, 2017",,"May 17, 2017",,,https://ClinicalTrials.gov/show/NCT03157310
6,NCT03722576,DB15446,COC1=CC(=CC=C1)C1=CC=C(NC(=O)C2=C(CCC2)C(O)=O)C(F)=C1,Vidofludimus Calcium for Primary Sclerosing Cholangitis,Completed,Has Results,Primary Sclerosing Cholangitis,Drug: Vidofludimus calcium,Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels.|Abnormal Aspartate Aminotransferase (AST)|Abnormal Alanine Aminotransferase (ALT)|Abnormal Total Bilirubin|Abnormal Direct Bilirubin,Elizabeth Carey|Arizona State University|Mayo Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,18.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND140679,"June 17, 2019","June 30, 2020","June 30, 2020","October 29, 2018","June 2, 2021","June 2, 2021","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Arizona State University, Tempe, Arizona, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03722576/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03722576
7,NCT01533181,DB16619,[Mg++].Cl.N[C@@H](CC([O-])=O)C([O-])=O,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
8,NCT01533181,DB01030,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
9,NCT01533181,DB06075,C[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
10,NCT01533181,DB06261,[H]N([H])CC(=O)CCC(=O)OCCCCCC,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
11,NCT01533181,DB06016,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
12,NCT01533181,DB09069,COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
13,NCT01533181,DB00387,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1,Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride,Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS),National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292,February 2012,November 2014,November 2014,"February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01533181
14,NCT01605526,DB00997,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
15,NCT01605526,DB11616,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
16,NCT01605526,DB12755,[H]OC[C@H](NC(=O)[C@H](CC1=CN([H])C2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O[H])C=C1)C(=O)N[C@H](CCCCNC(=O)CCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@@]2([H])C[C@H](N)[C@H](O)[C@H](C)O2)C2=C(O)C3=C(C(O)=C2C1)C(=O)C1=CC=CC(OC)=C1C3=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
17,NCT01605526,DB06013,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
18,NCT01605526,DB06420,C[C@@H]1O[C@@H](O[C@H]2C[C@@](O)(CC3=C2C(O)=C2C(=O)C4=CC=CC=C4C(=O)C2=C3O)C(=O)CO)[C@H](I)[C@H](O)[C@H]1O,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
19,NCT01605526,DB05706,COC1=C2C(=O)C3=C(O)C4=C(C[C@@](O)(CCO)C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(O)=C3C(=O)C2=CC=C1,A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Drug: RO5045337|Drug: doxorubicin,Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28021|2011-006279-21,May 2012,June 2013,June 2013,"May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,https://ClinicalTrials.gov/show/NCT01605526
20,NCT02419417,DB15435,CN1N=NC(C)=C1C1=CC2=C(N=C1)C1=C(C=C(C=C1)C(C)(C)O)N2[C@@H](C1CCOCC1)C1=CC=CC=C1,Study of BMS-986158 in Subjects With Select Advanced Cancers,Completed,No Results Available,Advanced Tumors,Drug: BMS-986158|Biological: Nivolumab,"Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs leading to discontinuation|Number of laboratory test toxicity grade shifting from baseline|Best Overall Response|Objective Response Rate (ORR)|Duration of Response|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))|Area under the concentration-time curve in one dosing interval (AUC(TAU))|Apparent terminal phase half-life (T-HALF)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Apparent total body clearance, reported only for parent, not for metabolite (CLT/F)|Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F)|Minimum observed concentration within a dosing interval (Cmin)|Concentration at the end of a dosing interval (Ctau)|Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough)|Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg])|[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing)|Accumulation Index (AI)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))|Electrocardiogram (ECG) QT (time of ventricular activity including both depolarization and repolarization) Interval",Bristol-Myers Squibb,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,83.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA011-001|2015-000324-29,"June 19, 2015","March 17, 2021","March 17, 2021","April 17, 2015",,"February 24, 2022","City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Oregon Health & Science University, Portland, Oregon, United States|Univ. Of Pa, Philadelphia, Pennsylvania, United States|Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States|Nucleus Network, Melbourne, Victoria, Australia|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Villejuif, France|H. Univ. Vall dHebron, Barcelona, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT02419417
21,NCT02777710,DB12978,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers,Completed,No Results Available,Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer,Drug: Pexidartinib|Drug: Durvalumab,part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT)|part 2 (extension part) : objective response rate (ORR)|The duration of response (DoR)|Progression-Free Survival (PFS)|Adverse events reporting|Area under the Pexidartinib plasma concentration (AUC) versus time curve|Peak Pexidartinib plasma concentration (Cmax),Centre Leon Berard|AstraZeneca|Plexxikon,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ET15-037 (MEDIPLEX)|2015-002438-31,June 2016,November 2019,December 2019,"May 19, 2016",,"September 5, 2021","Centre Léon Bérard, Lyon, France|IUCT-oncopole, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02777710
22,NCT00939770,DB08865,C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,Completed,Has Results,Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma,Drug: Crizotinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Questionnaire Administration,Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib|Number of Participants With Toxicities of Crizotinib|Steady State C Max of Crizotinib|Steady State C Average of Crizotinib|Steady State AUC of Crizotinib|Steady State Clearance of Crizotinib|Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib|Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib|Number of Participants With Minimum Residual Disease (MRD),Children's Oncology Group|National Cancer Institute (NCI)|Pfizer,All,"1 Year to 21 Years   (Child, Adult)",Phase 1|Phase 2,122.0,Other|NIH|Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADVL0912|NCI-2011-01937|P10666|COG-ADVL0912|CDR0000647587|UM1CA097452,"September 21, 2009","December 31, 2018","December 31, 2018","July 15, 2009","May 5, 2020","June 9, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT00939770/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00939770
23,NCT02806817,DB13062,CC1=C(O)C=CC2=C1OC[C@H]([C@H]2C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism,Completed,No Results Available,Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Early-Stage Breast Carcinoma,Drug: ME-344|Drug: Bevacizumab|Other: Normal saline,Reduction of FDG uptake|SDH (succinate dehydrogenase) levels staining|Toxicity profile: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Ki67 changes|Cleaved caspase-3 changes,Centro Nacional de Investigaciones Oncologicas CARLOS III|Fundacion CRIS de Investigación para Vencer el Cáncer,Female,"18 Years and older   (Adult, Older Adult)",Early Phase 1,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CNIO-BR-009|2015-005457-12,July 2016,October 2018,November 2018,"June 21, 2016",,"July 23, 2019","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|H. Arnau de Vilanova Lleida, Lleida, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Quirón, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT02806817
24,NCT03626415,DB14973,CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1,A Hepatic Impairment Study for PF-04965842.,Completed,Has Results,Hepatic Impairment,Drug: PF-04965842,Maximum Observed Plasma Concentration (Cmax) for PF-04965842|Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842|Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)|Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842|Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,24.0,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7451020,"October 1, 2018","April 30, 2019","April 30, 2019","August 13, 2018","May 18, 2020","May 18, 2020","Orlando Clinical Research Center, Orlando, Florida, United States|Prism Clinical Research, LLC, Saint Paul, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03626415/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03626415/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03626415
25,NCT02424617,DB12411,NC1=NC(NC2=CC=C3CC[C@@H](CCC3=C2)N2CCCC2)=NN1C1=CC2=C(N=N1)C1=CC=CC=C1CCC2,A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: erlotinib|Drug: bemcentinib,"Number of Participants with Treatment-emergent Adverse Events (TEAE)|Number of Participants with Clinically Significant Clinical Laboratory, Physical examination, Vital Signs, Echocardiogram or Multi-gated Acquisition (MUGA) Scan and Electrocardiogram (ECG) Abnormalities|Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status|Pharmacokinetics Parameter: Area Under The Curve Within A Dosing Interval (AUC0-t) of Bemcentinib|Pharmacokinetics Parameter: Maximum Observed Plasma Concentration (Cmax) of Bemcentinib|Pharmacokinetics Parameter: Time to Reach Maximum Plasma Concentration (Tmax) of Bemcentinib|Pharmacodynamic Parameter: Changes in the Phosphorylation Status of Signaling Proteins|Pharmacodynamic Parameter: Change from Baseline in Circulating Markers Levels|Pharmacodynamic Parameter: Changes in Gene Expression of Tumor Tissue or Circulating Nucleic Acids|Pharmacodynamic Parameter: Spectrum of Mutations (Including EGFR Mutations) Within Cancer Cell Population or In Circulating Nucleic Acids|Pharmacodynamic Parameter: Number of Participants with Epithelial-Mesenchymal Transition Gene Signature|Time To Progression",BerGenBio ASA,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGBC004,March 2015,"August 25, 2021","August 25, 2021","April 23, 2015",,"October 18, 2021","Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moores UC San Diego Cancer Center, San Diego, California, United States|Moffit Cancer Centre, Tampa, Florida, United States|Horizon Oncology,1345 Unity Place, Lafayette, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Tennessee Oncology, Nashville, Tennessee, United States|Mary Crowley Cancer Research Unit, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02424617
26,NCT02424617,DB00530,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: erlotinib|Drug: bemcentinib,"Number of Participants with Treatment-emergent Adverse Events (TEAE)|Number of Participants with Clinically Significant Clinical Laboratory, Physical examination, Vital Signs, Echocardiogram or Multi-gated Acquisition (MUGA) Scan and Electrocardiogram (ECG) Abnormalities|Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status|Pharmacokinetics Parameter: Area Under The Curve Within A Dosing Interval (AUC0-t) of Bemcentinib|Pharmacokinetics Parameter: Maximum Observed Plasma Concentration (Cmax) of Bemcentinib|Pharmacokinetics Parameter: Time to Reach Maximum Plasma Concentration (Tmax) of Bemcentinib|Pharmacodynamic Parameter: Changes in the Phosphorylation Status of Signaling Proteins|Pharmacodynamic Parameter: Change from Baseline in Circulating Markers Levels|Pharmacodynamic Parameter: Changes in Gene Expression of Tumor Tissue or Circulating Nucleic Acids|Pharmacodynamic Parameter: Spectrum of Mutations (Including EGFR Mutations) Within Cancer Cell Population or In Circulating Nucleic Acids|Pharmacodynamic Parameter: Number of Participants with Epithelial-Mesenchymal Transition Gene Signature|Time To Progression",BerGenBio ASA,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGBC004,March 2015,"August 25, 2021","August 25, 2021","April 23, 2015",,"October 18, 2021","Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moores UC San Diego Cancer Center, San Diego, California, United States|Moffit Cancer Centre, Tampa, Florida, United States|Horizon Oncology,1345 Unity Place, Lafayette, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Tennessee Oncology, Nashville, Tennessee, United States|Mary Crowley Cancer Research Unit, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02424617
27,NCT01561456,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung,Completed,No Results Available,Non-small-cell Lung Cancer|Squamous Cell Carcinoma|Adenocarcinoma of the Lung,Drug: AXL1717|Drug: Docetaxel,"Rate of progression-free survival (PFS)|Rate of complete response (CR), partial response (PR), stable disease, (SD), progressive disease (PD), disease control (CR + PR + SD), and objective response (CR + PR)|Median time to disease progression (TTP), time to objective response and time to treatment failure (TTF)|Median duration of progression-free-survival (PFS), objective response and disease control|12-week survival|1 year survival|Investigational product toxicity profile|Overall survival",Axelar AB,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AXL-003|2011-002007-15,December 2011,December 2013,December 2013,"March 23, 2012",,"December 5, 2013","State Medical Institution: Republic Scientific Oncology Center, Poselok, Minsk Region, Belarus|Gomel Regional Clinical Oncology Center, Gomel, Belarus|Minsk City Clinical Oncology Center, Minsk, Belarus|Vitebsk Regional Clinical Oncology Center, Vitebsk, Belarus|Semmelweis University; Clinic for Pulmonology, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Clinic of Pulmonology, Debrecen, Hungary|Kenezy Gyula County Hospital, Debrecen, Hungary|Hospital for Thoracic Diseases of Csongrad County Local Government, Deszk, Hungary|Wladyslaw Bieganski Regional Specialist Hospital, Grudziadz, Poland|Maria Sklodowska-Curie Institute of Oncology in Warsaw, Warsaw, Poland|State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Orel Oncology Center, Orel, Russian Federation|State Higher Educational Institution St. Petersburg State Medical University n. a. after I. P. Pavlov under Federal Agency for Healthcare and Social Development, Research Institute of Pulmonology, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution Municipal Clinical Oncology Center, St. Petersburg, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dniepropetrovsk, Ukraine|Public Clinical Treatment and Prophylaxis Institution: Donetsk Regional Antitumor Center, Donetsk, Ukraine|Kharkiv, State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Kharkiv, Ukraine|Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kyiv City Oncology Hospital, Kyiv, Ukraine|Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine|Zakarpattia Regional Clinical Oncology Center, Uzhhorod, Ukraine",,https://ClinicalTrials.gov/show/NCT01561456
28,NCT02935894,DB01050,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,"Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat",Completed,Has Results,Stability & Variability of Lipid-derived Molecules in Sweat,Drug: Ibuprofen|Other: Physiological induction of sweating|Drug: Pilocarpine,Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise|Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Plasma Ibuprofen Concentrations|Change in Sweat Ibuprofen Concentrations,"USDA, Western Human Nutrition Research Center|University of California, Davis",Male,20 Years to 40 Years   (Adult),Not Applicable,14.0,U.S. Fed|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,929370,"November 28, 2016","June 8, 2017","June 8, 2017","October 18, 2016","June 1, 2018","June 1, 2018","Western Human Nutrition Research Center, Davis, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02935894
29,NCT02935894,DB09213,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,"Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat",Completed,Has Results,Stability & Variability of Lipid-derived Molecules in Sweat,Drug: Ibuprofen|Other: Physiological induction of sweating|Drug: Pilocarpine,Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise|Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Plasma Ibuprofen Concentrations|Change in Sweat Ibuprofen Concentrations,"USDA, Western Human Nutrition Research Center|University of California, Davis",Male,20 Years to 40 Years   (Adult),Not Applicable,14.0,U.S. Fed|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,929370,"November 28, 2016","June 8, 2017","June 8, 2017","October 18, 2016","June 1, 2018","June 1, 2018","Western Human Nutrition Research Center, Davis, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02935894
30,NCT02935894,DB01085,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O,"Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat",Completed,Has Results,Stability & Variability of Lipid-derived Molecules in Sweat,Drug: Ibuprofen|Other: Physiological induction of sweating|Drug: Pilocarpine,Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise|Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Plasma Ibuprofen Concentrations|Change in Sweat Ibuprofen Concentrations,"USDA, Western Human Nutrition Research Center|University of California, Davis",Male,20 Years to 40 Years   (Adult),Not Applicable,14.0,U.S. Fed|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,929370,"November 28, 2016","June 8, 2017","June 8, 2017","October 18, 2016","June 1, 2018","June 1, 2018","Western Human Nutrition Research Center, Davis, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02935894
31,NCT04118842,DB12048,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin,Completed,No Results Available,Solid Tumors,Drug: Savolitinib|Drug: Rifampicin,"Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone)|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiograms (ECGs) (12-lead ECGs)|Number of subjects with abnormal findings in physical examinations|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in c-reactive protein (CRP)|Number of participants with abnormal findings in liver enzymes|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in urinalysis (microscopy)|Savolitinib: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of Cmax|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC(0 t)|Savolitinib, M2 and M3: Ratio of metabolite AUC to parent AUC (MRCAUC)|Savolitinib, M2 and M3: Ratio of metabolite AUC(0-t) to parent AUC(0-t) (MRCAUC[0-t])|Savolitinib, M2 and M3: metabolite-to-parent ratios for Time to reach maximum observed plasma concentration (tmax)|Savolitinib, M2 and M3: metabolite-to-parent ratios for Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2,λz)|Savolitinib, M2 and M3: metabolite-to-parent ratios for terminal elimination rate constant (λz)|Savolitinib: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only)CL/F|Savolitinib, M2 and M3: Ratio of metabolite Cmax to parent Cmax (MRCmax)|Savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) (Vz/F)",AstraZeneca,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D5084C00003,"October 17, 2019","February 26, 2020","February 26, 2020","October 8, 2019",,"April 3, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04118842
32,NCT04118842,DB01201,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin,Completed,No Results Available,Solid Tumors,Drug: Savolitinib|Drug: Rifampicin,"Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone)|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiograms (ECGs) (12-lead ECGs)|Number of subjects with abnormal findings in physical examinations|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in c-reactive protein (CRP)|Number of participants with abnormal findings in liver enzymes|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in urinalysis (microscopy)|Savolitinib: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of Cmax|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC(0 t)|Savolitinib, M2 and M3: Ratio of metabolite AUC to parent AUC (MRCAUC)|Savolitinib, M2 and M3: Ratio of metabolite AUC(0-t) to parent AUC(0-t) (MRCAUC[0-t])|Savolitinib, M2 and M3: metabolite-to-parent ratios for Time to reach maximum observed plasma concentration (tmax)|Savolitinib, M2 and M3: metabolite-to-parent ratios for Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2,λz)|Savolitinib, M2 and M3: metabolite-to-parent ratios for terminal elimination rate constant (λz)|Savolitinib: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only)CL/F|Savolitinib, M2 and M3: Ratio of metabolite Cmax to parent Cmax (MRCmax)|Savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) (Vz/F)",AstraZeneca,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D5084C00003,"October 17, 2019","February 26, 2020","February 26, 2020","October 8, 2019",,"April 3, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04118842
33,NCT04118842,DB01045,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin,Completed,No Results Available,Solid Tumors,Drug: Savolitinib|Drug: Rifampicin,"Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone)|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiograms (ECGs) (12-lead ECGs)|Number of subjects with abnormal findings in physical examinations|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in c-reactive protein (CRP)|Number of participants with abnormal findings in liver enzymes|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in urinalysis (microscopy)|Savolitinib: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of Cmax|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC(0 t)|Savolitinib, M2 and M3: Ratio of metabolite AUC to parent AUC (MRCAUC)|Savolitinib, M2 and M3: Ratio of metabolite AUC(0-t) to parent AUC(0-t) (MRCAUC[0-t])|Savolitinib, M2 and M3: metabolite-to-parent ratios for Time to reach maximum observed plasma concentration (tmax)|Savolitinib, M2 and M3: metabolite-to-parent ratios for Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2,λz)|Savolitinib, M2 and M3: metabolite-to-parent ratios for terminal elimination rate constant (λz)|Savolitinib: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only)CL/F|Savolitinib, M2 and M3: Ratio of metabolite Cmax to parent Cmax (MRCmax)|Savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) (Vz/F)",AstraZeneca,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D5084C00003,"October 17, 2019","February 26, 2020","February 26, 2020","October 8, 2019",,"April 3, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04118842
34,NCT04280328,DB16125,CC1=CC=C(O1)C1=C2N=NN(CC3=CC=CC(CO[C@H]4CCOC4)=N3)C2=NC(N)=N1,Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: Ciforadenant|Drug: daratumumab,Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.|Overall response rate.|Duration of response.|Disease control rate.|Time to next therapy.|Progression free survival.|Minimal Residual Disease.,"Corvus Pharmaceuticals, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,7.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPI-444-003,"February 20, 2020","September 21, 2021","March 1, 2022","February 21, 2020",,"March 11, 2022","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04280328
35,NCT00639002,DB00443,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
36,NCT00639002,DB01234,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
37,NCT00639002,DB14649,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
38,NCT00639002,DB14703,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
39,NCT00639002,DB08877,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
40,NCT00639002,DB11487,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=NC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg,Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma,Incyte Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCB 18424-255,March 2008,July 2010,July 2010,"March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00639002
41,NCT01975077,DB11679,CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12,A Phase Ib Study of Fruquintinib in 3rd Line mCRC,Completed,No Results Available,Colorectal Cancer,Drug: fruquintinib,safety and tolerability|objective response rate(ORR)|pharmacokinetic profiles|disease control rate (DCR)|progression-free survival (PFS)|overall survival (OS),Hutchison Medipharma Limited|Fudan University|Sun Yat-sen University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,62.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-013-00CH3,December 2012,April 2014,October 2014,"November 3, 2013",,"February 17, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Fudan University Cancer Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01975077
42,NCT03258515,DB00218,[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers,Completed,No Results Available,Solid Tumors,Drug: AZD6094 200 mg|Other: Placebo|Drug: Moxifloxacin,"Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT|Effect of AZD6094 at therapeutic dose (600 mg) on additional time-matched ECG variables|Effect of moxifloxacin 400 mg on Fridericia-corrected QT interval (QTcF) compared to placebo.|Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC(0-∞)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Area under the plasma concentration-time curve from time zero to t hours after dosing (AUC(0-t)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Observed maximum concentration (Cmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Time to reach maximum concentration (tmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Lag-time (tlag - from the individual concentration-time curve) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal rate constant (λz) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal half-life (t½) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent clearance for parent drug estimated as dose divided by AUC (CL/F) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent volume of distribution for parent drug at terminal phase (Vz/F, extravascular administration) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Assessment of relationship between the plasma concentration of AZD6094 and moxifloxacin and ECG variables, including baseline-adjusted and placebo-subtracted QTc interval.|Number of participants with adverse events (AEs) of AZD6094|Systolic blood pressure [SBP]|Diastolic blood pressure [DBP]|Pulse rate|Twelve-lead (12-Lead) electrocardiograms (ECGs)|Physical examination|Laboratory assessments of Hematology|Laboratory assessments of Clinical chemistry|Laboratory assessments of urinalysis|Effect of AZD6094 at therapeutic dose (600 mg) on time-matched ECG variable - heart rate (HR)",AstraZeneca|Parexel,Male,18 Years to 55 Years   (Adult),Phase 1,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5084C00001,"September 6, 2017","March 24, 2018","March 24, 2018","August 23, 2017",,"February 20, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03258515
43,NCT01583374,DB00694,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
44,NCT01583374,DB00190,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
45,NCT01583374,DB09479,[82Rb+],Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
46,NCT01583374,DB00837,NC(=O)CCC\N=C(\C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
47,NCT01583374,DB16171,C[C@@](CC1=CC=C(OP(O)(O)=O)C(O)=C1)(NN)C(O)=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
48,NCT01583374,DB06444,CCCCCCC(C)(C)C1=CC(O)=C2[C@H]3CC(CO)=CC[C@@H]3C(C)(C)OC2=C1,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
49,NCT01583374,DB01599,CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
50,NCT01583374,DB00883,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
51,NCT01583374,DB11346,[Rb],Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
52,NCT01583374,DB15243,CCCCCCOC(C)C1=C2NC(\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)C3=C4N\C(=C/C5=N/C(=C\2)/C(C)=C5CC)C(C)=C4C(=O)C3)=C1C,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
53,NCT01583374,DB09061,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
54,NCT01583374,DB13750,O\N=C\C1=CC=[N+](COC[N+]2=CC=C(\C=N\O)C=C2)C=C1,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
55,NCT01583374,DB01020,[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
56,NCT01583374,DB09401,[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H],Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
57,NCT01583374,DB14050,[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
58,NCT01583374,DB09270,COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
59,NCT01583374,DB05676,CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,"Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 3,490.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CC-10004-AS-001|2011-001555-37,"May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583374
60,NCT04355156,DB06626,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1,Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Drug: Axitinib|Drug: Placebo,Overall survival|Imaging|Objective response rate|Monitoring of adverse reactions|Progression free survival|Progression free survival secondary outcome|Monitoring dose reductions and the reasons behind them,Imperial College London|Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",WS913975|2011-002598-49,"September 17, 2012","February 22, 2019","February 22, 2019","April 21, 2020",,"April 21, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04355156
61,NCT00567554,DB00445,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
62,NCT00567554,DB12619,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
63,NCT00567554,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
64,NCT00567554,DB12633,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
65,NCT00567554,DB01590,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
66,NCT00567554,DB05297,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
67,NCT00567554,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
68,NCT00567554,DB00531,ClCCN(CCCl)P1(=O)NCCCO1,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
69,NCT00567554,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib,To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy,German Breast Group|AGO Study Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,2600.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 44|2006-005834-19,October 2007,August 2011,October 2015,"December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,https://ClinicalTrials.gov/show/NCT00567554
70,NCT02133157,DB15106,CN(C)CCNS(=O)(=O)CC1=CC(NC2=NC(OC3=CC4=C(NC(C)=C4)C=C3)=CC=N2)=CC=C1,Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors,Completed,No Results Available,Tumor,Drug: Sulfatinib,To assess number of participants with adverse events as a measure of safety and tolerability during dose escalating|To measure the plasma concentration of HMPL-012 in single and repeated doses,Hutchison Medipharma Limited,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,71.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-012-00CH1,April 2010,October 2014,October 2014,"May 7, 2014",,"July 8, 2020","Academy of Military Medical Affiliated Hopital, Beijing, China",,https://ClinicalTrials.gov/show/NCT02133157
71,NCT01645215,DB11679,CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12,Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors,Completed,No Results Available,Tumor,Drug: Fruquintinib,"Safety in the first 28-Days of Therapy|Objective Response Rate （ORR)|Pharmacokinetic Assessments for AUC, Cmax and Tmax",Hutchison Medipharma Limited|Fudan University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,40.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-013-00CH1,January 2011,October 2012,October 2012,"July 20, 2012",,"February 17, 2020","Fudan University Cancer Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01645215
72,NCT00736372,DB05448,CCC(C)SSC1=NC=CN1,A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer,Completed,No Results Available,Metastatic Cancer|Advanced Cancer,Drug: PX-12,"To determine the MTD of PX-12 delivered as a 72-hour infusion over days 1, 2, and 3 of a 21-day cycle|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Evaluate the safety profile of PX-12|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess the pharmacodynamics of PX-12 using surrogate tissues obtained pre- and post-drug treatment|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess pharmacokinetic profiles of PX-12 in plasma samples|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Identify any antitumor activity of PX-12 in this patient population",Cascadian Therapeutics Inc.|Seagen Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,14.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PX-12-004,June 2008,August 2009,August 2009,"August 15, 2008",,"May 17, 2018","TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Tyler Cancer Center, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT00736372
73,NCT05135871,DB14921,CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O,Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects,Completed,No Results Available,Hypertrophic Cardiomyopathy,Drug: Mavacamten,"Area under the curve (AUC) (0-last), AUC(0-inf)|Maximum concentration (Cmax)|Time to maximum concentration (Tmax)|Elimination half-life (T1⁄2)|Apparent volume of distribution (Vd/F)|Apparent clearance (CL/F)|Incidence of adverse events|Vital signs|Physical examination findings|Electrocardiogram (ECG) parameters|Clinical laboratory tests data",LianBio LLC,All,18 Years to 60 Years   (Adult),Phase 1,45.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LB2001-101,"October 31, 2021","February 5, 2022","February 28, 2022","November 26, 2021",,"March 25, 2022","Huashan Hospital Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT05135871
74,NCT02703298,DB16172,COC1=C(OP(O)(O)=O)C2=C(NC(=CC2=O)C2=CC(F)=CC=C2)C=C1,Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients,Completed,No Results Available,Carcinoma|Advanced Cancer,Drug: TRX-818 capsules,Dose limiting toxicity (DLT) of TRX-818 in Asians|Maximum tolerated dose (MTD) of TRX-818 in Asians|Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)|Composite measure of pharmacokinetics (PK) parameters of TRX-818: AUC(0-last)|Composite measure of pharmacokinetics (PK) parameters of TRX-818:Cmax|Composite measure of pharmacokinetics (PK) parameters of TRX-818: Tmax|Composite measure of pharmacokinetics (PK) parameters of TRX-818: T(1/2)|Time to tumor progression (TTP),"TaiRx, Inc.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CVM-002,"March 25, 2016","January 23, 2018","May 3, 2018","March 9, 2016",,"March 28, 2019","National Cheng Kung University Hospital, Tainan City, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT02703298
75,NCT02507544,DB16172,COC1=C(OP(O)(O)=O)C2=C(NC(=CC2=O)C2=CC(F)=CC=C2)C=C1,A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer,Completed,No Results Available,Carcinoma|Advanced Cancer,Drug: TRX-818 capsules,"Dose limiting toxicity (DLT) of TRX-818|Maximum tolerated dose (MTD) of TRX-818|Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)|Composite measure of pharmacokinetics (PK) parameters of TRX-818 and its metabolites TRX-818M1 to include AUC(0-last), Cmax, Tmax, T(1/2).|Time to tumor progression (TTP)","TaiRx, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CVM-001,September 2015,"April 29, 2017","May 20, 2019","July 24, 2015",,"May 21, 2020","START Midwest, Grand Rapids, Michigan, United States|South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02507544
76,NCT03402659,DB07138,FC1=CC(F)=C(SC2=NN3C=NC(=O)C(=C3C=C2)C2=C(Cl)C=CC=C2Cl)C=C1,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease",Completed,Has Results,Alzheimer Disease,Drug: neflamapimod|Other: placebo,Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)|Wechsler Memory Scale (WMS) Immediate and Delayed Recall|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Mini-Mental State Examination (MMSE)|Cerebrospinal Fluid Total Tau|Cerebrospinal Fluid Phospho-tau|Cerebrospinal Fluid Amyloid Beta 1-40|Cerebrospinal Fluid Amyloid Beta 1-42|Cerebrospinal Fluid Neurogranin|Cerebrospinal Fluid Neurofilament Light Chain|Cerebrospinal Fluid P-tau/AB1-42 Ratio,EIP Pharma Inc|Worldwide Clinical Trials|VU University Medical Center,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2,161.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EIP-VX17-745-304,"December 29, 2017","June 30, 2019","July 31, 2019","January 18, 2018","October 27, 2021","October 27, 2021","Alliance for Research, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|CITrials, Santa Ana, California, United States|Southern California Research, LLC, Simi Valley, California, United States|Viking Clinical Research, Temecula, California, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts, United States|Manhattan Behavioral Medicine, New York, New York, United States|Alzheimer's Memory Center and Research Institute, Charlotte, North Carolina, United States|Northwest Clinical Research Center, Seattle, Washington, United States|Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s., Choceň, Czechia|Cerebrovaskulární poradna s.r.o., Moravská Ostrava, Czechia|Clintrial S.R.O, Prague, Czechia|Private Psychiatric Centre, Prague, Czechia|Vestra Clinics S.R.O, Rychnov Nad Kněžnou, Czechia|CCBR Clinical Research, Aalborg, Aalborg, Denmark|CCBR Clinical Research, Ballerup, Ballerup, Denmark|CCBR Clinical Research, Vejle, Vejle, Denmark|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekhuis, Breda, Netherlands|MAC Clinical Research Tankersley, Barnsley, United Kingdom|Re:Cognition Health Birmingham, Birmingham, United Kingdom|MAC Clinical Research Blackpool, Blackpool, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|MAC Clinical Research Leeds, Leeds, United Kingdom|MAC Clinical Research Liverpool, Liverpool, United Kingdom|Re:Cognition Health London, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|MAC Clinical Research Manchester, Manchester, United Kingdom|Re:Cognition Health Plymouth, Plymouth, United Kingdom|5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust, Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03402659/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03402659/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03402659
77,NCT01773018,DB12048,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors,Completed,No Results Available,Tumor,Drug: Volitinib,"The safety and tolerability of single and multiple doses of HMPL-504 administered to patients.|Pharmacokinetic Assessments for area under curve (AUC), Cmax and Tmax .","Hutchison Medipharma Limited|Sir Charles Gairdner Hospital|Austin Hospital, Melbourne Australia|Monash University",All,"18 Years and older   (Adult, Older Adult)",Phase 1,47.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-504-00AU1,February 2012,December 2015,May 2016,"January 21, 2013",,"June 1, 2016","Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Southern Health and Monash Institute of Medical Research, Clayton, Australia|Austin Health, Melbourne, Australia",,https://ClinicalTrials.gov/show/NCT01773018
78,NCT00257114,DB16741,[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO,"Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability",Completed,No Results Available,Multiple Myeloma,Drug: bortezomib,,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C05004,,March 2007,,"November 22, 2005",,"February 11, 2008","Sinai Hospital of Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00257114
79,NCT00257114,DB00188,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,"Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability",Completed,No Results Available,Multiple Myeloma,Drug: bortezomib,,"Millennium Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 4,,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C05004,,March 2007,,"November 22, 2005",,"February 11, 2008","Sinai Hospital of Baltimore, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00257114
80,NCT03163966,DB00563,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis",Completed,No Results Available,"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients",Drug: CR6086|Drug: Methotrexate|Drug: Placebo,American College of Rheumatology 20% improvement (ACR20) responder rate|ACR50 responder rate|ACR70 responder rate|Disease Activity Score on 28-joint count (DAS28)|Clinical Disease Activity Index (CDAI)|Simplified Disease Activity Index (SDAI)|ACR/EULAR remission criteria|Adverse Events|Routine Laboratory determinations|Pharmacokinetics (PK) of Methotrexate and CR6086 in combination|Biochemical markers|Imaging biomarkers,Rottapharm Biotech,All,"18 Years and older   (Adult, Older Adult)",Phase 2,248.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR6086-2-02,"October 5, 2017","January 8, 2019","January 8, 2019","May 23, 2017",,"October 5, 2021","Institute of Rheumatology, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03163966
81,NCT03163966,DB16111,OC(=O)C1=CC=C(C=C1)C1(CC1)NC(=O)C1CC2(CC2)CCN1CC1=CC=C(C=C1)C(F)(F)F,"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis",Completed,No Results Available,"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients",Drug: CR6086|Drug: Methotrexate|Drug: Placebo,American College of Rheumatology 20% improvement (ACR20) responder rate|ACR50 responder rate|ACR70 responder rate|Disease Activity Score on 28-joint count (DAS28)|Clinical Disease Activity Index (CDAI)|Simplified Disease Activity Index (SDAI)|ACR/EULAR remission criteria|Adverse Events|Routine Laboratory determinations|Pharmacokinetics (PK) of Methotrexate and CR6086 in combination|Biochemical markers|Imaging biomarkers,Rottapharm Biotech,All,"18 Years and older   (Adult, Older Adult)",Phase 2,248.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR6086-2-02,"October 5, 2017","January 8, 2019","January 8, 2019","May 23, 2017",,"October 5, 2021","Institute of Rheumatology, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03163966
82,NCT03163966,DB16620,CN(CC1=CN=C2N=C(N)NC(=O)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis",Completed,No Results Available,"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients",Drug: CR6086|Drug: Methotrexate|Drug: Placebo,American College of Rheumatology 20% improvement (ACR20) responder rate|ACR50 responder rate|ACR70 responder rate|Disease Activity Score on 28-joint count (DAS28)|Clinical Disease Activity Index (CDAI)|Simplified Disease Activity Index (SDAI)|ACR/EULAR remission criteria|Adverse Events|Routine Laboratory determinations|Pharmacokinetics (PK) of Methotrexate and CR6086 in combination|Biochemical markers|Imaging biomarkers,Rottapharm Biotech,All,"18 Years and older   (Adult, Older Adult)",Phase 2,248.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR6086-2-02,"October 5, 2017","January 8, 2019","January 8, 2019","May 23, 2017",,"October 5, 2021","Institute of Rheumatology, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT03163966
83,NCT02655822,DB16125,CC1=CC=C(O1)C1=C2N=NN(CC3=CC=CC(CO[C@H]4CCOC4)=N3)C2=NC(N)=N1,Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers,Completed,No Results Available,Renal Cell Cancer|Metastatic Castration Resistant Prostate Cancer,Drug: Ciforadenant|Drug: Ciforadenant + atezolizumab,"Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab|Objective response rate per RECIST v1.1 criteria of ciforadenant as a single agent and in combination with atezolizumab|Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of ciforadenant as a single agent and in combination with atezolizumab|Mean and median Area under the curve (AUC) of ciforadenant|Mean and median Maximum concentration (Cmax) of ciforadenant|Identify the MDL (maximum dose level) of single agent ciforadenant","Corvus Pharmaceuticals, Inc.|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,502.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPI-444-001,January 2016,June 2021,July 2021,"January 14, 2016",,"August 30, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|University of California - San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Monash Health, Clayton, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02655822
84,NCT03703882,DB15010,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)C1=C(O)C=CC=C1,Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy,Completed,No Results Available,"Muscular Dystrophy, Duchenne",Drug: Edasalonexent|Drug: Placebo,Change from baseline in North Star Ambulatory Assessment (NSAA)|Safety and tolerability measured by number of treatment- emergent adverse events (TEAEs) and serious adverse events (SAEs)|Change from baseline in 10-meter walk/run test|Change from baseline in time to stand from supine|Change from baseline in 4-stair climb,Catabasis Pharmaceuticals,Male,4 Years to 7 Years   (Child),Phase 3,131.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CAT-1004-301,"October 2, 2018","September 22, 2020","September 22, 2020","October 12, 2018",,"November 20, 2020","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|UC Davis, Sacramento, California, United States|Nemours Children's Hospital, Orlando, Florida, United States|Rare Disease Research, LLC, Atlanta, Georgia, United States|Rush University Children's Hospital, Chicago, Illinois, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Shriners Hospitals for Children, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Children's Hospital of Richmond at VCU, Richmond, Virginia, United States|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Children's Health Queensland Children's Hospital and Health Service, South Brisbane, Queensland, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|London Health Sciences Centre - Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|University of Hamburg, Hamburg, Germany|University of Munich, Munich, Germany|Children's University Hospital, Dublin, Ireland|Hadassah Medical Center, Jerusalem, Israel|Queen Silvia Children's Hospital, Gothenburg, Sweden|Bristol Children's Hospital, Bristol, United Kingdom|Evelina Children's Hospital, London, United Kingdom|Great Ormond Street Hospital (GOSH), London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03703882
85,NCT03368170,DB16229,CCCNCCOC1=CC(=CC(F)=C1)S(C)(=O)=O,Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia,Completed,Has Results,Parkinson Disease,Drug: Mesdopetam (IRL790),"Unified Dyskinesia Rating Scale (UDysRS)|Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Question 4.1 and 4.2|Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part II and III",Integrative Research Laboratories AB|The Clinical Trial Company,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,75.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRL790C003,"April 12, 2018","June 12, 2019","June 12, 2019","December 11, 2017","March 24, 2020","August 25, 2020","Sahlgrenska University hospital, Göteborg, Sweden|University hospital, Linköping, Sweden|University hospital, Lund, Sweden|Karolinska University hospital, Stockholm, Sweden|Bristol Brain Centre, Southmead Hospital, Bristol, United Kingdom|Fairfield General Hospital (Pennine Acute NHS Trust), Bury, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|The National Hospital of Neurology and Neurosurgery (UCL), London, United Kingdom|Luton and Dunstable University Hospital NHS Foundation Trust, Luton, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Qeens' Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom|Queens's Hospital, Romford, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Torbay hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03368170/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03368170/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03368170
86,NCT02355535,DB13048,OC1=C(\C=N\NC(=O)CN2CCN(CC3=CC=CC=C3)CC2)C=CC=C1CC=C,Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1,Completed,No Results Available,Solid Tumor|Pancreatic Neuroendocrine Tumor|Neuroendocrine Tumors,Drug: PAC-1,Maximum Tolerated Dose|Adverse Effects|Disease Response based on RECIST Criteria for patients with solid tumors|Disease Response based on Deauville PET Criteria for patients with lymphoma,"Vanquish Oncology, Inc.|University of Illinois at Chicago",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,48.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0057,February 2015,"May 18, 2020","May 18, 2020","February 4, 2015",,"September 24, 2020","University of Illinois at Chicago, Chicago, Illinois, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Regions Hospital, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02355535
87,NCT02355535,DB12428,CCCC1=C(\C=C\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F,Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1,Completed,No Results Available,Solid Tumor|Pancreatic Neuroendocrine Tumor|Neuroendocrine Tumors,Drug: PAC-1,Maximum Tolerated Dose|Adverse Effects|Disease Response based on RECIST Criteria for patients with solid tumors|Disease Response based on Deauville PET Criteria for patients with lymphoma,"Vanquish Oncology, Inc.|University of Illinois at Chicago",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,48.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0057,February 2015,"May 18, 2020","May 18, 2020","February 4, 2015",,"September 24, 2020","University of Illinois at Chicago, Chicago, Illinois, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Regions Hospital, Saint Paul, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02355535
88,NCT01340846,DB08735,[H][C@@](C)(O)C[C@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
89,NCT01340846,DB08496,CC(=O)C[C@H](C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
90,NCT01340846,DB05667,CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
91,NCT01340846,DB01026,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
92,NCT01340846,DB14055,CC(=O)C[C@@H](C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
93,NCT01340846,DB01418,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
94,NCT01340846,DB00682,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
95,NCT01340846,DB08736,[H][C@](C)(O)C[C@@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
96,NCT01340846,DB01241,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,"A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",Completed,No Results Available,Cancer,Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg,"Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113771,"September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01340846
97,NCT02605746,DB09063,CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1,Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,Completed,No Results Available,Glioblastoma|Brain Metastases,Drug: ceritinib 750mg,Plasma Concentration|Cerebrospinal Concentration|Intratumoral Concentration|Tumor Tissue|Tumor Cells in M-Phase|Double Strand DNA|Tissue Concentration,"St. Joseph's Hospital and Medical Center, Phoenix|Novartis|Wayne State University|Translational Genomics Research Institute",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PHX15BN068,"February 17, 2016","November 29, 2018","July 12, 2019","November 16, 2015",,"December 11, 2020","Barrow Brain and Spine, Phoenix, Arizona, United States",,https://ClinicalTrials.gov/show/NCT02605746
98,NCT03497377,DB14805,OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O,Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.,Completed,No Results Available,Metastatic Prostate Cancer,Drug: 18F-DCFPyL Injection|Drug: 18F-NaF,Comparison of DCFPyL- PET/CT (or PET/MRI imaging) to NaF-PET/CT|Estimation of new or progressive metastatic lesions found on NaF and 18F-DCFPyL,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,25.0,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,J1559|IRB00065679|1U01CA183031-01A1,"May 16, 2016",April 2020,April 2020,"April 13, 2018",,"May 7, 2020","Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03497377
99,NCT02096913,DB01050,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury,Completed,No Results Available,Spinal Cord Injury,Drug: Dolormin® extra (Ibuprofen),Number of patients with severe gastroduodenal bleedings as a measure of safety|Spasticity on the Modified Ashworth Scale (MAS)|Pain on the Neuropathic Pain Scale (NPS)|International standards for neurological classification of spinal cord injury (ISNCSCI) - ASIA impairment scale (AIS) change from baseline|Neurological motor function on the ISNCSCI/ASIA motor scores change from baseline|Neurological sensory function on the ISNCSCI/ASIA sensory score change from baseline|Number of participants with adverse events as a measure of safety and tolerability|Ibuprofen levels in plasma|Ibuprofen levels in cerebrospinal fluid (CSF),"Jan M. Schwab, MD, PhD|Else Kröner Fresenius Foundation|Charite University, Berlin, Germany",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ibuprofen-SCI-Safety|2011-000584-28,June 2013,September 2017,September 2017,"March 26, 2014",,"October 30, 2017","Unfallkrankenhaus Berlin, Treatment Centre for Spinal Cord Injuries, Warener Straße 7, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02096913
100,NCT02096913,DB09213,CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O,Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury,Completed,No Results Available,Spinal Cord Injury,Drug: Dolormin® extra (Ibuprofen),Number of patients with severe gastroduodenal bleedings as a measure of safety|Spasticity on the Modified Ashworth Scale (MAS)|Pain on the Neuropathic Pain Scale (NPS)|International standards for neurological classification of spinal cord injury (ISNCSCI) - ASIA impairment scale (AIS) change from baseline|Neurological motor function on the ISNCSCI/ASIA motor scores change from baseline|Neurological sensory function on the ISNCSCI/ASIA sensory score change from baseline|Number of participants with adverse events as a measure of safety and tolerability|Ibuprofen levels in plasma|Ibuprofen levels in cerebrospinal fluid (CSF),"Jan M. Schwab, MD, PhD|Else Kröner Fresenius Foundation|Charite University, Berlin, Germany",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ibuprofen-SCI-Safety|2011-000584-28,June 2013,September 2017,September 2017,"March 26, 2014",,"October 30, 2017","Unfallkrankenhaus Berlin, Treatment Centre for Spinal Cord Injuries, Warener Straße 7, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02096913
101,NCT02096913,DB14020,OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1,Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury,Completed,No Results Available,Spinal Cord Injury,Drug: Dolormin® extra (Ibuprofen),Number of patients with severe gastroduodenal bleedings as a measure of safety|Spasticity on the Modified Ashworth Scale (MAS)|Pain on the Neuropathic Pain Scale (NPS)|International standards for neurological classification of spinal cord injury (ISNCSCI) - ASIA impairment scale (AIS) change from baseline|Neurological motor function on the ISNCSCI/ASIA motor scores change from baseline|Neurological sensory function on the ISNCSCI/ASIA sensory score change from baseline|Number of participants with adverse events as a measure of safety and tolerability|Ibuprofen levels in plasma|Ibuprofen levels in cerebrospinal fluid (CSF),"Jan M. Schwab, MD, PhD|Else Kröner Fresenius Foundation|Charite University, Berlin, Germany",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ibuprofen-SCI-Safety|2011-000584-28,June 2013,September 2017,September 2017,"March 26, 2014",,"October 30, 2017","Unfallkrankenhaus Berlin, Treatment Centre for Spinal Cord Injuries, Warener Straße 7, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02096913
102,NCT03130790,DB05944,C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1,Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line),Completed,No Results Available,Gastric Cancer,Drug: Varlitinib|Drug: mFOLFOX6|Drug: Placebo,Percentage change from baseline in tumor size at Week 12 - Phase 2 part|Overall Survival (OS) - Phase 3 part|Objective Response Rate (ORR) - Phase 2 part|Progression-free survival (PFS) - Phase 2 part|Time to response (TTR) - Phase 2 part|Duration of Response (DoR) - Phase 2 part|Disease Control Rate (DCR) - Phase 2 part|Overall Survival (OS) - Phase 2 part|Pharmacokinetic: area under the plasma concentration time curve (AUC) from 0 to 6 hours (AUC0-6) - Phase 2 part|Pharmacokinetic: maximum observed plasma concentration (Cmax) - Phase 2 part|Pharmacokinetic: time to Cmax (tmax) - Phase 2 part|Pharmacokinetic: accumulation ratio for AUC (Rac AUC0-6) - Phase 2 part|Pharmacokinetic: accumulation ratio for Cmax (Rac Cmax) - Phase 2 part|Objective Response Rate (ORR) - Phase 3 part|Progression-free survival (PFS) - Phase 3 part|Time to response (TTR) - Phase 3 part|Duration of Response (DoR) - Phase 3 part|Disease Control Rate (DCR) - Phase 3 part|Incidence of Adverse Events (AEs) - Phase 3 part|Health-related quality of life (QoL) - Phase 3 part|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30) measuring patients general cancer symptoms and functioning - Phase 3 part|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part,Aslan Pharmaceuticals,All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,52.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ASLAN001-012,"August 31, 2017","December 20, 2018","February 22, 2019","April 26, 2017",,"February 15, 2022","2 Sites, Tallinn, Estonia|1 Site, Hong Kong, Hong Kong|2 Sites, Daegu, Korea, Republic of|1 Site, Incheon, Korea, Republic of|1 Site, Jeongnam, Korea, Republic of|11 Sites, Seoul, Korea, Republic of|2 Sites, Suwon, Korea, Republic of|2 Sites, Kaunas, Lithuania|1 Site, Vilnius, Lithuania|2 Sites, Kuala Lumpur, Malaysia|1 Site, Singapore, Singapore|1 Site, Kaohsiung, Taiwan|1 Site, Taichung, Taiwan|1 Site, Taipei, Taiwan|1 Site, Khon Kaen, Thailand|1 Site, Pathum Thani, Thailand",,https://ClinicalTrials.gov/show/NCT03130790
103,NCT03223337,DB11682,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,Daprodustat Hepatic Impairment Study,Completed,Has Results,Anaemia,Drug: Daprodustat (GSK1278863),"Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites|Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites|Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites|Part 2: Percentage AUCex of GSK1278863 and Its Metabolites|Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites|Part 2: AUC (0-t) of GSK1278863 and Its Metabolites|Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites|Part 2: Cmax of GSK1278863 and Its Metabolites.|Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites|Part 2: T1/2 of GSK1278863 and Its Metabolites|Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites|Part 2: Tmax of GSK1278863 and Its Metabolites|Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites|Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites|Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites|Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites|Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863|Part 2: Cmax, EPO Following Administration of GSK1278863|Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863|Part 2: Tmax, EPO Following Administration of GSK1278863|Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863|Part 2: AUC (0-t, EPO) Following Administration of GSK1278863|Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants With AEs and SAEs|Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Abnormal Urinalysis Findings|Part 2: Number of Participants With Abnormal Urinalysis Findings",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,37.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200231,"July 24, 2017","August 20, 2018","August 20, 2018","July 21, 2017","September 4, 2019","September 4, 2019","GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03223337
104,NCT03231176,DB01101,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer,Completed,No Results Available,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine,Objective Response Rate (ORR)|Progression-free survival (PFS)|Disease Control Rate (DCR)|Duration of Response (DoR)|Overall Survival (OS)|Safety and tolerability of varlitinib when combined with capecitabine,Aslan Pharmaceuticals,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,62.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASLAN001-008,"December 19, 2017","July 5, 2019","April 13, 2020","July 27, 2017",,"November 19, 2020","No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China|There is 22 sites located in other cities of China, including Nanjing, Nanjing, China",,https://ClinicalTrials.gov/show/NCT03231176
105,NCT03231176,DB05944,C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1,Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer,Completed,No Results Available,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine,Objective Response Rate (ORR)|Progression-free survival (PFS)|Disease Control Rate (DCR)|Duration of Response (DoR)|Overall Survival (OS)|Safety and tolerability of varlitinib when combined with capecitabine,Aslan Pharmaceuticals,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,62.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASLAN001-008,"December 19, 2017","July 5, 2019","April 13, 2020","July 27, 2017",,"November 19, 2020","No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China|There is 22 sites located in other cities of China, including Nanjing, Nanjing, China",,https://ClinicalTrials.gov/show/NCT03231176
106,NCT03093870,DB01101,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,Completed,Has Results,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine|Drug: Placebo (for Varlitinib),Objective Response Rate (ORR) - Part 1|Progression-free Survival (PFS) - Part 1|Object Response Rates (ORR) - Safety Lead-In|Overall Survival (OS) - Part 1|Overall Survival (OS) - Safety Lead-In|Duration of Response (DoR) - Part 1|Disease Control Rate DCR - Part 1|Tumor Size - Part 1|Number of Participants With Clinically Significant Laboratory Tests- Safety Lead-in|Number of Participants With Clinically Significant Laboratory Tests - Part 1|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Safety Lead-In|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Part 1|Number of Participants With ECG Parameters of Interest - Safety Lead-In|Number of Participants With ECG Parameters of Interest - Part 1|ECOG Performance Status - Part 1,"Aslan Pharmaceuticals|bioRASI, LLC|CMIC Co, Ltd. Japan|Syneos Health",All,"Child, Adult, Older Adult",Phase 2|Phase 3,151.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ASLAN001-009,"July 4, 2017","November 12, 2019","April 17, 2020","March 28, 2017","August 3, 2021","August 3, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCCN, Las Vegas, Nevada, United States|Ruttenberg Cancer Center, Mount Sinai Hospital, New York, New York, United States|Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|There are 5 sites in different cities in Australia, Camperdown, Australia|There are 6 sites in different cities in China, Nanjing, Nanjing, China|There are 2 sites in Hong Kong, Hong Kong, Hong Kong|There are 2 sites in Hungary, Budapest, Hungary|There are 7 sites in different cities in Japan, Chiba, Japan|There are 15 sites in different cities in South Korea, Seoul, Korea, Republic of|There are 2 sites in different cities in Poland, Otwock, Poland|There are 2 sites in Singapore., Singapore, Singapore|There are 5 sites in different cities in Spain, Barcelona, Spain|There are 5 sites in different cities in Taiwan, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03093870
107,NCT03093870,DB05944,C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1,Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,Completed,Has Results,Biliary Tract Cancer,Drug: Varlitinib|Drug: Capecitabine|Drug: Placebo (for Varlitinib),Objective Response Rate (ORR) - Part 1|Progression-free Survival (PFS) - Part 1|Object Response Rates (ORR) - Safety Lead-In|Overall Survival (OS) - Part 1|Overall Survival (OS) - Safety Lead-In|Duration of Response (DoR) - Part 1|Disease Control Rate DCR - Part 1|Tumor Size - Part 1|Number of Participants With Clinically Significant Laboratory Tests- Safety Lead-in|Number of Participants With Clinically Significant Laboratory Tests - Part 1|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Safety Lead-In|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Part 1|Number of Participants With ECG Parameters of Interest - Safety Lead-In|Number of Participants With ECG Parameters of Interest - Part 1|ECOG Performance Status - Part 1,"Aslan Pharmaceuticals|bioRASI, LLC|CMIC Co, Ltd. Japan|Syneos Health",All,"Child, Adult, Older Adult",Phase 2|Phase 3,151.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ASLAN001-009,"July 4, 2017","November 12, 2019","April 17, 2020","March 28, 2017","August 3, 2021","August 3, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCCN, Las Vegas, Nevada, United States|Ruttenberg Cancer Center, Mount Sinai Hospital, New York, New York, United States|Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|There are 5 sites in different cities in Australia, Camperdown, Australia|There are 6 sites in different cities in China, Nanjing, Nanjing, China|There are 2 sites in Hong Kong, Hong Kong, Hong Kong|There are 2 sites in Hungary, Budapest, Hungary|There are 7 sites in different cities in Japan, Chiba, Japan|There are 15 sites in different cities in South Korea, Seoul, Korea, Republic of|There are 2 sites in different cities in Poland, Otwock, Poland|There are 2 sites in Singapore., Singapore, Singapore|There are 5 sites in different cities in Spain, Barcelona, Spain|There are 5 sites in different cities in Taiwan, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03093870
108,NCT02447380,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,"Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment",Completed,No Results Available,Advanced Gastric Adenocarcinoma,Drug: AZD6094|Drug: Docetaxel,Objective response rate (ORR) by RECIST 1.1|Duration of response|Disease control rate|Overall survival (OS)|progression-free survival (PFS)|Number of subjects with Adverse Events as a Measure of safety and Tolerability|Biomarker analysis,Samsung Medical Center,All,"up to 20 Years   (Child, Adult)",Phase 2,2.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-07-168,"July 10, 2017","February 18, 2019","February 18, 2019","May 18, 2015",,"December 30, 2019","Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02447380
109,NCT01083524,DB14105,[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
110,NCT01083524,DB14622,O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
111,NCT01083524,DB00815,[Na+].CCCCCCCCCCCCOS([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
112,NCT01083524,DB09154,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
113,NCT01083524,DB09325,[F-].[Na+],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
114,NCT01083524,DB09380,[Na+].[Na+].[O-][51Cr]([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
115,NCT01083524,DB13911,[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
116,NCT01083524,DB09153,[Na+].[Cl-],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
117,NCT01083524,DB09395,[Na+].CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
118,NCT01083524,DB14598,[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
119,NCT01083524,DB06705,[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
120,NCT01083524,DB09449,[Na+].OP(O)([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
121,NCT01083524,DB14496,[Na+].[Na+].[O-][Mo]([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
122,NCT01083524,DB09072,[Na+].OCCCC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
123,NCT01083524,DB14048,[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
124,NCT01083524,DB15908,[OH-].[Na+].[Al+3].[O-]C([O-])=O.OCC(O)C(O)C(O)C(O)CO,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
125,NCT01083524,DB08809,OC(=O)C(Cl)Cl,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
126,NCT01083524,DB09183,COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
127,NCT01083524,DB15825,[Na+].O[Al+]O.[O-]C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
128,NCT01083524,DB09276,[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
129,NCT01083524,DB11590,[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
130,NCT01083524,DB00464,[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
131,NCT01083524,DB11493,[Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
132,NCT01083524,DB13743,O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([S-])(=O)=O.[O-]S([S-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
133,NCT01083524,DB15951,[Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2NC3=CC4=NC5=CC(=CC=C5NC4=CC3=NC2=C1)S([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
134,NCT01083524,DB09484,[Na+].[Na+].[O-]P([O-])(F)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
135,NCT01083524,DB14015,[Na+].OS([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
136,NCT01083524,DB09332,[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
137,NCT01083524,DB11159,[Na+].[Na+].[S--],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
138,NCT01083524,DB13771,[Na+].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
139,NCT01083524,DB15950,[Na+].[H][C@]12CC[C@@](CS([O-])(=O)=O)(C(=O)C1)C2(C)C,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
140,NCT01083524,DB13707,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
141,NCT01083524,DB15952,[Na+].[O-][N+]([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
142,NCT01083524,DB01583,[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
143,NCT01083524,DB09382,[Na+].[O-]C(=O)CNC(=O)C1=C([131I])C=CC=C1,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
144,NCT01083524,DB14502,[Na+].[Na+].OP([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
145,NCT01083524,DB14516,[Na+],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
146,NCT01083524,DB09448,[Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1[123I],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
147,NCT01083524,DB13404,[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
148,NCT01083524,DB14600,[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
149,NCT01083524,DB09370,[Na+].[Na+].O[32P]([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
150,NCT01083524,DB09561,[Na+].[Na+].OCC(O)COP([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
151,NCT01083524,DB09472,[Na+].[Na+].[O-]S([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
152,NCT01083524,DB11151,[OH-].[Na+],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
153,NCT01083524,DB01390,[Na+].OC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
154,NCT01083524,DB11119,[Na+].[I-],Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
155,NCT01083524,DB13210,[Na+].[O-][Cl]=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
156,NCT01083524,DB13157,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
157,NCT01083524,DB14505,[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
158,NCT01083524,DB14599,[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
159,NCT01083524,DB15974,[Na+].[Na+].[Na+].O=S1(=O)O[Au]2(OS(=O)(=O)S2)S1,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
160,NCT01083524,DB09517,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
161,NCT01083524,DB15842,[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
162,NCT01083524,DB16585,[Na+].[Na+].[Na+].[K+].[K+].[K+].[H]O[H].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
163,NCT01083524,DB14702,[Na+].[O-][V](=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
164,NCT01083524,DB09460,[Na+].[Na+].[O-]C([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
165,NCT01083524,DB15835,[Na+].[Na+].[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COP([O-])([O-])=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
166,NCT01083524,DB13381,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
167,NCT01083524,DB16608,[Na+].[O-][Cl](=O)(=O)=O,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
168,NCT01083524,DB05630,O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
169,NCT01083524,DB14482,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension,Completed,No Results Available,"Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)",Drug: Dichloroacetate Sodium,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)",University of Alberta|Imperial College London,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 20001,March 2010,September 2013,September 2013,"March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01083524
170,NCT01837667,DB15412,CN1CCN(CC1)C(=O)C1[C@@H]2CC[C@@H](O2)C1C(O)=O,Phase I Study of LB-100 With Docetaxel in Solid Tumors,Completed,No Results Available,Tumors|Neoplasms|Cancer,Drug: LB-100 for Injection|Drug: Docetaxel,Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.,"Lixte Biotechnology Holdings, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L12-20661,February 2013,September 2016,September 2016,"April 23, 2013",,"January 24, 2017","City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT01837667
171,NCT01837667,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Phase I Study of LB-100 With Docetaxel in Solid Tumors,Completed,No Results Available,Tumors|Neoplasms|Cancer,Drug: LB-100 for Injection|Drug: Docetaxel,Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.,"Lixte Biotechnology Holdings, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,29.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L12-20661,February 2013,September 2016,September 2016,"April 23, 2013",,"January 24, 2017","City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT01837667
172,NCT01887197,DB12097,CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
173,NCT01887197,DB03206,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
174,NCT01887197,DB01592,[Fe],Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
175,NCT01887197,DB00742,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
176,NCT01887197,DB02399,C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
177,NCT01887197,DB14513,[MgH2],Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
178,NCT01887197,DB14154,[Au],Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
179,NCT01887197,DB16741,[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
180,NCT01887197,DB04733,O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O,Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
181,NCT01887197,DB01370,[Al],Repeatability and Response Study of Absorptive Clearance Scans,Completed,No Results Available,Cystic Fibrosis,Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder,absorptive clearance variability|absorptive clearance response,Tim Corcoran|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1RO1 HL108929-01 (B),June 2013,December 2017,May 2018,"June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01887197
182,NCT02406209,DB14629,CC(=O)OCC(F)(F)F,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
183,NCT02406209,DB00591,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
184,NCT02406209,DB14672,CC(=O)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
185,NCT02406209,DB14632,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
186,NCT02406209,DB00823,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
187,NCT02406209,DB13179,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
188,NCT02406209,DB01837,CC(=O)OC[C@H](N)C(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
189,NCT02406209,DB09378,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
190,NCT02406209,DB14646,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
191,NCT02406209,DB00426,CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
192,NCT02406209,DB01670,CCCOC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
193,NCT02406209,DB00597,[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
194,NCT02406209,DB02637,OC(=O)C(=O)CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
195,NCT02406209,DB00860,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
196,NCT02406209,DB13981,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
197,NCT02406209,DB15903,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
198,NCT02406209,DB07957,[H][C@](OC(C)=O)(C(=O)OC)C1=CC=C(N)C=C1C(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
199,NCT02406209,DB07955,NC1=CC(C=O)=C(CC(=O)OCCBr)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
200,NCT02406209,DB08497,[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
201,NCT02406209,DB00603,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
202,NCT02406209,DB14627,CC(=O)OC1=CC=C(C=C1)C1(C(=O)NC2=CC=CC=C12)C1=CC=C(OC(C)=O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
203,NCT02406209,DB06756,C[N+](C)(C)CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
204,NCT02406209,DB08753,CC(=O)OC1=CC=C(\C=C\C(=O)NCCC2=CC=CC=C2)C=C1OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
205,NCT02406209,DB14631,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
206,NCT02406209,DB03128,CC(=O)OCC[N+](C)(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
207,NCT02406209,DB05288,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
208,NCT02406209,DB13157,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
209,NCT02406209,DB14665,CC(=O)O[C@@H]1C[C@@H]2CC[C@@]1(C)C2(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
210,NCT02406209,DB15777,[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
211,NCT02406209,DB09144,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
212,NCT02406209,DB13910,[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
213,NCT02406209,DB08115,NCCOC(=O)CC1=C2C=CC=CC2=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
214,NCT02406209,DB14007,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
215,NCT02406209,DB00957,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
216,NCT02406209,DB04898,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
217,NCT02406209,DB04380,NC(=O)NC(NC(N)=O)C([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
218,NCT02406209,DB14498,[K+].CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
219,NCT02406209,DB09020,CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
220,NCT02406209,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
221,NCT02406209,DB14679,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(OC4CCCC4)=CC3=CC[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
222,NCT02406209,DB06781,[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
223,NCT02406209,DB00959,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
224,NCT02406209,DB06736,OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
225,NCT02406209,DB12112,CC(=O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
226,NCT02406209,DB15957,CC(=O)OC(C)(C)C1CCC(C)=CC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
227,NCT02406209,DB14659,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
228,NCT02406209,DB00443,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
229,NCT02406209,DB11509,[Cu++].NCC([O-])=O.NCC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
230,NCT02406209,DB01918,C[Te]CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
231,NCT02406209,DB07950,OC(=O)CC1=CNC2=CC=CC=C12,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
232,NCT02406209,DB14634,[H][C@@]12CC(=C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
233,NCT02406209,DB15679,CC(=O)O[Al](O)OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
234,NCT02406209,DB00620,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
235,NCT02406209,DB00945,CC(=O)OC1=CC=CC=C1C(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
236,NCT02406209,DB16005,CC(=O)OCC(COC(C)=O)OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
237,NCT02406209,DB08806,CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
238,NCT02406209,DB01562,CC(=O)OC1(CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
239,NCT02406209,DB00769,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
240,NCT02406209,DB14633,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
241,NCT02406209,DB01380,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
242,NCT02406209,DB13958,[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C[C@@H](C)[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
243,NCT02406209,DB01260,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
244,NCT02406209,DB14599,[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
245,NCT02406209,DB00422,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
246,NCT02406209,DB00511,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
247,NCT02406209,DB01433,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
248,NCT02406209,DB15202,OC(=O)C[18F],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
249,NCT02406209,DB14643,[H][C@@]12CC[C@](OC(=O)CC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
250,NCT02406209,DB01227,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
251,NCT02406209,DB14487,[Zn++].CC([O-])=O.CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
252,NCT02406209,DB14626,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
253,NCT02406209,DB11522,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
254,NCT02406209,DB15999,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCCCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
255,NCT02406209,DB14673,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
256,NCT02406209,DB04839,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
257,NCT02406209,DB14637,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
258,NCT02406209,DB08014,CCOC(=O)C1=CC=C(OCCCCC2CCN(CC2)C2=NN=C(C)C=C2)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
259,NCT02406209,DB08152,[H][C@@]1(COC(=O)CC2=CC(Cl)=CC=C2)CCCN1C(=O)CNC(=O)OC(C)(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
260,NCT02406209,DB14640,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
261,NCT02406209,DB02176,CC(=O)O[Hg+],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
262,NCT02406209,DB06703,OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
263,NCT02406209,DB13996,[Mg++].CC([O-])=O.CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
264,NCT02406209,DB14657,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
265,NCT02406209,DB14662,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
266,NCT02406209,DB15927,CCCCCOC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
267,NCT02406209,DB15566,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
268,NCT02406209,DB03040,OC(=O)CN(CC(O)=O)CC(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
269,NCT02406209,DB08498,[H][C@@](OC(C)=O)(C(=O)NC1=CC=CC2=C1C(=O)C(=O)NC2=O)C1=CC=CC(Cl)=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
270,NCT02406209,DB05253,[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
271,NCT02406209,DB08809,OC(=O)C(Cl)Cl,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
272,NCT02406209,DB14668,C\C=C(\C(=C\C)\C1=CC=C(OC(C)=O)C=C1)/C1=CC=C(OC(C)=O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
273,NCT02406209,DB00995,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
274,NCT02406209,DB00258,[Ca++].CC([O-])=O.CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
275,NCT02406209,DB15984,[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
276,NCT02406209,DB14002,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
277,NCT02406209,DB14583,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
278,NCT02406209,DB09119,CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
279,NCT02406209,DB13657,CC(=O)NC1=CC=C(OC(=O)C2=CC=CC=C2OC(C)=O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
280,NCT02406209,DB16474,CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
281,NCT02406209,DB00979,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
282,NCT02406209,DB00351,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
283,NCT02406209,DB14539,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
284,NCT02406209,DB15480,CC(=O)OC1=CC(O)=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
285,NCT02406209,DB14649,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
286,NCT02406209,DB14654,CC(=O)OC1=CC=C(C=C1)C1(OC2=C(NC1=O)C=CC=C2)C1=CC=C(OC(C)=O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
287,NCT02406209,DB00343,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
288,NCT02406209,DB08794,CCOC(=O)C(C1=C(O)C2=CC=CC=C2OC1=O)C1=C(O)C2=CC=CC=C2OC1=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
289,NCT02406209,DB14518,[Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
290,NCT02406209,DB13141,CN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O.NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@H](O)CC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
291,NCT02406209,DB04308,[H][C@](N)(C(O)=O)C1=CC=C(O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
292,NCT02406209,DB13280,[Al+3].CC(=O)CC([O-])=O.CC(=O)CC([O-])=O.CC(=O)CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
293,NCT02406209,DB13952,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
294,NCT02406209,DB13381,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
295,NCT02406209,DB13626,O.[OH-].[OH-].[Al+3].NCC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
296,NCT02406209,DB03045,CC(=O)OCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COC(=O)C(C)(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
297,NCT02406209,DB05442,[H][C@@]12CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
298,NCT02406209,DB00890,[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
299,NCT02406209,DB14652,[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
300,NCT02406209,DB09395,[Na+].CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
301,NCT02406209,DB01134,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
302,NCT02406209,DB14511,CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
303,NCT02406209,DB06701,[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
304,NCT02406209,DB09409,O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
305,NCT02406209,DB14671,CN1C2=CC=C(Cl)C=C2C(=NC(OC(C)=O)C1=O)C1=CC=CC=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
306,NCT02406209,DB14648,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@H](CC(=O)O3)OC(C)=O)[C@@H]12,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
307,NCT02406209,DB06780,[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
308,NCT02406209,DB13951,[H][C@@]12CC[C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
309,NCT02406209,DB02419,CCOC(=O)C(=O)N1CCCCC1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
310,NCT02406209,DB14625,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
311,NCT02406209,DB14660,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CCC4=C3C=C[C@]12C)OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
312,NCT02406209,DB00974,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
313,NCT02406209,DB01452,[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
314,NCT02406209,DB01469,[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
315,NCT02406209,DB09137,[Tc].CC1=CC(C)=C(Br)C(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
316,NCT02406209,DB14644,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
317,NCT02406209,DB12187,NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](COC(=O)CO)C=C3)C2=N1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
318,NCT02406209,DB08013,CCOC(=O)C1=CC=C(OCCCC2CCN(CC2)C2=NN=C(C)C=C2)C=C1,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
319,NCT02406209,DB00240,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
320,NCT02406209,DB03517,CSCC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
321,NCT02406209,DB03098,C[Se]CC([O-])=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
322,NCT02406209,DB01234,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
323,NCT02406209,DB01321,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
324,NCT02406209,DB15111,C[11C](O)=O,A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis,Completed,No Results Available,Non-infectious Anterior Uveitis,Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%),Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability,"Aldeyra Therapeutics, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,45.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS2-02,March 2015,April 2016,April 2016,"April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02406209
325,NCT04682444,DB13666,[I-].C[N+]1(CCC(O)(C2=CC=CS2)C2=CC=CC=C2)CCOCC1,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
326,NCT04682444,DB04445,I[Hg]I,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
327,NCT04682444,DB13702,[I-].CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2N=C(C1)C1=CC=C(SC2=CC=CC=C2)C=C1,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
328,NCT04682444,DB13769,[I-].CC[N+](C)(CC)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
329,NCT04682444,DB14492,[K+].I[I-]I,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
330,NCT04682444,DB09420,[123I-],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
331,NCT04682444,DB15961,I[Zn]I,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
332,NCT04682444,DB12754,[I-],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
333,NCT04682444,DB01057,CCOP(=O)(OCC)SCC[N+](C)(C)C,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
334,NCT04682444,DB02252,IC1=CC=CC=C1,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
335,NCT04682444,DB00483,[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
336,NCT04682444,DB15778,I[H],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
337,NCT04682444,DB06715,[K+].[I-],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
338,NCT04682444,DB13813,[H]C(I)(I)I,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
339,NCT04682444,DB09293,[131I-],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
340,NCT04682444,DB00416,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
341,NCT04682444,DB11119,[Na+].[I-],"Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",Completed,No Results Available,Acute Respiratory Viral Infections|Human Influenza,Drug: Enisamium Iodide|Drug: Placebo,Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status,"Joint Stock Company ""Farmak""",All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AM-STP-2-2008,"April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,https://ClinicalTrials.gov/show/NCT04682444
342,NCT02439216,DB15010,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)C1=C(O)C=CC=C1,Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy,Completed,No Results Available,"Muscular Dystrophy, Duchenne",Drug: Edasalonexent|Drug: Placebo,"Safety and tolerability (Adverse Events)|Muscle composition and inflammation as measured by MRI|Physical function, muscle strength, and parent/proxy reported physical functioning/quality of life|Edasalonexent PK and PD measures",Catabasis Pharmaceuticals,Male,4 Years to 7 Years   (Child),Phase 1|Phase 2,31.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CAT-1004-201,April 2016,"January 12, 2017",August 2019,"May 8, 2015",,"November 15, 2019","Los Angeles, California, United States|Gainesville, Florida, United States|Orlando, Florida, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02439216
343,NCT02029716,DB01857,N[C@@H](CC(=O)OP(O)(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
344,NCT02029716,DB00303,[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
345,NCT02029716,DB13775,CC(C)(C)NCC(O)COC1=CC=CC2=C1SCCC2,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
346,NCT02029716,DB14914,[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
347,NCT02029716,DB15033,FC1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
348,NCT02029716,DB00174,N[C@@H](CC(N)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
349,NCT02029716,DB00796,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
350,NCT02029716,DB00966,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
351,NCT02029716,DB01349,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
352,NCT02029716,DB01694,O[C@@H]([C@H](O)C(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
353,NCT02029716,DB13220,[Fe++].N[C@@H](CC([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
354,NCT02029716,DB04785,[H][C@@]1([C@H](C)C(=O)NC)N([C@@H]2CC[C@H](O)[C@H](C)O2)C(=O)\C(=C(\O)/C=C/C(/C)=C/[C@@H](C)[C@@]2([H])O[C@@]3(C)O[C@H](C=C[C@@]33CO3)[C@@H]2C)C1=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
355,NCT02029716,DB15993,N[C@@H](CC(O)=O)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
356,NCT02029716,DB16619,[Mg++].Cl.N[C@@H](CC([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
357,NCT02029716,DB15819,[H+].[H+].O.[K+].[K+].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
358,NCT02029716,DB14646,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
359,NCT02029716,DB12081,C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
360,NCT02029716,DB13664,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CC(C=O)=C4C=C(CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C)OCCCl,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
361,NCT02029716,DB13359,O.O.O.O.[Mg++].N[C@@H](CC(O)=O)C([O-])=O.N[C@@H](CC(O)=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
362,NCT02029716,DB00860,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
363,NCT02029716,DB15587,O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-][C@H]([C@@H]([O-])C([O-])=O)C([O-])=O.[O-][C@H]([C@@H]([O-])C([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
364,NCT02029716,DB04156,N[C@@H](CC(=O)O[Be--](F)(F)F)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
365,NCT02029716,DB13707,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
366,NCT02029716,DB01153,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
367,NCT02029716,DB06455,COC1=CC=CC(OC)=C1C1=CC(=NN1C1=C2C=CC(Cl)=CC2=NC=C1)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
368,NCT02029716,DB09459,O[C@H]([C@@H](O)C(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
369,NCT02029716,DB09187,CN1CCC23NC(=O)CC(C2C1)C1=CC(Cl)=CC=C1O3,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
370,NCT02029716,DB04498,[H][C@@](N)(CC=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
371,NCT02029716,DB00769,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
372,NCT02029716,DB01029,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
373,NCT02029716,DB00370,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
374,NCT02029716,DB00168,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
375,NCT02029716,DB05288,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
376,NCT02029716,DB13919,CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
377,NCT02029716,DB04538,C[C@@H]([C@H](N)C(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
378,NCT02029716,DB01347,CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
379,NCT02029716,DB15998,[K+].NC(CC([O-])=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
380,NCT02029716,DB06678,[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
381,NCT02029716,DB00876,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
382,NCT02029716,DB09279,CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
383,NCT02029716,DB14756,O[C@@H]([C@@H](O)C(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
384,NCT02029716,DB11669,CC(C)C[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@H]1[C@@H]2OC(=O)O[C@@]22[C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
385,NCT02029716,DB00177,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
386,NCT02029716,DB16006,[Zn++].[NH3+]C(CC([O-])=O)C([O-])=O.[NH3+]C(CC([O-])=O)C([O-])=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
387,NCT02029716,DB00275,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
388,NCT02029716,DB00310,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
389,NCT02029716,DB01342,CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
390,NCT02029716,DB00128,N[C@@H](CC(O)=O)C(O)=O,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
391,NCT02029716,DB00678,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
392,NCT02029716,DB08822,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1,RTA 408 Lotion in Healthy Volunteers,Completed,No Results Available,Healthy,"Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo",Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle,"Reata Pharmaceuticals, Inc.|AbbVie",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,109.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RTA 408-C-1305,December 2013,April 2014,April 2014,"January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02029716
393,NCT03243838,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,Completed,No Results Available,Triple-Negative Breast Cancer,Drug: Apatinib,The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0)|Objective response rate (ORR)|Event-free survival (EFS)|Overall survival (OS)|Adverse events,Guangdong Provincial People's Hospital,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,31.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170328,"August 1, 2018","October 13, 2021","December 31, 2021","August 9, 2017",,"February 2, 2022","Guangdong general hospital, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT03243838
394,NCT03243838,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,Completed,No Results Available,Triple-Negative Breast Cancer,Drug: Apatinib,The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0)|Objective response rate (ORR)|Event-free survival (EFS)|Overall survival (OS)|Adverse events,Guangdong Provincial People's Hospital,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,31.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170328,"August 1, 2018","October 13, 2021","December 31, 2021","August 9, 2017",,"February 2, 2022","Guangdong general hospital, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT03243838
395,NCT01666444,DB06420,C[C@@H]1O[C@@H](O[C@H]2C[C@@](O)(CC3=C2C(O)=C2C(=O)C4=CC=CC=C4C(=O)C2=C3O)C(=O)CO)[C@H](I)[C@H](O)[C@H]1O,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
396,NCT01666444,DB06013,COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
397,NCT01666444,DB05706,COC1=C2C(=O)C3=C(O)C4=C(C[C@@](O)(CCO)C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(O)=C3C(=O)C2=CC=C1,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
398,NCT01666444,DB00681,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
399,NCT01666444,DB00997,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
400,NCT01666444,DB11616,[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
401,NCT01666444,DB12755,[H]OC[C@H](NC(=O)[C@H](CC1=CN([H])C2=C1C=CC=C2)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O[H])C=C1)C(=O)N[C@H](CCCCNC(=O)CCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@@]2([H])C[C@H](N)[C@H](O)[C@H](C)O2)C2=C(O)C3=C(C(O)=C2C1)C(=O)C1=CC=CC(OC)=C1C3=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,"VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Completed,Has Results,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo,Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs),Celgene|Gynecologic Oncology Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,297.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GOG-3003,"October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01666444
402,NCT03359018,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma,Completed,No Results Available,Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity,Drug: Apatinib|Drug: SHR-1210,progression-free survival|clinical benefit rate|overall survival,"Peking University People's Hospital|Jiangsu HengRui Medicine Co., Ltd.",All,"11 Years and older   (Child, Adult, Older Adult)",Phase 2,43.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKUPH-sarcoma 02,"January 1, 2018","October 22, 2019","January 30, 2020","December 2, 2017",,"May 19, 2020","Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, China|Peking University Shougang Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03359018/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03359018
403,NCT03359018,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma,Completed,No Results Available,Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity,Drug: Apatinib|Drug: SHR-1210,progression-free survival|clinical benefit rate|overall survival,"Peking University People's Hospital|Jiangsu HengRui Medicine Co., Ltd.",All,"11 Years and older   (Child, Adult, Older Adult)",Phase 2,43.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKUPH-sarcoma 02,"January 1, 2018","October 22, 2019","January 30, 2020","December 2, 2017",,"May 19, 2020","Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, China|Peking University Shougang Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03359018/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03359018
404,NCT03765554,DB09099,C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
405,NCT03765554,DB03371,[H][C@](N)(CCC(=O)O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]1(O)F)C(O)=O,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
406,NCT03765554,DB15003,CN1C=C(NC2=NC=CC(=N2)N2C[C@@H]3CC[C@H](C2)N3C(=O)[C@@H]2CC2(F)F)C=N1,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
407,NCT03765554,DB03617,[H][C@]1(C)O[C@]([H])(O[C@]2([H])[C@@]([H])(CO)O[C@]([H])(O[C@]3([H])C(CO)=C[C@]([H])(N[C@]4([H])[C@@]([H])(C)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O[C@]6([H])[C@@]([H])(C)O[C@@]([H])(O)[C@]([H])(O)[C@@]6([H])O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
408,NCT03765554,DB04439,[H][C@]1(C)O[C@]([H])(O[C@]2([H])C(CO)=C[C@]([H])(N[C@]3([H])[C@@]([H])(C)O[C@]([H])(O[C@]4([H])[C@@]([H])(CO)O[C@]([H])(O[C@]5([H])[C@@]([H])(CO)O[C@]([H])(O)[C@]([H])(O)[C@@]5([H])O)[C@]([H])(O)[C@@]4([H])O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]([H])(O)[C@]1([H])O,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
409,NCT03765554,DB16403,[H][C@@]1(O[C@@H](OC2=C(OC3=C(C(O)=CC(O)=C3)C2=O)C2=CC=C(O)C(O)=C2)[C@H](O)[C@H]1O)[C@H](O)CO,Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations,Completed,No Results Available,Healthy Participants,Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets,"Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs",Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,8.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,B7931010|2018-003512-41,"January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03765554
410,NCT02342587,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer,Completed,No Results Available,HER2-positive Refractory Advanced Cancer,Drug: Lapatinib,overall response rate,Samsung Medical Center,All,"20 Years and older   (Adult, Older Adult)",Phase 2,7.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-10-028,"December 3, 2014",January 2016,"August 21, 2016","January 21, 2015",,"February 17, 2017","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02342587
411,NCT00566410,DB08809,OC(=O)C(Cl)Cl,"A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours",Completed,No Results Available,Neoplasms,Drug: Dichloroacetate,To assess safety and tolerability of oral DCA|To determine the dose-limiting toxicity (DLT) and phase II dose|To characterize pharmacokinetic (PK) profile|To evaluate the effect of oral DCA|To evaluate the clinical response rate|To evaluate the change in standard uptake value by FDG-PET scans before and after treatment with DCA,AHS Cancer Control Alberta|Cross Cancer Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,23.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,23596,December 2007,March 2013,March 2013,"December 3, 2007",,"March 11, 2016","Cross Cancer Institute, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00566410
412,NCT02436408,DB08828,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1,VISmodegib for ORbital and Periocular Basal Cell Carcinoma,Completed,Has Results,"Carcinoma, Basal Cell",Drug: Vismodegib,"The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS).|Number of Patients With Progressive Disease (PD)|Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Good Tolerance of Vismodegib|Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Poor Tolerance of Vismodegib",University of Michigan Rogel Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 4,35.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UMCC 2014.022|HUM00082579,"July 15, 2015",September 2020,September 2020,"May 6, 2015","October 28, 2021","October 28, 2021","University of Michigan Hospital, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02436408/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02436408
413,NCT04682873,DB13666,[I-].C[N+]1(CCC(O)(C2=CC=CS2)C2=CC=CC=C2)CCOCC1,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
414,NCT04682873,DB04445,I[Hg]I,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
415,NCT04682873,DB13702,[I-].CC[N+](C)(CC)CCSC1=NC2=CC=CC=C2N=C(C1)C1=CC=C(SC2=CC=CC=C2)C=C1,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
416,NCT04682873,DB13769,[I-].CC[N+](C)(CC)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
417,NCT04682873,DB14492,[K+].I[I-]I,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
418,NCT04682873,DB09420,[123I-],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
419,NCT04682873,DB15961,I[Zn]I,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
420,NCT04682873,DB12754,[I-],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
421,NCT04682873,DB01057,CCOP(=O)(OCC)SCC[N+](C)(C)C,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
422,NCT04682873,DB02252,IC1=CC=CC=C1,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
423,NCT04682873,DB00483,[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
424,NCT04682873,DB15778,I[H],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
425,NCT04682873,DB06715,[K+].[I-],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
426,NCT04682873,DB13813,[H]C(I)(I)I,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
427,NCT04682873,DB09293,[131I-],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
428,NCT04682873,DB00416,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
429,NCT04682873,DB11119,[Na+].[I-],"A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",Completed,No Results Available,Covid-19 Disease,Drug: Enisamium Iodide|Drug: Placebo,"Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,592.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FK/FAV00А-CoV/2020,"May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,https://ClinicalTrials.gov/show/NCT04682873
430,NCT01609595,DB07665,[H]N([H])C(=NOCCN([H])C(=O)CC1=C(C=CC(N([H])CC(F)(F)C2=CC=CC=N2)=C1F)C#N)N([H])[H],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
431,NCT01609595,DB14629,CC(=O)OCC(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
432,NCT01609595,DB07638,[H][C@@]12CC(F)(F)C[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
433,NCT01609595,DB07520,[H][C@@](CS(=O)(=O)N1CCOCC1)(N[C@@]([H])(C1=CC=C(F)C=C1)C(F)(F)F)C(=O)NC1(CN)CC1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
434,NCT01609595,DB11397,COP(=O)(OC)OC=C(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
435,NCT01609595,DB13911,[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C1C=C(Br)C([O-])=C2Br,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
436,NCT01609595,DB09153,[Na+].[Cl-],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
437,NCT01609595,DB07316,C[C@](O)(C1=CC=C(C=C1)C(=O)N(C1CC1)C1CCN(CC2(CC2)C(N)=O)CC1)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
438,NCT01609595,DB03648,[H]N([H])CCCC[C@H](N([H])C(=O)[C@@H](CCCC)CN([H])N([H])C[C@@H](CCCC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])C1=CC=CC=C1)C(=O)N([H])C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
439,NCT01609595,DB07159,COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
440,NCT01609595,DB09449,[Na+].OP(O)([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
441,NCT01609595,DB14496,[Na+].[Na+].[O-][Mo]([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
442,NCT01609595,DB08227,CC1(C)CC(CC(C)(C)N1O)N1C(=O)CCC1=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
443,NCT01609595,DB08617,[H][C@](N)(CC1=CC=C(CC(F)(F)F)C=C1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
444,NCT01609595,DB09072,[Na+].OCCCC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
445,NCT01609595,DB09276,[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
446,NCT01609595,DB00464,[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
447,NCT01609595,DB07174,CCC1=C(C(N)=NC(N)=N1)C1=CC=C2OC(C)(C)C(=O)N(CCCOC)C2=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
448,NCT01609595,DB00597,[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
449,NCT01609595,DB02118,[H][C@@]1(CN(CC2=CC=CC=C2)C(=O)CO1)C1=CC2=C(C=C1)N(C)S(=O)(=O)C2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
450,NCT01609595,DB05592,CN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
451,NCT01609595,DB08124,O=C1NC2=CC=C(C=C2\C1=C\NC1=CC2=C(CS(=O)(=O)C2)C=C1)C1=CN=CO1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
452,NCT01609595,DB01583,[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
453,NCT01609595,DB14516,[Na+],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
454,NCT01609595,DB03678,C[C@H](NC1=NC=NC2=C1C=C(F)C(F)=C2)C(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
455,NCT01609595,DB14505,[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
456,NCT01609595,DB13157,[Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
457,NCT01609595,DB00888,CN(CCCl)CCCl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
458,NCT01609595,DB07821,[H][C@](C)(O[P@]([H])(C)=O)C(C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
459,NCT01609595,DB00628,OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
460,NCT01609595,DB01081,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
461,NCT01609595,DB13937,CCC1=C(C)C2=C(C=CC3=C2C(Cl)=CC(=O)N3)N1CC(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
462,NCT01609595,DB07127,CC1=NC(=NO1)C(CC1=CC=CC=C1)(CC1=CC=C(NS(O)(=O)=O)C=C1)C1=NOC(C)=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
463,NCT01609595,DB15842,[Na+].[Na+].[O-]S(=O)S([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
464,NCT01609595,DB11932,CC1=CC=C(N=C1)C1=CC=C(C)C=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
465,NCT01609595,DB07549,CC1=C[NH+]=C(NCC(F)(F)C2=[NH+]C=CC=C2)C(=O)N1CC(=O)NCC1=C(F)C(C)=CC=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
466,NCT01609595,DB14702,[Na+].[O-][V](=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
467,NCT01609595,DB00587,CCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
468,NCT01609595,DB05351,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
469,NCT01609595,DB01199,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
470,NCT01609595,DB15908,[OH-].[Na+].[Al+3].[O-]C([O-])=O.OCC(O)C(O)C(O)C(O)CO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
471,NCT01609595,DB08408,[H][C@](O)(C(=O)NCCC(=O)NCCS)C(C)(C)COC(=O)C(C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
472,NCT01609595,DB03588,OC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
473,NCT01609595,DB00815,[Na+].CCCCCCCCCCCCOS([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
474,NCT01609595,DB03429,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)COP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
475,NCT01609595,DB07805,CC(C)(CCl)C(=O)NC1=CC=C(C=C1)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
476,NCT01609595,DB00641,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
477,NCT01609595,DB07121,[H][C@]1(N(CCSC1(C)C)S(=O)(=O)C1=CC=C(OCC#CCN)C=C1)C(=O)NO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
478,NCT01609595,DB07515,CC1N[C@@H](N)CCC1CNCCN1C(O)C(NCC(F)(F)C2=CC=CC=N2)=NC=C1Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
479,NCT01609595,DB11590,[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
480,NCT01609595,DB00559,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
481,NCT01609595,DB11493,[Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
482,NCT01609595,DB13743,O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([S-])(=O)=O.[O-]S([S-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
483,NCT01609595,DB01635,CC1(C)N[C@@H](CS1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
484,NCT01609595,DB14015,[Na+].OS([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
485,NCT01609595,DB00771,C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
486,NCT01609595,DB09332,[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
487,NCT01609595,DB07059,CCC1=NC(N)=NC(N)=C1C1=CC2=C(OC(C)(C)C(=O)N2CCNC(C)=O)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
488,NCT01609595,DB07530,[H][C@]1(CC[C@](C)(CCC#CC(O)(C(F)(F)F)C(F)(F)F)C1(C)C)\C=C\C=C1C[C@](O)([H])C[C@@](O)([H])C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
489,NCT01609595,DB13771,[Na+].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
490,NCT01609595,DB09531,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
491,NCT01609595,DB15950,[Na+].[H][C@]12CC[C@@](CS([O-])(=O)=O)(C(=O)C1)C2(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
492,NCT01609595,DB08676,[H][C@]12CCN(C1=O)C1=CC=CC3=C1C=C(OC1([H])CC(CN4C=NC=C4CCN2)=CC[C@]1([H])C#N)C=C3,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
493,NCT01609595,DB13707,[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
494,NCT01609595,DB08217,CC1(C)C=C(CSS(C)(=O)=O)C(C)(C)N1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
495,NCT01609595,DB14201,S(SC1=NC2=CC=CC=C2S1)C1=NC2=CC=CC=C2S1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
496,NCT01609595,DB03546,[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(C=C1)[C@@]([H])(CCCC1C(O)=N[C@]([H])(N)N[C@]1([H])N)C(O)(O)C(F)(F)F)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
497,NCT01609595,DB07903,CC(C)(C)C(=O)NC1=C(N=CC=C1)C(=O)NC1=NC=CS1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
498,NCT01609595,DB01189,FC(F)OC(F)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
499,NCT01609595,DB08089,FC(F)(F)CN(CC(F)(F)F)C1=CC2=C(NC(=O)C=C2C(F)(F)F)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
500,NCT01609595,DB09448,[Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1[123I],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
501,NCT01609595,DB02531,CC(C)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
502,NCT01609595,DB13404,[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
503,NCT01609595,DB04461,CC1=C2CC3=C(C)C(CCC(O)=O)=C(CC4=C(CCC(O)=O)C(C)=C(CC5=C(CCC(O)=O)C(C)=C(CC(N2)=C1CCC(O)=O)N5)N4)N3,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
504,NCT01609595,DB03232,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC=CC=C1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
505,NCT01609595,DB09561,[Na+].[Na+].OCC(O)COP([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
506,NCT01609595,DB09132,[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
507,NCT01609595,DB11151,[OH-].[Na+],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
508,NCT01609595,DB04258,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\C=C\C(O)(CC)CC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
509,NCT01609595,DB08613,OC(O)(C1=CC=C(S1)C(=O)N1CCN2C(C1)=NC=C2C1=CC=CC=C1)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
510,NCT01609595,DB11119,[Na+].[I-],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
511,NCT01609595,DB04930,CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
512,NCT01609595,DB07619,[H][C@@]1(CC[C@@]([H])(CC1)C1=CC=CN=C1)N(C1CC1)C(=O)C1=CC=C(C=C1)[C@](C)(O)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
513,NCT01609595,DB07624,[H][C@@]1(C)CN(CC2(CC2)C(N)=O)CCN1S(=O)(=O)C1=CC=C(C=C1)[C@](C)(O)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
514,NCT01609595,DB14599,[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
515,NCT01609595,DB11221,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
516,NCT01609595,DB03359,C[N+](C)(C)C1=CC=CC(=C1)C(O)(O)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
517,NCT01609595,DB09517,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
518,NCT01609595,DB01227,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
519,NCT01609595,DB07550,[O-][N+]1=CC=CC=C1C(F)(F)CNC1=NC=C(Cl)N(CC(=O)NCC2=C(F)C=CC=C2)C1=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
520,NCT01609595,DB07946,[H]N([H])C(=NOCCN([H])C(=O)CC1=C(Cl)C=CC(N([H])CC(F)(F)C2=CC=CC=C2)=C1F)N([H])[H],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
521,NCT01609595,DB08475,CC1(C)OC[C@@H](COP(O)(=O)CCCCC=C)O1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
522,NCT01609595,DB09460,[Na+].[Na+].[O-]C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
523,NCT01609595,DB16608,[Na+].[O-][Cl](=O)(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
524,NCT01609595,DB04722,C[C@@H](NC(=O)CC1=C(Cl)C=C\C(=N/CC(F)(F)C2=CC=CC=[N+]2[O-])N1O)C1=CC(Cl)=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
525,NCT01609595,DB01159,[H]C(Cl)(Br)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
526,NCT01609595,DB03226,OCC(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
527,NCT01609595,DB07383,[H][C@@](CC1=CC=CC=C1)(NC(C)=O)C(O)(O)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
528,NCT01609595,DB05630,O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
529,NCT01609595,DB09319,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC1=CC2=C(CCC2)C=C1)C1=CC=CC=C1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
530,NCT01609595,DB14105,[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
531,NCT01609595,DB02433,[H][C@@](O)(COP(O)(O)=O)[C@@]([H])(O)[C@]([H])(O)[C@]([H])(O)CN(CC(O)O)CP(O)(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
532,NCT01609595,DB01195,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
533,NCT01609595,DB09154,[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
534,NCT01609595,DB14598,[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
535,NCT01609595,DB01912,[Cl-].[Pt++].C1=CC=C(N=C1)C1=CC=CC(=N1)C1=CC=CC=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
536,NCT01609595,DB09380,[Na+].[Na+].[O-][51Cr]([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
537,NCT01609595,DB04813,OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
538,NCT01609595,DB06703,OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
539,NCT01609595,DB07068,CCOC(=O)C(CCNC(=O)OC(C)(C)C)(CC1=CC=C(NS(O)(=O)=O)C=C1)C(=O)OCC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
540,NCT01609595,DB06705,[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
541,NCT01609595,DB08456,CC1(C)N(O)C(C)(C)C(=C1CSS(C)(=O)=O)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
542,NCT01609595,DB14048,[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
543,NCT01609595,DB02935,COCCOCCOC,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
544,NCT01609595,DB03040,OC(=O)CN(CC(O)=O)CC(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
545,NCT01609595,DB09183,COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
546,NCT01609595,DB07094,NCC1=CC=C(S1)C1=CC=CS1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
547,NCT01609595,DB15951,[Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2NC3=CC4=NC5=CC(=CC=C5NC4=CC3=NC2=C1)S([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
548,NCT01609595,DB09484,[Na+].[Na+].[O-]P([O-])(F)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
549,NCT01609595,DB07964,[H][C@]1(N(CCSC1(C)C)S(=O)(=O)C1=CC=C(OCC#CC)C=C1)C(=O)NO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
550,NCT01609595,DB07548,[H]N(CC1=C(F)C=CC=N1)C(=O)CN1C(C)=CN=C(N([H])CC(F)(F)C2=CC=CC=N2)C1=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
551,NCT01609595,DB02650,[H]C(=O)C(Cl)(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
552,NCT01609595,DB07503,FC1(F)OC2=C(O1)C=C(\C=C1/SC(=O)NC1=O)C=C2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
553,NCT01609595,DB15952,[Na+].[O-][N+]([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
554,NCT01609595,DB00756,OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
555,NCT01609595,DB07589,[H][C@@](CS(=O)(=O)CC1=CC=CC=C1)(N[C@@]([H])(C1=CC=C(O)C=C1)C(F)(F)F)C(=O)NC1(CN)CC1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
556,NCT01609595,DB08548,CC1(C)OC[C@H](COP(O)(=O)CCCCC=C)O1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
557,NCT01609595,DB08733,[H][C@@](CNC(=O)C1=NC=CS1)(C(=O)NO)[C@@]([H])(CC(C)C)C(=O)N[C@]([H])(C(=O)NC)C(C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
558,NCT01609595,DB09280,CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
559,NCT01609595,DB00446,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
560,NCT01609595,DB13008,CC(C)(C)C1=CC(=CC=C1O)C(C)(C)C1=CC=C(O)C(=C1)C(C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
561,NCT01609595,DB14600,[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
562,NCT01609595,DB09370,[Na+].[Na+].O[32P]([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
563,NCT01609595,DB00330,CC[C@@H](CO)NCCN[C@@H](CC)CO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
564,NCT01609595,DB09472,[Na+].[Na+].[O-]S([O-])(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
565,NCT01609595,DB04591,[H][C@@]1(CCCCN1)C(F)(F)CNC1=NC=CC2=C1N=C(CC1=CC=CC=C1N1C=NC=N1)O2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
566,NCT01609595,DB05885,CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
567,NCT01609595,DB11396,OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
568,NCT01609595,DB08556,CC(=O)C1=CC=C(S1)C1=CC(NS(=O)(=O)C2=CC=C(C)C=C2C)=C(S1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
569,NCT01609595,DB13747,OCCN(CCO)CCO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
570,NCT01609595,DB13210,[Na+].[O-][Cl]=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
571,NCT01609595,DB14638,CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
572,NCT01609595,DB07271,N[C@@H](CC(=O)N1CCCNC(=O)C1CC(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
573,NCT01609595,DB15974,[Na+].[Na+].[Na+].O=S1(=O)O[Au]2(OS(=O)(=O)S2)S1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
574,NCT01609595,DB01563,OC(O)C(Cl)(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
575,NCT01609595,DB00202,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
576,NCT01609595,DB13381,[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
577,NCT01609595,DB08994,OCCN(CCO)C1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
578,NCT01609595,DB13957,COC1=CC(\C=N\N(C(=O)C(F)(F)F)C2=C(C)C=C(C)C=C2)=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
579,NCT01609595,DB14622,O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
580,NCT01609595,DB00556,FC(F)(F)C(F)(F)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
581,NCT01609595,DB00753,FC(F)OC(Cl)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
582,NCT01609595,DB07221,CCCCCCCCCCCC[P+](C)(C)CC(P(O)(O)=O)P(O)(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
583,NCT01609595,DB09325,[F-].[Na+],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
584,NCT01609595,DB01028,COC(F)(F)C(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
585,NCT01609595,DB09395,[Na+].CC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
586,NCT01609595,DB02946,CC[C@]1([C@@H](C)C1(Cl)Cl)C(=O)N[C@H](C)C1=CC=C(Cl)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
588,NCT01609595,DB15825,[Na+].O[Al+]O.[O-]C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
589,NCT01609595,DB01241,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
590,NCT01609595,DB07555,[H][C@](OCC[As+](C)(C)C)(C1=CC=CC=C1[N+](O)=O)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
591,NCT01609595,DB14038,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
592,NCT01609595,DB11159,[Na+].[Na+].[S--],"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
593,NCT01609595,DB06888,[H][C@]12CN(CCN3NC4=C(C=CC=C4C3=O)C3=NC4=C(NC3=O)C=CC=C4O1)[C@]([H])(C)C2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
594,NCT01609595,DB03871,[Ru+3].[N-]1C=CN=C1.C1=CC=C(N=C1)C1=CC=CC=N1.C1=CC=C(N=C1)C1=CC=CC=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
595,NCT01609595,DB01529,C[C@H](CN1CCOCC1)C(C(=O)N1CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
596,NCT01609595,DB07034,ON=C1C2=CC(OCC(O)=O)=CC=C2C2=C1C=C(OCC(O)=O)C=C2,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
597,NCT01609595,DB07036,[H][C@@]12CC(F)(F)C[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1COC)C1=CC=C(O)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
598,NCT01609595,DB07082,OC(C1=CC=C(NCC(F)(F)F)C=C1)(C(F)(F)F)C(F)(F)F,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
599,NCT01609595,DB07587,[H][C@@](CS(=O)(=O)C[C@]1([H])CCC(=O)N1)(N[C@@]([H])(C1=CC=C(F)C=C1)C(F)(F)F)C(=O)NC1(CC1)C#N,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
600,NCT01609595,DB09382,[Na+].[O-]C(=O)CNC(=O)C1=C([131I])C=CC=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
601,NCT01609595,DB14502,[Na+].[Na+].OP([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
602,NCT01609595,DB06899,CCC1=NC(N)=NC(N)=C1C1=CC=C2SC(C)(C)C(=O)N(CCNC(C)=O)C2=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
603,NCT01609595,DB02408,[H][C@](N)(CCCC)C(O)(O)CNC1CC1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
604,NCT01609595,DB06797,CCC(C)C(C)(COC(N)=O)COC(N)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
605,NCT01609595,DB00974,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
606,NCT01609595,DB01663,CC1=CC2=C3C=C(CCCCCCCCC(=O)N[C@H]4[C@H]5C[C@@H]6C[C@@H](C[C@H]4C6)C5)C=CN3[Ru++]34(N5C=CC=CC5=C5C=CC=CN35)(N3C=CC=CC3=C3C=CC=CN43)N2C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
607,NCT01609595,DB04458,CC(NC(=O)[C@@]1([C@@H](C)C1(Cl)Cl)[S@](C)=O)C1=CC=C(Br)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
608,NCT01609595,DB11473,COP(=O)(OC)C(O)C(Cl)(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
609,NCT01609595,DB01390,[Na+].OC([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
610,NCT01609595,DB01597,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
611,NCT01609595,DB11413,CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
612,NCT01609595,DB08373,CS(=O)(=O)C1=CC(Cl)=C(C=C1Cl)C1=C(Cl)C=C(C(Cl)=C1)S(C)(=O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
613,NCT01609595,DB02350,[H][C@@]1(N(CCCSC1(C)C)S(=O)(=O)C1=CC=C(OC)C=C1)C(=O)NO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
614,NCT01609595,DB07559,C\C(O)=C(/C#N)C(=O)NC1=CC(Cl)=C(C=C1)C1=CC=CC=C1Cl,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
615,NCT01609595,DB00385,[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
616,NCT01609595,DB00739,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
617,NCT01609595,DB00921,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
618,NCT01609595,DB16585,[Na+].[Na+].[Na+].[K+].[K+].[K+].[H]O[H].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
619,NCT01609595,DB08270,[H][C@@](CC(C)C)(N[C@@]([H])(C1=CC=C(C=C1)C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F)C(=O)NCCN,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
620,NCT01609595,DB15835,[Na+].[Na+].[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COP([O-])([O-])=O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
621,NCT01609595,DB04627,OC[C@H]1O[C@@H]2[C@@H](OC3=NC(=O)C=CN23)[C@@H]1O,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
622,NCT01609595,DB14083,CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
623,NCT01609595,DB07756,CC1=C(CSCC2=CC(=CC=C2)C(O)(O)C(F)(F)F)C(N)=C2C(F)=CC=CC2=N1,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
624,NCT01609595,DB14482,[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO,"Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",Completed,No Results Available,Beta Thalassemia Intermedia,"Drug: sodium 2,2 dimethylbutyrate",The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.,Boston University|Mahidol University,All,18 Years to 55 Years   (Adult),Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ST20-P2T|HQK-1001-Thal P2,March 2012,November 2012,December 2012,"June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,https://ClinicalTrials.gov/show/NCT01609595
625,NCT01538238,DB06589,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,"pazopanib_NCRCC,Ph2 STUDY",Completed,No Results Available,Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma,Drug: pazopanib,Overall response rates|Progression-free survival|Overall survival|Number of Adverse Events|Exploratory analysis,Samsung Medical Center,All,"19 Years and older   (Adult, Older Adult)",Phase 2,10.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012-01-056,"May 2, 2012","February 28, 2015","November 14, 2015","February 24, 2012",,"April 26, 2017","Samsung medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01538238
626,NCT03010982,DB12887,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,"Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",Completed,No Results Available,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Advanced Solid Tumors,Drug: Tazemetostat and [14C] Tazemetostat,"Plasma PK of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 after IV administration of approximately 12 µg of [14C] tazemetostat containing approximately 500 nCi of radioactivity and oral BID administration of 800 mg tazemetostat (AUC 0-7)|Total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Estimate tazemetostat absolute bioavailability (F) after repeated oral administration of 800 mg BID (AUC 0-12 and AUC 0-~)|Compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14C] tazemetostat (AUC 0-t, AUC 0-12, AUC 0-~)|Determine peak plasma concentration (Cmax) after oral administration of [14C] tazemetostat|Determine the plasma terminal half-life (t1/2) after oral administration of [14C] tazemetostat|Plasma PK of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity (Plasma AUC 0-t, AUC 0-12)|Determine the peak plasma concentration (Cmax) of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Determine the time to peak plasma concentration (Tmax) tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,3.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-103,"June 20, 2018","January 8, 2019","January 8, 2019","January 5, 2017",,"January 13, 2020","The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom",,https://ClinicalTrials.gov/show/NCT03010982
627,NCT03964558,DB14492,[K+].I[I-]I,"Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)",Completed,No Results Available,Heathy Volunteers,Drug: [14C]-acebilustat solution,"Mass balance recovery of total radioactivity in all excreta: amount excreted (Ae) and Ae as a percentage of the administered dose (%Ae), cumulative recovery (CumAe), and cumulative recovery expressed as a percentage of the administered dose (Cum%Ae)","Celtaxsys, Inc.|Quotient Sciences",Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CTX-4430-ADME-101,"April 1, 2019","April 14, 2019","April 14, 2019","May 28, 2019",,"May 30, 2019","Quotient Sciences, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03964558
628,NCT03964558,DB03843,[H]C([H])=O,"Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)",Completed,No Results Available,Heathy Volunteers,Drug: [14C]-acebilustat solution,"Mass balance recovery of total radioactivity in all excreta: amount excreted (Ae) and Ae as a percentage of the administered dose (%Ae), cumulative recovery (CumAe), and cumulative recovery expressed as a percentage of the administered dose (Cum%Ae)","Celtaxsys, Inc.|Quotient Sciences",Male,"30 Years to 65 Years   (Adult, Older Adult)",Phase 1,6.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CTX-4430-ADME-101,"April 1, 2019","April 14, 2019","April 14, 2019","May 28, 2019",,"May 30, 2019","Quotient Sciences, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03964558
629,NCT00543049,DB01268,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,"Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor",Completed,No Results Available,Platinum Refractory Epithelial Ovarian Cancer|Primary Cancer of the Peritoneum|Cancer of the Fallopian Tube,Drug: Sunitinib|Drug: SUNITINIB,"objective response rate|tolerability and toxicity, overall survival, duration of response, time to progression, stable disease",AGO Study Group|Philipps University Marburg Medical Center|HSK Reasearch GmbH Wiesbaden,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,73.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AGO-OVAR 2.11,September 2007,June 2012,,"October 12, 2007",,"March 7, 2014","Malterser-Krankenhaus Bonn-Rhein/Sieg, Frauenklinik, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Frauenklinik, Bremen, Germany|Universitätsklinikum Carl Gustav Carus, Klinik u. Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany|Universitätsklinikum, Universitätsfrauenklinik, Essen, Germany|Klinikum der JWG Universität Frankfurt, Universitätsfrauenklinik, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Department Universitäts-Frauenklinik, Freiburg, Germany|Klinikum der Ernst-Moritz-Universität, Klinik u. Poliklinik für Gyn. - u. Geb.Hilfe, Greifswald, Germany|Med. Hochschule Hannover, Frauenklinik, Hannover, Germany|St. Vincentius Kliniken AG, Frauenklinik, Karlsruhe, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe, Kiel, Germany|Otto-von-Guericke-Universität, Klinik für Frauenheilkunde und Geburtshilfe, Magdeburg, Germany|Universitätsklinikum Gießen u. Marburg, Standort Marburg, Klinik f. Gynäkologie, Gyn. Endokrinologie u. Onkologie, Marburg, Germany|Elblandkliniken Meißen-Radebeul GmbH, Gynäkologie, Radebeul, Germany|Universitätsklinikum Tübingen, Frauenklinik, Tübingen, Germany|Universitätsklinikum, Universitätsfrauenklinik, Ulm, Germany|Dr. Horst Schmidt Kliniken GmbH, Klinik f. Gynäkologie u. Gyn. Onkologie, Wiesbaden, Germany",,https://ClinicalTrials.gov/show/NCT00543049
630,NCT01683994,DB14646,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
631,NCT01683994,DB15970,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
632,NCT01683994,DB12952,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
633,NCT01683994,DB09383,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
634,NCT01683994,DB00635,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
635,NCT01683994,DB08875,COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
636,NCT01683994,DB14625,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
637,NCT01683994,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone,Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,49.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120204|12-C-0204,"September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01683994
638,NCT03123016,DB05676,CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O,Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo,Completed,No Results Available,Vitiligo,Drug: Apremilast|Procedure: NB-UVB phototherapy,Change in proportion of responders to treatment from Week 16 to Week 32|Body Surface Area (BSA)|VASI score - Vitiligo Area and Severity Index (VASI)|VETF score - Vitiligo European Task Force (VETF) score|Dermatology Life Quality Index|Visual Analogue Scale (VAS)|Number of Adverse Events,Icahn School of Medicine at Mount Sinai|Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 2,23.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCO 16-1261,"April 14, 2017","August 5, 2019","August 5, 2019","April 21, 2017",,"August 28, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03123016
639,NCT02109328,DB12619,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
640,NCT02109328,DB12633,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
641,NCT02109328,DB05297,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
642,NCT02109328,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
643,NCT02109328,DB05220,COC1=CC(NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C2=C(OC)C=CC=C2F)=CC=C1C(O)=O,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
644,NCT02109328,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Alisertib in Chemotherapy-pretreated Urothelial Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Carcinoma,Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo,Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,"18 Years and older   (Adult, Older Adult)",Phase 2,22.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,UC-Aurora_INT01|2014-000557-36,"August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,https://ClinicalTrials.gov/show/NCT02109328
645,NCT01283945,DB11845,CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1,"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",Completed,No Results Available,Solid Tumors,Drug: Lucitanib,"Maximum Tolerated Dose (MTD)|Objective response rate (CR and PR according to RECIST) and rate of non-progressive disease at 24 weeks|Pharmacokinetics following single and multiple dose administration|Tumor perfusion measured by DCE MRI and DCE-US|Circulating markers of angiogenesis: VEGFR2, VEGFR1, VEGF, Collagen IV, bFGF, CEC and CEP|Tumor response according to RECIST; CTC|Safety profile and dose limiting toxicities (DLT)|Free tumor circulating DNA",Institut de Recherches Internationales Servier|Servier,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,134.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E-3810-I-01,July 2010,September 2016,"May 4, 2017","January 26, 2011",,"January 3, 2020","Institute Gustave Roussy, Villejuif, Paris, France|Hopital Louis Pradel, Lyon, France|European Institute of Oncology, Milano, Italy|Vall d' Hebron University Hospital, Barcellona, Spain",,https://ClinicalTrials.gov/show/NCT01283945
646,NCT00901563,DB13067,C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CC=C(O)C=C1)NC(C)=O)C(=O)NCC(N)=O,Gap Junction Potentiation of Endothelial Function With Rotigaptide,Completed,No Results Available,Vascular Disease|Heart Disease,Drug: Rotigaptide|Other: Forearm vascular study,Change in Substance P and ACh vasodilatation caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction|Change in Substance P induced t PA release caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction,University of Edinburgh|Chief Scientist Office of the Scottish Government|NHS Lothian,All,18 Years to 64 Years   (Adult),Not Applicable,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CZB/4/520/b,March 2009,"August 3, 2015","August 3, 2015","May 14, 2009",,"June 21, 2021","Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT00901563
647,NCT01824615,DB01268,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma,Completed,No Results Available,Ovarian Cancer|Adverse Effects,Drug: Sunitinib,Response rate,Cathay General Hospital,Female,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT99076|TGOG-101,January 2013,January 2016,January 2016,"April 5, 2013",,"July 18, 2018","Cathay General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01824615
648,NCT01210911,DB00331,CN(C)C(=N)NC(N)=N,Metformin Combined With Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo,Survival after 6 months|Progression free survival|Objective response rate|toxicity profile,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMCmedonc10/003,August 2010,February 2014,April 2014,"September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01210911
649,NCT01210911,DB00441,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,Metformin Combined With Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo,Survival after 6 months|Progression free survival|Objective response rate|toxicity profile,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMCmedonc10/003,August 2010,February 2014,April 2014,"September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01210911
650,NCT01210911,DB15057,C[C@H](NP(=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1,Metformin Combined With Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo,Survival after 6 months|Progression free survival|Objective response rate|toxicity profile,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMCmedonc10/003,August 2010,February 2014,April 2014,"September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01210911
651,NCT01210911,DB12564,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O,Metformin Combined With Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo,Survival after 6 months|Progression free survival|Objective response rate|toxicity profile,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMCmedonc10/003,August 2010,February 2014,April 2014,"September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01210911
652,NCT01210911,DB00530,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,Metformin Combined With Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer,Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo,Survival after 6 months|Progression free survival|Objective response rate|toxicity profile,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AMCmedonc10/003,August 2010,February 2014,April 2014,"September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01210911
653,NCT04690751,DB06119,NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1,Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet,Completed,No Results Available,Healthy,Drug: Cenobamate,Cmax|tmax|Area Under the Concentration Curve to last measurable concentration|Area Under the Concentration Curve from 0 to infinity|Incidence of Treatment-Emergent Adverse Events|Risk of Suicidality,"SK Life Science, Inc.",All,18 Years to 50 Years   (Adult),Phase 1,28.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YKP3089C037,"December 21, 2020","May 17, 2021","May 17, 2021","December 31, 2020",,"October 7, 2021","PRA Health Sciences Salt Lake City, Millcreek, Utah, United States",,https://ClinicalTrials.gov/show/NCT04690751
654,NCT02860286,DB12887,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,Completed,Has Results,Mesothelioma|BAP1 Loss of Function,Drug: Tazemetostat,"Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-t)|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-∞)|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2|Part 2: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)|Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability|Part 1 and 2: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR])|Progression-free Survival (PFS)|Part 1 and 2: Overall Survival (OS)|Part 1 and 2: To Evaluate the Duration of Response (DOR) in Subjects With Confirmed CR or PR|Part 1: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,74.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-203,July 2016,June 2018,May 2019,"August 9, 2016","April 9, 2021","April 9, 2021","University of California, Los Angeles, Los Angeles, California, United States|City of Hope National Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Institut Bergonie, Bordeaux Cedex, France|CHRU de Lille, Lille, France|Institut Gustave Roussy, Villejuif cedex, France|University of Leicester & Leicester University Hospitals, Leicester, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Royal Marsden Hospital - Chelsea, London, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02860286/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02860286
655,NCT03251443,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma,Completed,No Results Available,Intrahepatic Cholangiocarcinoma|Second-line Treatment,Drug: Apatinib,Progression-free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Incidence of Treatment-Emergent Adverse Event,"Peking Union Medical College Hospital|Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,34.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JS-1392,"August 8, 2017","March 8, 2019","May 8, 2019","August 16, 2017",,"December 2, 2020","Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03251443
656,NCT03251443,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma,Completed,No Results Available,Intrahepatic Cholangiocarcinoma|Second-line Treatment,Drug: Apatinib,Progression-free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Incidence of Treatment-Emergent Adverse Event,"Peking Union Medical College Hospital|Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,34.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JS-1392,"August 8, 2017","March 8, 2019","May 8, 2019","August 16, 2017",,"December 2, 2020","Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03251443
657,NCT02601937,DB12887,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,Completed,No Results Available,Rhabdoid Tumors|INI1-negative Tumors|Synovial Sarcoma|Malignant Rhabdoid Tumor of Ovary,Drug: Tazemetostat,To determine the MTD or the RP2D (Dose Escalation)|Dose expansion: Number of subjects with objective response using disease appropriate standardized response criteria|Dose escalation: Number of subjects with objective response using disease appropriate standardized response criteria|Dose Expansion: Progression-free survival (PFS)|Dose Expansion: Overall Survival (OS)|Incidence of treatment-emergent adverse events as a measure of safety and tolerability|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Cmax|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Tmax|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-t)|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-12)|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): t1/2|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): CL/F|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Vd/F|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ka|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ctrough,"Epizyme, Inc.",All,6 Months to 17 Years   (Child),Phase 1,109.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-102,"January 7, 2016","October 22, 2021","October 22, 2021","November 11, 2015",,"December 27, 2021","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|John Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States|Memorial Sloan Kettering, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|Lady Cilento/Queensland Children's Hospital, South Brisbane, Queensland, Australia|The Royal Children's Hospital, Melbourne, Victoria, Australia|The Childrens Hospital at Westmead Oncology Unit, Westmead, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|Rigshospitalet Department of Oncology Blegdamsvej, Copenhagen, Denmark|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif, France|Children's Hospital Augsburg Klinikum, Augsburg, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Westfalische Wilhelms - Universitat Munster Padiatrische, Munster, Germany|Istituto Giannina Gaslini- UOSD Centro di Neuro-Oncologia, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Erasmus University Medical Center - Sophia Children's Hospital, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Central Manchester University Hospital - Royal Manchester Children's Hospital, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02601937
658,NCT02711007,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy,Completed,No Results Available,Osteosarcoma|Metastasis,Drug: apatinib,"Progression-free survival, PFS|Objective response rate, ORR|Overall survival, OS|Clinical benefit rate, CBR|Duration of response, DOR",GUO WEI|Peking University People's Hospital,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,37.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKUPH-sarcoma,March 2016,"December 30, 2017","January 8, 2018","March 17, 2016",,"April 23, 2018","Peking University People's Hospital, Beijing, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02711007
659,NCT02711007,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy,Completed,No Results Available,Osteosarcoma|Metastasis,Drug: apatinib,"Progression-free survival, PFS|Objective response rate, ORR|Overall survival, OS|Clinical benefit rate, CBR|Duration of response, DOR",GUO WEI|Peking University People's Hospital,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,37.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PKUPH-sarcoma,March 2016,"December 30, 2017","January 8, 2018","March 17, 2016",,"April 23, 2018","Peking University People's Hospital, Beijing, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02711007
660,NCT02107963,DB00531,ClCCN(CCCl)P1(=O)NCCCO1,A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors,Completed,No Results Available,Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma,Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide,Feasibility|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalence of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Safety,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"1 Year to 35 Years   (Child, Adult)",Phase 1,15.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,140059|14-C-0059,"February 28, 2014","August 15, 2016","January 31, 2017","April 9, 2014",,"March 16, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02107963
661,NCT01300026,DB15639,COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1,AMG 319 Lymphoid Malignancy FIH,Completed,No Results Available,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,Drug: AMG 319,"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101262|AMG 319 FIH Lymphoid,April 2011,October 2013,December 2016,"February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01300026
662,NCT01300026,DB06011,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,AMG 319 Lymphoid Malignancy FIH,Completed,No Results Available,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,Drug: AMG 319,"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101262|AMG 319 FIH Lymphoid,April 2011,October 2013,December 2016,"February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01300026
663,NCT01300026,DB05490,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,AMG 319 Lymphoid Malignancy FIH,Completed,No Results Available,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,Drug: AMG 319,"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101262|AMG 319 FIH Lymphoid,April 2011,October 2013,December 2016,"February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01300026
664,NCT01300026,DB08079,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,AMG 319 Lymphoid Malignancy FIH,Completed,No Results Available,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,Drug: AMG 319,"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101262|AMG 319 FIH Lymphoid,April 2011,October 2013,December 2016,"February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01300026
665,NCT00922883,DB06210,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients,Completed,Has Results,"Anemia, Aplastic|Anemia, Hypoplastic|Thrombocytopenia",Drug: Eltrombopag,The Portion of Drug Responders as Defined by Hematologic Improvements,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,43.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,090154|09-H-0154,"May 29, 2009","May 7, 2013","April 24, 2018","June 17, 2009","July 16, 2018","October 20, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00922883
666,NCT00540176,DB16026,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(=O)OC1=CC=C(\C=C\C(=O)OCCCCO[N+]([O-])=O)C=C1OC,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
667,NCT00540176,DB14107,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2N)C(O)=O,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
668,NCT00540176,DB01586,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
669,NCT00540176,DB05990,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
670,NCT00540176,DB08834,[H][C@@]12CC[C@H]([C@H](C)CCC(=O)NCCS(O)(=O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@]2([H])C[C@H](O)CC[C@]12C,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
672,NCT00540176,DB08809,OC(=O)C(Cl)Cl,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
673,NCT00540176,DB06777,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,The Safety and Efficacy of DCA for the Treatment of Brain Cancer,Completed,No Results Available,"Malignant Gliomas, Glioblastoma Multiforme",Drug: Dichloroacetate (DCA),"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCA 10002,October 2007,August 2009,August 2009,"October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT00540176
674,NCT01253707,DB15639,COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1,A Study of AMG 337 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors,Drug: AMG 337,"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,111.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101132,December 2010,October 2015,December 2016,"December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01253707
675,NCT01253707,DB06011,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,A Study of AMG 337 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors,Drug: AMG 337,"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,111.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101132,December 2010,October 2015,December 2016,"December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01253707
676,NCT01253707,DB05490,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,A Study of AMG 337 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors,Drug: AMG 337,"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,111.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101132,December 2010,October 2015,December 2016,"December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01253707
677,NCT01253707,DB08079,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,A Study of AMG 337 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors,Drug: AMG 337,"To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,111.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20101132,December 2010,October 2015,December 2016,"December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01253707
678,NCT00390468,DB05465,COC1=C(OCCCN2CCCCC2)C=C2N=CN=C(N3CCN(CC3)C(=O)NC3=CC=C(OC(C)C)C=C3)C2=C1,Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases,Completed,Has Results,Metastatic Cancer|Pain|Prostate Cancer,Drug: Tandutinib,8-week Freedom-From-Progression (FFP),National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Older Adult)",Phase 2,18.0,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2012-02865|P30CA016672|MDA-2005-0717|NCI-7409|CDR0000504104,October 2006,November 2009,November 2009,"October 19, 2006","June 7, 2011","May 28, 2014","M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00390468
679,NCT01064336,DB06210,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,Promacta Pregnancy Registry,Completed,No Results Available,"Purpura, Thrombocytopaenic, Idiopathic",Drug: Eltrombopag,Outcome of Pregnancy (see Detailed Description for a complete list),GlaxoSmithKline,All,"Child, Adult, Older Adult",,1.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,113327|WE4032,March 2010,July 2014,July 2014,"February 8, 2010",,"July 25, 2016",,,https://ClinicalTrials.gov/show/NCT01064336
680,NCT03690141,DB15219,CC1=C2N(C(=O)C(NC3=CC(N)=NC=N3)=C1)C1(CCCCC1)NC2=O,An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC),Completed,No Results Available,Castrate-resistant Prostate Cancer (CRPC),Drug: tomivosertib (eFT508),Anti-tumor response as defined by a patient achieving either of the following outcomes:|PSA progression-free survival from start of study therapy until the date PSA progression is first observed.,Effector Therapeutics,Male,"18 Years and older   (Adult, Older Adult)",Phase 2,16.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,eFT508-0009,"October 12, 2018","April 27, 2020","April 27, 2020","October 1, 2018",,"April 28, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Kimmel Center at Johns Hopkins, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Urology Group, Cincinnati, Ohio, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03690141
681,NCT02366312,DB08828,CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1,"A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors",Completed,Has Results,Keratocystic Odontogenic Tumor,Drug: vismodegib,KCOT Volume (Greatest Dimension),"NYU College of Dentistry|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,2.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-00254|ML28859,"October 27, 2015",August 2019,August 2019,"February 19, 2015","February 18, 2021","February 18, 2021","NYU Bluestone Center For Cllinical Research, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02366312
682,NCT04179071,DB12048,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine,Completed,No Results Available,Solid Tumours,Drug: Savolitinib|Drug: Famotidine,"Maximum observed plasma concentration (Cmax) ratio|Area under plasma concentration-time curve from zero to infinity (AUC) ratio|Number of subjects with having adverse events and/or abnormal findings in vital signs and/or laboratory evaluation and/or physical examination|AUC geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Area under the plasma concentration curve from time zero to time of last quantifiable concentration AUC(0-t)|Cmax geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Cmax metabolite-to-parent ratios (MRCmax)|AUC metabolite-to-parent ratios (MRAUC)|AUC(0-t) metabolite-to-parent ratios [MRAUC(0-t)]|Time to reach maximum observed plasma concentration (tmax)|Half-life associated with terminal slope (λz) of a semi logarithmic concentration-time curve (t½,λz)|Terminal elimination rate constant (λz)|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Apparent total body clearance of drug from plasma after extravascular administration (CL/F)",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5084C00005,"December 13, 2019","March 11, 2020","March 11, 2020","November 26, 2019",,"July 7, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04179071
683,NCT04179071,DB00927,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine,Completed,No Results Available,Solid Tumours,Drug: Savolitinib|Drug: Famotidine,"Maximum observed plasma concentration (Cmax) ratio|Area under plasma concentration-time curve from zero to infinity (AUC) ratio|Number of subjects with having adverse events and/or abnormal findings in vital signs and/or laboratory evaluation and/or physical examination|AUC geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Area under the plasma concentration curve from time zero to time of last quantifiable concentration AUC(0-t)|Cmax geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Cmax metabolite-to-parent ratios (MRCmax)|AUC metabolite-to-parent ratios (MRAUC)|AUC(0-t) metabolite-to-parent ratios [MRAUC(0-t)]|Time to reach maximum observed plasma concentration (tmax)|Half-life associated with terminal slope (λz) of a semi logarithmic concentration-time curve (t½,λz)|Terminal elimination rate constant (λz)|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Apparent total body clearance of drug from plasma after extravascular administration (CL/F)",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5084C00005,"December 13, 2019","March 11, 2020","March 11, 2020","November 26, 2019",,"July 7, 2020","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04179071
684,NCT03376958,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma,Completed,No Results Available,Relapsed and Refractory|Diffuse Large B Cell Lymphoma,Drug: Apatinib,Overall Response Rate|Progression-free Survival|Overall Survival,Zhengzhou University,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Phase 4,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,hnslblzlzx2017-1,"January 1, 2017","February 1, 2019","April 30, 2019","December 19, 2017",,"July 25, 2019","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,https://ClinicalTrials.gov/show/NCT03376958
685,NCT03376958,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma,Completed,No Results Available,Relapsed and Refractory|Diffuse Large B Cell Lymphoma,Drug: Apatinib,Overall Response Rate|Progression-free Survival|Overall Survival,Zhengzhou University,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Phase 4,32.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,hnslblzlzx2017-1,"January 1, 2017","February 1, 2019","April 30, 2019","December 19, 2017",,"July 25, 2019","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,https://ClinicalTrials.gov/show/NCT03376958
686,NCT02714036,DB05266,CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C,A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS),Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: ibudilast,To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks|To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers|To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.|To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)|To evaluate the effect of ibudilast on slow vital capacity (SVC)|To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD),MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,35.0,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MN-166-ALS-1202,"May 6, 2016","December 31, 2019","June 30, 2020","March 21, 2016",,"July 21, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, United States",,https://ClinicalTrials.gov/show/NCT02714036
687,NCT04216082,DB11885,COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1,A Study of Anlotinib in Subjects With Advanced Malignancy,Completed,No Results Available,Advanced Malignancy,Drug: Anlotinib,Overall response rate (ORR)|Progression-free survival (PFS)|Disease control rate（DCR）|Duration of Response (DOR),"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,93.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALTN-00-II,"August 1, 2013","August 31, 2014","August 1, 2015","January 2, 2020",,"January 2, 2020","Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT04216082
688,NCT00490139,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab,Disease-free Survival (DFS)|Overall Survival (OS)|Time to Recurrence|Time to Distant Recurrence|Time to Central Nervous System Recurrence|DFS Ignoring Non-breast Second Primary Malignancies,Novartis Pharmaceuticals|North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,8382.0,Industry|Other|NIH,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106708|CLAP016B2301|2006-000562-36,"May 16, 2007","December 6, 2013","July 1, 2021","June 22, 2007","August 18, 2014","July 23, 2021","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Fairbanks, Alaska, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Burlingame, California, United States|Novartis Investigative Site, Castro Valley, California, United States|Novartis Investigative Site, Duarte, California, United States|Novartis Investigative Site, Fairfield, California, United States|Novartis Investigative Site, Fremont, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Martinez, California, United States|Novartis Investigative Site, Marysville, California, United States|Novartis Investigative Site, Monterey, California, United States|Novartis Investigative Site, Mountain View, California, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Pismo Beach, California, United States|Novartis Investigative Site, Pleasanton, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Leandro, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Edwards, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Glenwood Springs, Colorado, United States|Novartis Investigative Site, Grand Junction, Colorado, United States|Novartis Investigative Site, Greeley, Colorado, United States|Novartis Investigative Site, Lone Tree, Colorado, United States|Novartis Investigative Site, Longmont, Colorado, United States|Novartis Investigative Site, Loveland, Colorado, United States|Novartis Investigative Site, Montrose, Colorado, United States|Novartis Investigative Site, Pueblo, Colorado, United States|Novartis Investigative Site, Thornton, Colorado, United States|Novartis Investigative Site, Wheat Ridge, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Torrington, Connecticut, United States|Novartis Investigative Site, Dover, Delaware, United States|Novartis Investigative Site, Milford, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Titusville, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Austell, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Fort Gordon, Georgia, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Riverdale, Georgia, United States|Novartis Investigative Site, Rome, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Valdosta, Georgia, United States|Novartis Investigative Site, 'Aiea, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Lihue, Hawaii, United States|Novartis Investigative Site, Wailuku, Hawaii, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Alton, Illinois, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Berwyn, Illinois, United States|Novartis Investigative Site, Bloomington, Illinois, United States|Novartis Investigative Site, Canton, Illinois, United States|Novartis Investigative Site, Carthage, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Eureka, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Galesburg, Illinois, United States|Novartis Investigative Site, Harvey, Illinois, United States|Novartis Investigative Site, Havana, Illinois, United States|Novartis Investigative Site, Highland Park, Illinois, United States|Novartis Investigative Site, Hopedale, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Kankakee, Illinois, United States|Novartis Investigative Site, Kewanee, Illinois, United States|Novartis Investigative Site, La Grange, Illinois, United States|Novartis Investigative Site, Libertyville, Illinois, United States|Novartis Investigative Site, Macomb, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Moline, Illinois, United States|Novartis Investigative Site, Monmouth, Illinois, United States|Novartis Investigative Site, Mount Vernon, Illinois, United States|Novartis Investigative Site, Naperville, Illinois, United States|Novartis Investigative Site, Niles, Illinois, United States|Novartis Investigative Site, Normal, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Ottawa, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peru, Illinois, United States|Novartis Investigative Site, Princeton, Illinois, United States|Novartis Investigative Site, Rockford, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Spring Valley, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Urbana, Illinois, United States|Novartis Investigative Site, Warrenville, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Beech Grove, Indiana, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Fort Wayne, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Kokomo, Indiana, United States|Novartis Investigative Site, La Porte, Indiana, United States|Novartis Investigative Site, Michigan City, Indiana, United States|Novartis Investigative Site, Mishawaka, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, Ames, Iowa, United States|Novartis Investigative Site, Bettendorf, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Mason City, Iowa, United States|Novartis Investigative Site, Ottumwa, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Anthony, Kansas, United States|Novartis Investigative Site, Chanute, Kansas, United States|Novartis Investigative Site, Dodge City, Kansas, United States|Novartis Investigative Site, El Dorado, Kansas, United States|Novartis Investigative Site, Fort Scott, Kansas, United States|Novartis Investigative Site, Independence, Kansas, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Kingman, Kansas, United States|Novartis Investigative Site, Lawrence, Kansas, United States|Novartis Investigative Site, Liberal, Kansas, United States|Novartis Investigative Site, Newton, Kansas, United States|Novartis Investigative Site, Olathe, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Parsons, Kansas, United States|Novartis Investigative Site, Prairie Village, Kansas, United States|Novartis Investigative Site, Pratt, Kansas, United States|Novartis Investigative Site, Salina, Kansas, United States|Novartis Investigative Site, Shawnee Mission, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wellington, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Winfield, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Scarborough, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Bethesda, Maryland, United States|Novartis Investigative Site, Easton, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Westminster, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Burlington, Massachusetts, United States|Novartis Investigative Site, Gloucester, Massachusetts, United States|Novartis Investigative Site, Hyannis, Massachusetts, United States|Novartis Investigative Site, Lowell, Massachusetts, United States|Novartis Investigative Site, Peabody, Massachusetts, United States|Novartis Investigative Site, Adrian, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Battle Creek, Michigan, United States|Novartis Investigative Site, Big Rapids, Michigan, United States|Novartis Investigative Site, Byron Center, Michigan, United States|Novartis Investigative Site, Dearborn, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Escanaba, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Iron Mountain, Michigan, United States|Novartis Investigative Site, Jackson, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Livonia, Michigan, United States|Novartis Investigative Site, Monroe, Michigan, United States|Novartis Investigative Site, Muskegon, Michigan, United States|Novartis Investigative Site, Pontiac, Michigan, United States|Novartis Investigative Site, Port Huron, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Traverse City, Michigan, United States|Novartis Investigative Site, Warren, Michigan, United States|Novartis Investigative Site, Albert Lea, Minnesota, United States|Novartis Investigative Site, Alexandria, Minnesota, United States|Novartis Investigative Site, Bemidji, Minnesota, United States|Novartis Investigative Site, Burnsville, Minnesota, United States|Novartis Investigative Site, Coon Rapids, Minnesota, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, Fergus Falls, Minnesota, United States|Novartis Investigative Site, Fridley, Minnesota, United States|Novartis Investigative Site, Hutchinson, Minnesota, United States|Novartis Investigative Site, Litchfield, Minnesota, United States|Novartis Investigative Site, Mankato, Minnesota, United States|Novartis Investigative Site, Maplewood, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Louis Park, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Shakopee, Minnesota, United States|Novartis Investigative Site, Waconia, Minnesota, United States|Novartis Investigative Site, Willmar, Minnesota, United States|Novartis Investigative Site, Woodbury, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Keesler Air Force Base, Mississippi, United States|Novartis Investigative Site, Pascagoula, Mississippi, United States|Novartis Investigative Site, Bolivar, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Independence, Missouri, United States|Novartis Investigative Site, Joplin, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Liberty, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Havre, Montana, United States|Novartis Investigative Site, Helena, Montana, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Concord, New Hampshire, United States|Novartis Investigative Site, Exeter, New Hampshire, United States|Novartis Investigative Site, Hooksett, New Hampshire, United States|Novartis Investigative Site, Keene, New Hampshire, United States|Novartis Investigative Site, Laconia, New Hampshire, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Manchester, New Hampshire, United States|Novartis Investigative Site, Portsmouth, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Hamilton, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Marlton, New Jersey, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Mount Holly, New Jersey, United States|Novartis Investigative Site, Neptune, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Pomona, New Jersey, United States|Novartis Investigative Site, Princeton, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Somerville, New Jersey, United States|Novartis Investigative Site, Sparta, New Jersey, United States|Novartis Investigative Site, Summit, New Jersey, United States|Novartis Investigative Site, Vineland, New Jersey, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Las Cruces, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Clifton Springs, New York, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Elmhurst, New York, United States|Novartis Investigative Site, Jamaica, New York, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New Hyde Park, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Utica, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Fayetteville, North Carolina, United States|Novartis Investigative Site, Gastonia, North Carolina, United States|Novartis Investigative Site, Goldsboro, North Carolina, United States|Novartis Investigative Site, Hendersonville, North Carolina, United States|Novartis Investigative Site, Kinston, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Rutherfordton, North Carolina, United States|Novartis Investigative Site, Statesville, North Carolina, United States|Novartis Investigative Site, Washington, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Minot, North Dakota, United States|Novartis Investigative Site, Beachwood, Ohio, United States|Novartis Investigative Site, Bellefontaine, Ohio, United States|Novartis Investigative Site, Bowling Green, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Chillicothe, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Clyde, Ohio, United States|Novartis Investigative Site, Columbia, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Delaware, Ohio, United States|Novartis Investigative Site, Elyria, Ohio, United States|Novartis Investigative Site, Findlay, Ohio, United States|Novartis Investigative Site, Franklin, Ohio, United States|Novartis Investigative Site, Greenville, Ohio, United States|Novartis Investigative Site, Independence, Ohio, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Lambertville, Ohio, United States|Novartis Investigative Site, Lima, Ohio, United States|Novartis Investigative Site, Marietta, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Mayfield Heights, Ohio, United States|Novartis Investigative Site, Newark, Ohio, United States|Novartis Investigative Site, Oregon, Ohio, United States|Novartis Investigative Site, Sandusky, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Sylvania, Ohio, United States|Novartis Investigative Site, Tiffin, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Troy, Ohio, United States|Novartis Investigative Site, Wauseon, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Wilmington, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Wright-Patterson Air Force Base, Ohio, United States|Novartis Investigative Site, Xenia, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Coos Bay, Oregon, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Gresham, Oregon, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Klamath Falls, Oregon, United States|Novartis Investigative Site, Milwaukie, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Bryn Mawr, Pennsylvania, United States|Novartis Investigative Site, Butler, Pennsylvania, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Ephrata, Pennsylvania, United States|Novartis Investigative Site, Hazleton, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Kingston, Pennsylvania, United States|Novartis Investigative Site, Lancaster, Pennsylvania, United States|Novartis Investigative Site, Langhorne, Pennsylvania, United States|Novartis Investigative Site, Lewistown, Pennsylvania, United States|Novartis Investigative Site, Media, Pennsylvania, United States|Novartis Investigative Site, Nashville, Pennsylvania, United States|Novartis Investigative Site, Paoli, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Phoenixville, Pennsylvania, United States|Novartis Investigative Site, Pottstown, Pennsylvania, United States|Novartis Investigative Site, Sayre, Pennsylvania, United States|Novartis Investigative Site, Scranton, Pennsylvania, United States|Novartis Investigative Site, Sellersville, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Anderson, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Spartanburg, South Carolina, United States|Novartis Investigative Site, Aberdeen, South Dakota, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Franklin, Tennessee, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Abilene, Texas, United States|Novartis Investigative Site, Amarillo, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Bedford, Texas, United States|Novartis Investigative Site, Cedar Park, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Sam Houston, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lackland Air Force Base, Texas, United States|Novartis Investigative Site, Longview, Texas, United States|Novartis Investigative Site, McAllen, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Midland, Texas, United States|Novartis Investigative Site, Paris, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Marcos, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Wichita Falls, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Berlin, Vermont, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, Saint Johnsbury, Vermont, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Danville, Virginia, United States|Novartis Investigative Site, Fredericksburg, Virginia, United States|Novartis Investigative Site, Hampton, Virginia, United States|Novartis Investigative Site, Norfolk, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Auburn, Washington, United States|Novartis Investigative Site, Bellingham, Washington, United States|Novartis Investigative Site, Bremerton, Washington, United States|Novartis Investigative Site, Burien, Washington, United States|Novartis Investigative Site, Centralia, Washington, United States|Novartis Investigative Site, Federal Way, Washington, United States|Novartis Investigative Site, Kennewick, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Olympia, Washington, United States|Novartis Investigative Site, Port Angeles, Washington, United States|Novartis Investigative Site, Poulsbo, Washington, United States|Novartis Investigative Site, Puyallup, Washington, United States|Novartis Investigative Site, Renton, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Wenatchee, Washington, United States|Novartis Investigative Site, Charleston, West Virginia, United States|Novartis Investigative Site, Huntington, West Virginia, United States|Novartis Investigative Site, Wheeling, West Virginia, United States|Novartis Investigative Site, Chippewa Falls, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, La Crosse, Wisconsin, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States|Novartis Investigative Site, Marinette, Wisconsin, United States|Novartis Investigative Site, Marshfield, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Minocqua, Wisconsin, United States|Novartis Investigative Site, Oconto Falls, Wisconsin, United States|Novartis Investigative Site, Oshkosh, Wisconsin, United States|Novartis Investigative Site, Rhinelander, Wisconsin, United States|Novartis Investigative Site, Rice Lake, Wisconsin, United States|Novartis Investigative Site, Stevens Point, Wisconsin, United States|Novartis Investigative Site, Sturgeon Bay, Wisconsin, United States|Novartis Investigative Site, Weston, Wisconsin, United States|Novartis Investigative Site, Wisconsin Rapids, Wisconsin, United States|Novartis Investigative Site, Casper, Wyoming, United States|Novartis Investigative Site, Sheridan, Wyoming, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Coffs Harbour, New South Wales, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Port Macquarie, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Taree, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Nambour, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, East Bentleigh, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Footscray, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, Wendouree, Victoria, Australia|Novartis Investigative Site, Bunbury, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Campbelltown, Australia|Novartis Investigative Site, Lismore, Australia|Novartis Investigative Site, Murdoch, Australia|Novartis Investigative Site, Guessing, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Steyr, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Villach, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wolfsberg, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine Saint Paul, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Tournai, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Porte Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Sault Ste. Marie, Ontario, Canada|Novartis Investigative Site, St Catharines, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Charlottetown, Prince Edward Island, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Temuco, Región De La Araucania, Chile|Novartis Investigative Site, Valdivia, Región De Los Lagos, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Valparaiso, Valparaíso, Chile|Novartis Investigative Site, Vina del Mar, Valparaíso, Chile|Novartis Investigative Site, Arica, Chile|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Varazdin, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ceske Budejovice, Czechia|Novartis Investigative Site, Chomutov, Czechia|Novartis Investigative Site, Jihlava, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Praha 4, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Praha 8, Czechia|Novartis Investigative Site, Usti nad Labem, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Arhus C, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hilleroed, Denmark|Novartis Investigative Site, Koebenhavn Oe, Denmark|Novartis Investigative Site, Naestved, Denmark|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, ANGERS Cedex 2, France|Novartis Investigative Site, Annecy, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bethune, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brive La Gaillarde, France|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Clermont Ferrand, France|Novartis Investigative Site, Coudekerque Branche, France|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Draguignan, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Grenoble Cedex, France|Novartis Investigative Site, Hyeres, France|Novartis Investigative Site, La Seyne Sur Mer, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Havre, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille Cedex 09, France|Novartis Investigative Site, Marseille cedex 5, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz cedex 01, France|Novartis Investigative Site, Mont de Marsan, France|Novartis Investigative Site, Montauban, France|Novartis Investigative Site, Montbeliard, France|Novartis Investigative Site, Mulhouse, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes cedex 9, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 14, France|Novartis Investigative Site, Paris Cedex 5, France|Novartis Investigative Site, Perigueux, France|Novartis Investigative Site, Perin Sur Mer, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen cedex 1, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint Gregoire, France|Novartis Investigative Site, Saint Jean, France|Novartis Investigative Site, Saint-Cloud, France|Novartis Investigative Site, Saint-Herblain, France|Novartis Investigative Site, Saint-Martin Boulogne, France|Novartis Investigative Site, Saint-Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours cedex, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Aalen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Baden-Baden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Boeblingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Emmendingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Esslingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Goeppingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Konstanz, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Loerrach, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ludwigsburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mutlangen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Reutlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Rheinfelden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwaebisch Hall, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwetzingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Sigmaringen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuttlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ansbach, Bayern, Germany|Novartis Investigative Site, Aschaffenburg, Bayern, Germany|Novartis Investigative Site, Augsburg, Bayern, Germany|Novartis Investigative Site, Bad Reichenhall, Bayern, Germany|Novartis Investigative Site, Bayreuth, Bayern, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Dachau, Bayern, Germany|Novartis Investigative Site, Deggendorf, Bayern, Germany|Novartis Investigative Site, Donauwoerth, Bayern, Germany|Novartis Investigative Site, Ebersberg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Erlangen, Bayern, Germany|Novartis Investigative Site, Forchheim, Bayern, Germany|Novartis Investigative Site, Freising, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Garmisch-Partenkirchen, Bayern, Germany|Novartis Investigative Site, Kempten, Bayern, Germany|Novartis Investigative Site, Kronach, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Marktredwitz, Bayern, Germany|Novartis Investigative Site, Memmingen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muhr, Bayern, Germany|Novartis Investigative Site, Munchen, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Roth, Bayern, Germany|Novartis Investigative Site, Schwandorf, Bayern, Germany|Novartis Investigative Site, Traunstein, Bayern, Germany|Novartis Investigative Site, Waldmuenchen, Bayern, Germany|Novartis Investigative Site, Weiden, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Koenigs Wusterhausen, Brandenburg, Germany|Novartis Investigative Site, Luckenwalde, Brandenburg, Germany|Novartis Investigative Site, Ludwigsfelde, Brandenburg, Germany|Novartis Investigative Site, Bremerhaven, Bremen, Germany|Novartis Investigative Site, Bad Soden, Hessen, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Fulda, Hessen, Germany|Novartis Investigative Site, Hanau, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Limburg, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Offenbach, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Greifswald, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Guestrow, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Schwerin, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Aurich, Niedersachsen, Germany|Novartis Investigative Site, Braunschweig, Niedersachsen, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Cuxhaven, Niedersachsen, Germany|Novartis Investigative Site, Georgsmarienhuette, Niedersachsen, Germany|Novartis Investigative Site, Goettingen, Niedersachsen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hameln, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Leer, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Osnabrueck, Niedersachsen, Germany|Novartis Investigative Site, Rotenburg (Wuemme), Niedersachsen, Germany|Novartis Investigative Site, Stade, Niedersachsen, Germany|Novartis Investigative Site, Stadthagen, Niedersachsen, Germany|Novartis Investigative Site, Vechta, Niedersachsen, Germany|Novartis Investigative Site, Westerstede, Niedersachsen, Germany|Novartis Investigative Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duisburg, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Eschweiler, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Gummersbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Hamm-Heessen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Krefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Leverkusen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Minden, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muelheim, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Olpe, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Solingen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wesel, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuerselen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Ludwigshafen, Rheinland-Pfalz, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Trier, Rheinland-Pfalz, Germany|Novartis Investigative Site, Homburg/Saar, Saarland, Germany|Novartis Investigative Site, Landstuhl, Saarland, Germany|Novartis Investigative Site, Neunkirchen, Saarland, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Aschersleben, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Stendal, Sachsen-Anhalt, Germany|Novartis Investigative Site, Weissenfels, Sachsen-Anhalt, Germany|Novartis Investigative Site, Chemnitz, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Hoyerswerda, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Radebeul, Sachsen, Germany|Novartis Investigative Site, Rodewisch, Sachsen, Germany|Novartis Investigative Site, Schkeuditz, Sachsen, Germany|Novartis Investigative Site, Torgau, Sachsen, Germany|Novartis Investigative Site, Zittau, Sachsen, Germany|Novartis Investigative Site, Zwickau, Sachsen, Germany|Novartis Investigative Site, Bad Oldesloe, Schleswig-Holstein, Germany|Novartis Investigative Site, Flensburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Geesthacht, Schleswig-Holstein, Germany|Novartis Investigative Site, Heide, Schleswig-Holstein, Germany|Novartis Investigative Site, Itzehoe, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Neumuenster, Schleswig-Holstein, Germany|Novartis Investigative Site, Rendsburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Erfurt, Thueringen, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Jena, Thueringen, Germany|Novartis Investigative Site, Meiningen, Thueringen, Germany|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion,Crete, Greece|Novartis Investigative Site, Patra, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Gurgaon, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Kolkatta (w.b.), India|Novartis Investigative Site, Mangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Trivandrum, India|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Sligo, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Netanya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Avellino, Campania, Italy|Novartis Investigative Site, Carpi (MO), Emilia-Romagna, Italy|Novartis Investigative Site, Lugo (Ravenna), Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Ravenna, Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Viterbo, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Alzano Lombardo (BG), Lombardia, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Cremona, Lombardia, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Mantova, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Rozzano (MI), Lombardia, Italy|Novartis Investigative Site, San Fermo Della Battaglia (Co), Lombardia, Italy|Novartis Investigative Site, Saronno (VA), Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Varese, Lombardia, Italy|Novartis Investigative Site, Fano (Pesaro Urbino), Marche, Italy|Novartis Investigative Site, Fermo (AP), Marche, Italy|Novartis Investigative Site, Asti, Piemonte, Italy|Novartis Investigative Site, Biella, Piemonte, Italy|Novartis Investigative Site, Candiolo (TO), Piemonte, Italy|Novartis Investigative Site, Brindisi, Puglia, Italy|Novartis Investigative Site, Lecce, Puglia, Italy|Novartis Investigative Site, Monserrato (CA), Sardegna, Italy|Novartis Investigative Site, Sassari, Sardegna, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Ragusa, Sicilia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Lido Di Camaiore (LU), Toscana, Italy|Novartis Investigative Site, Livorno, Toscana, Italy|Novartis Investigative Site, Montepulciano (Siena, Toscana, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Poggibonsi (Siena), Toscana, Italy|Novartis Investigative Site, Prato, Toscana, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Cosenza, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Kubang Kerian, Malaysia|Novartis Investigative Site, Sarawak, Malaysia|Novartis Investigative Site, Toluca, Estado De México, Mexico|Novartis Investigative Site, Merida, Yucatán, Mexico|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Mexico D.F., Mexico|Novartis Investigative Site, Mexico DF, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Leidschendam, Netherlands|Novartis Investigative Site, Purmerend, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Hamilton, New Zealand|Novartis Investigative Site, Palmerston North, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Forde, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Tromso, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Rawalpindi, Pakistan|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Cebu, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Sampaloc Manila, Philippines|Novartis Investigative Site, San Juan, Philippines|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Elblag, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Groenkloof, Pretoria, 0001, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Observatory, South Africa|Novartis Investigative Site, Panorama, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Alcoy/Alicante, Spain|Novartis Investigative Site, Barakaldo (Vizcaya), Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Cadiz, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, Coria, Spain|Novartis Investigative Site, Elda, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Huesca, Spain|Novartis Investigative Site, La Laguna (Santa Cruz De Tenerife), Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Lugo, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Mostoles (Madrid), Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Santiago, Spain|Novartis Investigative Site, Segovia, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Tarrasa, Barcelona, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zamora, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Aarau, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Locarno, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Thun, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Hatyai, Songkhla, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Phitsanulok, Thailand|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Ivano-Frankivsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Uzhorod, Ukraine|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Prittlewell Chase, Essex, United Kingdom|Novartis Investigative Site, Nottingham, Gloucestershire, United Kingdom|Novartis Investigative Site, Canterbury, Kent, United Kingdom|Novartis Investigative Site, Manchester, Lancashire, United Kingdom|Novartis Investigative Site, Preston, Lancashire, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Edinburgh, Midlothian, United Kingdom|Novartis Investigative Site, Headington, Oxford, Oxfordshire, United Kingdom|Novartis Investigative Site, Ashford, United Kingdom|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Cottingham, United Kingdom|Novartis Investigative Site, Dorchester, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Grimsby, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Gwynedd, United Kingdom|Novartis Investigative Site, Ipswich, United Kingdom|Novartis Investigative Site, Lancaster, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Lindley, Huddersfield, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Margate, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Romford, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Southport, United Kingdom|Novartis Investigative Site, St Helens, United Kingdom|Novartis Investigative Site, Stoke on Trent, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom|Novartis Investigative Site, Whitchurch, Cardiff, United Kingdom|Novartis Investigative Site, Worthing, United Kingdom",,https://ClinicalTrials.gov/show/NCT00490139
689,NCT03353740,DB11744,NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
690,NCT03353740,DB13727,C=CCN1CC2=CC=CC=C2C2=CC=CC=C2C1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
691,NCT03353740,DB15297,CN1C=C(C=N1)C1=CC(=C(C=C1)S(=O)(=O)[C@@H]1C[C@H](N(C1)C(=O)C1(CC1)C(F)(F)F)C(=O)NC1(CC1)C#N)C(F)(F)F,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
692,NCT03353740,DB15888,OC(C(=O)OCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
693,NCT03353740,DB09498,[Cl-].[Cl-].[89Sr++],Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
694,NCT03353740,DB16229,CCCNCCOC1=CC(=CC(F)=C1)S(C)(=O)=O,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
695,NCT03353740,DB15494,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
696,NCT03353740,DB00454,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
697,NCT03353740,DB15424,[18F]C1=CC=C(C=C1)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
698,NCT03353740,DB15952,[Na+].[O-][N+]([O-])=O,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
699,NCT03353740,DB16019,[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
700,NCT03353740,DB12043,CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
701,NCT03353740,DB15995,O[N+]([O-])=O,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
702,NCT03353740,DB13925,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
703,NCT03353740,DB04752,[H]\C(CCCCCC)=C(/[H])CCCCCCCC(=O)O[C@@]([H])(COC(=O)CCCCCCC\C([H])=C(\[H])CCCCCCCC)COP(O)(=O)OCCO,Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,346.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,175518|NCI-2018-00040,"September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03353740
704,NCT02919111,DB11744,NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
705,NCT02919111,DB13727,C=CCN1CC2=CC=CC=C2C2=CC=CC=C2C1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
706,NCT02919111,DB15297,CN1C=C(C=N1)C1=CC(=C(C=C1)S(=O)(=O)[C@@H]1C[C@H](N(C1)C(=O)C1(CC1)C(F)(F)F)C(=O)NC1(CC1)C#N)C(F)(F)F,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
707,NCT02919111,DB15888,OC(C(=O)OCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
708,NCT02919111,DB09498,[Cl-].[Cl-].[89Sr++],Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
709,NCT02919111,DB16229,CCCNCCOC1=CC(=CC(F)=C1)S(C)(=O)=O,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
710,NCT02919111,DB15494,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
711,NCT02919111,DB00454,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
712,NCT02919111,DB15424,[18F]C1=CC=C(C=C1)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
713,NCT02919111,DB15952,[Na+].[O-][N+]([O-])=O,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
714,NCT02919111,DB16019,[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
715,NCT02919111,DB12043,CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
716,NCT02919111,DB15995,O[N+]([O-])=O,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
717,NCT02919111,DB13925,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
718,NCT02919111,DB04752,[H]\C(CCCCCC)=C(/[H])CCCCCCCC(=O)O[C@@]([H])(COC(=O)CCCCCCC\C([H])=C(\[H])CCCCCCCC)COP(O)(=O)OCCO,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,299.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,16559|NCI-2018-00038,"September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02919111
719,NCT02918357,DB11744,NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
720,NCT02918357,DB13727,C=CCN1CC2=CC=CC=C2C2=CC=CC=C2C1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
721,NCT02918357,DB15297,CN1C=C(C=N1)C1=CC(=C(C=C1)S(=O)(=O)[C@@H]1C[C@H](N(C1)C(=O)C1(CC1)C(F)(F)F)C(=O)NC1(CC1)C#N)C(F)(F)F,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
722,NCT02918357,DB15888,OC(C(=O)OCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
723,NCT02918357,DB09498,[Cl-].[Cl-].[89Sr++],Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
724,NCT02918357,DB16229,CCCNCCOC1=CC(=CC(F)=C1)S(C)(=O)=O,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
725,NCT02918357,DB15494,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
726,NCT02918357,DB00454,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
727,NCT02918357,DB15424,[18F]C1=CC=C(C=C1)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
728,NCT02918357,DB15952,[Na+].[O-][N+]([O-])=O,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
729,NCT02918357,DB16019,[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
730,NCT02918357,DB12043,CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
731,NCT02918357,DB15995,O[N+]([O-])=O,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
732,NCT02918357,DB13925,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
733,NCT02918357,DB04752,[H]\C(CCCCCC)=C(/[H])CCCCCCCC(=O)O[C@@]([H])(COC(=O)CCCCCCC\C([H])=C(\[H])CCCCCCCC)COP(O)(=O)OCCO,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11 PET,Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure,"University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,165510|NCI-2018-00039,"September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02918357
734,NCT03274011,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,Completed,No Results Available,Esophageal Neoplasms,Drug: Apatinib,Progression Free Survival|Overall Survival|Overall Response Rate,Fudan University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESO-Shanghai11,"July 1, 2017","March 15, 2019","June 26, 2019","September 6, 2017",,"January 26, 2021","Shanghai Yangpu District East Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03274011
735,NCT03274011,DB14765,O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1,Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma,Completed,No Results Available,Esophageal Neoplasms,Drug: Apatinib,Progression Free Survival|Overall Survival|Overall Response Rate,Fudan University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESO-Shanghai11,"July 1, 2017","March 15, 2019","June 26, 2019","September 6, 2017",,"January 26, 2021","Shanghai Yangpu District East Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03274011
736,NCT01695876,DB15639,COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",Completed,No Results Available,Inflammatory Disease,Drug: AMG 357|Drug: Placebo,Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357,Amgen,All,25 Years to 55 Years   (Adult),Phase 1,58.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110246|Inflammation,October 2012,September 2014,October 2014,"September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT01695876
737,NCT01695876,DB06011,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",Completed,No Results Available,Inflammatory Disease,Drug: AMG 357|Drug: Placebo,Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357,Amgen,All,25 Years to 55 Years   (Adult),Phase 1,58.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110246|Inflammation,October 2012,September 2014,October 2014,"September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT01695876
738,NCT01695876,DB05490,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",Completed,No Results Available,Inflammatory Disease,Drug: AMG 357|Drug: Placebo,Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357,Amgen,All,25 Years to 55 Years   (Adult),Phase 1,58.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110246|Inflammation,October 2012,September 2014,October 2014,"September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT01695876
739,NCT01695876,DB08079,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",Completed,No Results Available,Inflammatory Disease,Drug: AMG 357|Drug: Placebo,Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357,Amgen,All,25 Years to 55 Years   (Adult),Phase 1,58.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20110246|Inflammation,October 2012,September 2014,October 2014,"September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT01695876
740,NCT01703754,DB05668,OP(=O)(NCCCl)NCCCl,Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.,Completed,No Results Available,Breast Cancer Nos Metastatic Recurrent,Genetic: Ad-RTS-hIL-12 and Veledimex|Drug: Palifosfamide,"Safety and tolerability of study drug therapy based on type and rate of adverse events and 16-week PFS rate.|Objective response rate (ORR) by modified RECIST v1.1|Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1|Estimate PFS by modified RECIST v1.1|Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome",Alaunos Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ATI001-201,March 2013,December 2014,December 2014,"October 10, 2012",,"January 27, 2015","Baptist Cancer Institute, Jacksonville, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Billings Clinic, Billings, Montana, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT01703754
741,NCT00813384,DB15639,COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1,A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients,Drug: AMG 208,"To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,54.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080895,December 2008,February 2013,December 2014,"December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00813384
742,NCT00813384,DB06011,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients,Drug: AMG 208,"To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,54.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080895,December 2008,February 2013,December 2014,"December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00813384
743,NCT00813384,DB05490,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients,Drug: AMG 208,"To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,54.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080895,December 2008,February 2013,December 2014,"December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00813384
744,NCT00813384,DB08079,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors,Completed,No Results Available,Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients,Drug: AMG 208,"To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208",Amgen,All,"18 Years and older   (Adult, Older Adult)",Phase 1,54.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20080895,December 2008,February 2013,December 2014,"December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00813384
745,NCT03773952,DB12216,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
746,NCT03773952,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
747,NCT03773952,DB14514,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
748,NCT03773952,DB08924,CC(CC1=CC=CC=C1)\N=C\C(Cl)(Cl)Cl,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
749,NCT03773952,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
750,NCT03773952,DB02650,[H]C(=O)C(Cl)(Cl)Cl,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
751,NCT03773952,DB01494,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
752,NCT03773952,DB12120,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
753,NCT03773952,DB01563,OC(O)C(Cl)(Cl)Cl,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
754,NCT03773952,DB00553,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
755,NCT03773952,DB13402,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
756,NCT03773952,DB01534,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients,Completed,No Results Available,Ulcerative Colitis,Drug: PBF-677|Drug: Placebo oral capsule,"Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677",Palobiofarma SL|Qualitecfarma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,34.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PBF-677-3,"July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03773952
757,NCT03647670,DB00683,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers,Completed,No Results Available,Phase 1,Drug: PF-04965842|Drug: Midazolam,AUCinf of midazolam.|AUClast of midazolam|Blood Pressure|Cmax of midazolam.|Tmax of midazolam.|t1/2 of midazolam.|Pulse|Temperature|Adverse Events|Laboratory tests,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,25.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451022|2018-001198-26,"July 3, 2018","October 16, 2018","October 16, 2018","August 27, 2018",,"March 23, 2020","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03647670
758,NCT03647670,DB14973,CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1,A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers,Completed,No Results Available,Phase 1,Drug: PF-04965842|Drug: Midazolam,AUCinf of midazolam.|AUClast of midazolam|Blood Pressure|Cmax of midazolam.|Tmax of midazolam.|t1/2 of midazolam.|Pulse|Temperature|Adverse Events|Laboratory tests,Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,25.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451022|2018-001198-26,"July 3, 2018","October 16, 2018","October 16, 2018","August 27, 2018",,"March 23, 2020","Pfizer Clinical Research Unit, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03647670
759,NCT04006145,DB12216,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
760,NCT04006145,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
761,NCT04006145,DB14514,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
762,NCT04006145,DB08924,CC(CC1=CC=CC=C1)\N=C\C(Cl)(Cl)Cl,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
763,NCT04006145,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
764,NCT04006145,DB02650,[H]C(=O)C(Cl)(Cl)Cl,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
765,NCT04006145,DB01494,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
766,NCT04006145,DB12120,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
767,NCT04006145,DB01563,OC(O)C(Cl)(Cl)Cl,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
768,NCT04006145,DB00553,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
769,NCT04006145,DB12486,CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C=C2S(=O)(=O)C1,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
770,NCT04006145,DB13402,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
771,NCT04006145,DB01534,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,Completed,Has Results,NAFLD|NASH,Drug: Elobixibat|Drug: Placebo oral tablet,Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16,Albireo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,47.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3309-012,"June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04006145
772,NCT03662516,DB00977,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
773,NCT03662516,DB04573,[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
774,NCT03662516,DB01031,NC(=O)OC1(CCCCC1)C#C,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
775,NCT03662516,DB01196,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
776,NCT03662516,DB13954,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]12C)OC(=O)CCC1CCCC1,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
777,NCT03662516,DB13956,[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
778,NCT03662516,DB14973,CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=C2C=CNC2=NC=N1,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
779,NCT03662516,DB07891,[H][C@@]12CC[C@H](OC(=O)CCC(O)=O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
780,NCT03662516,DB04575,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
781,NCT03662516,DB06713,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
782,NCT03662516,DB13323,ClC=C(Cl)Cl,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
783,NCT03662516,DB15690,[H][C@@]12C[C@@H]([18F])[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
784,NCT03662516,DB06597,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OS(N)(=O)=O)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
785,NCT03662516,DB07706,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(C=C(O)C(O)=C4)[C@@]3([H])CC[C@]12C,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
786,NCT03662516,DB00783,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
787,NCT03662516,DB00367,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
788,NCT03662516,DB13955,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(OC(=O)CCCCCC)=CC=C4[C@H]3CC[C@]12C,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
789,NCT03662516,DB00717,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
790,NCT03662516,DB13953,[H][C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(OC(=O)C5=CC=CC=C5)=CC=C4[C@@]3([H])CC[C@]12C,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
791,NCT03662516,DB13952,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
792,NCT03662516,DB02342,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3,A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects,Completed,No Results Available,Healthy Females,Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN),AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs,Pfizer,Female,18 Years to 55 Years   (Adult),Phase 1,17.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,B7451016,"September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT03662516
793,NCT03566238,DB16261,CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1,This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2,Completed,Has Results,PFIC1|PFIC2,Drug: A4250 (odevixibat)|Drug: Placebo,Proportion of Positive Pruritus Assessments at the Participant Level Over the 24-week Treatment Period Based on the Albireo Observer-reported Outcome (ObsRO) Instrument (United States Primary Endpoint)|Percentage of Participants Experiencing at Least a 70% Reduction in Fasting s-BA Concentration From Baseline to the End of Treatment or Reaching a Level <= 70 μmol/L After 24 Weeks of Treatment (European Union and Rest of the World Primary Endpoint),Albireo,All,"6 Months to 18 Years   (Child, Adult)",Phase 3,62.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A4250-005,"May 16, 2018","July 27, 2020","July 28, 2020","June 25, 2018","September 5, 2021","September 5, 2021","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's Hospital Colorado, Denver, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center - Presbyterian Hospital Building, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine - Texas Children's Liver Center, Houston, Texas, United States|The Royal Children's Hospital, Melbourne, Australia|UZ Leuven, Leuven, Belgium|Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium|The Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|University and Pediatric Hospital of Lyon, Bron, France|Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre, le Kremlin Bicetre, France|Hospital de la Timone, Marseille, France|Hospital Necker-Enfants maladies, Paris, France|Uniklinikum Essen- Kinderklinik II, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Kinderklinik Tübingen, Universitätsklinikum Tübingen, Tubingen, Germany|Rambam Medical Centre, Haifa, Israel|Shaare-Zedek Mc, Jerusalem, Israel|Schneider Children's Medical Center Of Israel, Petach-Tikva, Israel|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|University Hospital Of Padova, Padova, Italy|Ospedale Regina Margherita, Torino, Italy|University Medical Center Groningen, Groningen, Netherlands|Universitair Medisch Centrum (UMC) Utrecht, Utrecht, Netherlands|Instytut Pomnik - Centrum Zdrowia Dziecka, Warsaw, Poland|King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, Sweden|Gazi University, Ankara, Turkey|Hacettepe University Faculty of Medicine, Ankara, Turkey|Akdeniz University, Antalya, Turkey|Istanbul University Medical Faculty, Istanbul, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Institute of Liver Studies - Kings College Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03566238/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03566238/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03566238
794,NCT02932566,DB04951,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction,Completed,No Results Available,Cardiac Failure,Drug: Pirfenidone|Drug: Placebo,Extracellular volume fraction (ECV)|Left ventricular (LV) mass|Left ventricular volume|Left ventricular ejection fraction|Left ventricular strain - CMR|Left ventricular strain - Echo|Left ventricular torsion|Myocardial cell structure|Diastolic function|Left atrial volume|Myocardial energetic status|Cardiac biomarkers - N-Terminal-Pro-Brain Natriuretic Peptide (NT-Pro BNP)|Cardiac biomarkers - high-sensitivity Troponin T (hsTnT)|Patient exercise capacity|Patient morbidity|All cause mortality|Cardiovascular mortality|Hospitalisation for heart failure,"Manchester University NHS Foundation Trust|National Institute for Health Research, United Kingdom|University of Manchester|University of Liverpool, Clinical Trials Research Centre|Hoffmann-La Roche",All,"40 Years and older   (Adult, Older Adult)",Phase 2,129.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016CD004,"March 2, 2017","November 29, 2019","April 29, 2020","October 13, 2016",,"July 2, 2020","Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02932566
795,NCT04044664,DB12216,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
796,NCT04044664,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
797,NCT04044664,DB14514,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
798,NCT04044664,DB08924,CC(CC1=CC=CC=C1)\N=C\C(Cl)(Cl)Cl,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
799,NCT04044664,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
800,NCT04044664,DB02650,[H]C(=O)C(Cl)(Cl)Cl,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
801,NCT04044664,DB01494,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
802,NCT04044664,DB12120,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
803,NCT04044664,DB01563,OC(O)C(Cl)(Cl)Cl,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
804,NCT04044664,DB00553,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
805,NCT04044664,DB13402,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
806,NCT04044664,DB01534,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder,Completed,No Results Available,Post-Traumatic Stress Disorder,Drug: Placebo oral capsule|Drug: NYX-783,"CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)",Aptinyx|Premier Research Group plc|Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,160.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NYX-783-2004,"January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,https://ClinicalTrials.gov/show/NCT04044664
807,NCT03249103,DB12216,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
808,NCT03249103,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
809,NCT03249103,DB14514,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
810,NCT03249103,DB08924,CC(CC1=CC=CC=C1)\N=C\C(Cl)(Cl)Cl,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
811,NCT03249103,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
812,NCT03249103,DB02650,[H]C(=O)C(Cl)(Cl)Cl,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
813,NCT03249103,DB01494,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
814,NCT03249103,DB12120,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
815,NCT03249103,DB01563,OC(O)C(Cl)(Cl)Cl,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
816,NCT03249103,DB00553,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
817,NCT03249103,DB13402,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
818,NCT03249103,DB01534,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: NYX-2925|Drug: Placebo oral capsule,Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale,Aptinyx|inVentiv Health Clinical,Female,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NYX-2925-2002,"August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03249103
819,NCT02207504,DB08899,CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F,Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,Completed,No Results Available,Castration-resistant Prostate Cancer,Drug: Crizotinib|Drug: Enzalutamide,Rate of dose limiting toxicity (DLT)|Pharmacokinetics profiles of crizotinib and enzalutamide when used in combination|The number of patients who experience adverse events and laboratory abnormalities,Dana-Farber Cancer Institute|Astellas Pharma Inc|Pfizer,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-230,August 2014,"February 2, 2018","January 3, 2022","August 4, 2014",,"January 6, 2022","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02207504
820,NCT02207504,DB08865,C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl,Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,Completed,No Results Available,Castration-resistant Prostate Cancer,Drug: Crizotinib|Drug: Enzalutamide,Rate of dose limiting toxicity (DLT)|Pharmacokinetics profiles of crizotinib and enzalutamide when used in combination|The number of patients who experience adverse events and laboratory abnormalities,Dana-Farber Cancer Institute|Astellas Pharma Inc|Pfizer,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-230,August 2014,"February 2, 2018","January 3, 2022","August 4, 2014",,"January 6, 2022","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02207504
821,NCT02644525,DB11552,CCOC(=O)C1=CC(N)=CC=C1,Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa,Completed,No Results Available,Loaisis,Drug: Imatinib Mesylate|Drug: Placebo,To determine the short-term microfilaricidal kinetics of imatinib against Loa loa.|To assess the safety of a single dose of imatinib in Loa loa infection,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,115.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",999916042|16-I-N042,"September 16, 2019","December 31, 2020","March 19, 2021","January 1, 2016",,"June 10, 2021","Centre de Recherche sur les Filarioses et Autres Maladies Tropicales, Mbalmayo, Cameroon",,https://ClinicalTrials.gov/show/NCT02644525
822,NCT02644525,DB00619,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa,Completed,No Results Available,Loaisis,Drug: Imatinib Mesylate|Drug: Placebo,To determine the short-term microfilaricidal kinetics of imatinib against Loa loa.|To assess the safety of a single dose of imatinib in Loa loa infection,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,115.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",999916042|16-I-N042,"September 16, 2019","December 31, 2020","March 19, 2021","January 1, 2016",,"June 10, 2021","Centre de Recherche sur les Filarioses et Autres Maladies Tropicales, Mbalmayo, Cameroon",,https://ClinicalTrials.gov/show/NCT02644525
823,NCT02644525,DB05478,CS(O)(=O)=O.NC1=C2N=CN(CCOC[P@@]3(=O)OCC[C@H](O3)C3=CC(Cl)=CC=C3)C2=NC=N1,Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa,Completed,No Results Available,Loaisis,Drug: Imatinib Mesylate|Drug: Placebo,To determine the short-term microfilaricidal kinetics of imatinib against Loa loa.|To assess the safety of a single dose of imatinib in Loa loa infection,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,115.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",999916042|16-I-N042,"September 16, 2019","December 31, 2020","March 19, 2021","January 1, 2016",,"June 10, 2021","Centre de Recherche sur les Filarioses et Autres Maladies Tropicales, Mbalmayo, Cameroon",,https://ClinicalTrials.gov/show/NCT02644525
824,NCT03575598,DB15036,COCCNCC1=CC=C(N=C1)C1=CC2=C(S1)C(OC1=C(F)C=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2,Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study,Completed,No Results Available,"Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Squamous Cell Carcinoma of the Oral Cavity",Drug: Sitravatinib|Biological: Nivolumab,Pharmacodynamic effects with biomarker analyses|Immune effects with biomarker analyses|Toxicities as per NCI CTCAE v5.0|Rate of completion of surgery within the initially planned window|Rate of post-operative complications|Rate of disease progression as per RECIST v1.1 during the pre-operative treatment period|Pathologic treatment effect in tumor and/ or lymph nodes|Rate of nodal extracapsular extension and positive margins|Analysis of plasma Sitravatinib concentration before and after Nivolumab therapy,"University Health Network, Toronto|Mirati Therapeutics Inc.",All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNOW-001,"August 30, 2018","February 18, 2020","February 18, 2020","July 2, 2018",,"April 1, 2021","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03575598
825,NCT01039948,DB00317,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small Cell-Lung|Lung Neoplasms|Lung Cancer|Respiratory Tract Neoplasms",Biological: AV-299 + gefitinib|Drug: Gefitinib,"Phase Ib: Dose Limiting Toxicity and Recommended Phase II Dose|Phase 2: Objective Response Rate|Phase 1b: Cmax, Tmax, AUC, t1/2, clearance, and Vd|Phase 2: Progression Free Survival, Overall Survival, Safety","AVEO Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,203.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P06162,December 2009,August 2013,August 2013,"December 25, 2009",,"April 8, 2015","Investigational Site 1, Shatin N.T., Hong Kong|Investigational Site 2, Chungcheongbuk-do, Korea, Republic of|Investigational Site 3, Gyeonggi-do, Korea, Republic of|Investigational Site 4, Jeollanam-do, Korea, Republic of|Investigational Site 5, Seoul, Korea, Republic of|Investigational Site 6, Seoul, Korea, Republic of|Investigational Site 7, Seoul, Korea, Republic of|Investigational Site 8, Seoul, Korea, Republic of|Investigational Site 10, Kuala Lumpur, Malaysia|Investigational Site 9, Kuala Lumpur, Malaysia|Investigational Site 11, Pahang, Malaysia|Investigational Site 12, Manila, Philippines|Investigational Site 13, Pasig City, Philippines|Investigational Site 14, Quezon City, Philippines|Investigational Site 15, Singapore, Singapore|Investigational Site 16, Changhua, Taiwan|Investigational Site 17, Chiayi, Taiwan|Investigational Site 18, Taichung, Taiwan|Investigational Site 19, Tainan, Taiwan|Investigational Site 20, Taipei, Taiwan|Investigational Site 21, Taipei, Taiwan|Investigational Site 22, Taoyuan, Taiwan|Investigational Site 23, Bangkok, Thailand|Investigational Site 24, Chiang Mai, Thailand|Investigational Site 25, KhonKaen, Thailand|Investigational Site 26, Songkla, Thailand",,https://ClinicalTrials.gov/show/NCT01039948
826,NCT03291314,DB06626,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1,Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma,Completed,No Results Available,Recurrent Glioblastoma (WHO-Grade IV Glioma),Drug: Axitinib|Drug: Avelumab,6-month PFS%|Median OS (Overall survival)|Objective Tumor Response (OR)|Overall Safety profile|Evolution of neuro-cognitive function|Continuous activity,Universitair Ziekenhuis Brussel,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017-BN-001,"May 3, 2017","January 1, 2019","January 1, 2019","September 25, 2017",,"January 23, 2019","UZ Brussel, Brussel, Belgium",,https://ClinicalTrials.gov/show/NCT03291314
827,NCT01621204,DB06210,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients,Completed,No Results Available,Immune Thrombocytopenic Purpura,Drug: Eltrombopag|Drug: IVIG infusion,Achievement of a platelet count level that is above the platelet count threshold for surgery preoperatively and that is maintained above the threshold during the post-hemostasis period without the use of rescue treatment|Time to treatment failure|Surgical delays or cancellations|Bleeding|Thrombocytosis|Blood product transfusions|Rescue treatment|Platelet count change over time|Patient satisfaction with treatment|Hospitalizations|Thrombosis|Adverse Events,McMaster University|GlaxoSmithKline|Hamilton Health Sciences Corporation|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,74.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,M-EIBS-A-12,October 2012,June 2019,August 2019,"June 18, 2012",,"September 9, 2020","University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Center, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St.Micheal's Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|The Haga Hospital, The Hague, Netherlands",,https://ClinicalTrials.gov/show/NCT01621204
828,NCT00158782,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: GW786034|Drug: lapatinib,"Changes in pre and post treatment lab values and monitoring/reporting AES.AE's throughout study|Labs every wk first cycle:day 1 subsequent cycles|find max conc of drugs in blood and time it occurs find out if drugs are taken up by the body, how much/for how long find out if drugs affect the size of the tumor. Blood taken day 15, 22 or 37 and tumor assessed every 8 wks",GlaxoSmithKline,All,"21 Years and older   (Adult, Older Adult)",Phase 1,75.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VEG10006,"September 28, 2004","August 21, 2007","August 21, 2007","September 12, 2005",,"November 17, 2017","GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00158782
829,NCT00370383,DB04996,N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1,A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC),Completed,No Results Available,Lung Cancer,Drug: Erlotinib|Drug: Satraplatin,"To compare Progression-Free Survival (PFS) in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To assess Overall Survival in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To compare response rates.|To compare the toxicity profiles between patients treated with satraplatin and erlotinib and single-agent erlotinib",Agennix,All,70 Years and older   (Older Adult),Phase 2,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAT2-05-07,July 2006,February 2009,March 2009,"August 31, 2006",,"August 7, 2012","Pacific Cancer Medical Center, Anaheim, California, United States|Scripps Clinic, La Jolla, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Highlands Oncology Group, Bentonville, Ohio, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Signal Point Hematology/Oncology, Middleton, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|McGill University, Montreal, Canada|Princess Margaret Hospital, Toronto, Canada|Hospital San Borja Arriaran, Santiago, Chile|Instituto Nacional del Cancer, Santiago, Chile|Research Center, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT00370383
830,NCT00370383,DB00530,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC),Completed,No Results Available,Lung Cancer,Drug: Erlotinib|Drug: Satraplatin,"To compare Progression-Free Survival (PFS) in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To assess Overall Survival in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To compare response rates.|To compare the toxicity profiles between patients treated with satraplatin and erlotinib and single-agent erlotinib",Agennix,All,70 Years and older   (Older Adult),Phase 2,100.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAT2-05-07,July 2006,February 2009,March 2009,"August 31, 2006",,"August 7, 2012","Pacific Cancer Medical Center, Anaheim, California, United States|Scripps Clinic, La Jolla, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Highlands Oncology Group, Bentonville, Ohio, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Signal Point Hematology/Oncology, Middleton, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|McGill University, Montreal, Canada|Princess Margaret Hospital, Toronto, Canada|Hospital San Borja Arriaran, Santiago, Chile|Instituto Nacional del Cancer, Santiago, Chile|Research Center, Santiago, Chile",,https://ClinicalTrials.gov/show/NCT00370383
831,NCT04187456,DB12048,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body,Completed,No Results Available,Solid Tumors,Drug: Savolitinib|Drug: Midazolam,"Midazolam: Area under the plasma concentration-time curve from time zero to infinity (AUC) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Maximum observed plasma concentration (Cmax) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Cmax|Midazolam: [AUC(0-t)]|Midazolam: Time to reach maximum observed plasma concentration (tmax)|Midazolam: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration time curve (t½,λz)|Midazolam: Terminal elimination rate constant (λz)|Midazolam and savolitinib: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)|Midazolam and savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Number of subjects with adverse events|Number of subjects with abnormal systolic blood pressure (BP)|Number of subjects with abnormal diastolic blood pressure (BP)|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in White blood cell (WBC) count|Number of subjects with abnormal findings in Red blood cell (RBC) count|Number of subjects with abnormal findings in Hemoglobin (Hb)|Number of subjects with abnormal findings in Hematocrit (HCT)|Number of subjects with abnormal findings in Mean corpuscular volume (MCV)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in Neutrophils absolute count|Number of subjects with abnormal findings in Monocytes absolute count|Number of subjects with abnormal findings in Eosinophils absolute count|Number of subjects with abnormal findings in Basophils absolute count|Number of subjects with abnormal findings in Platelets|Number of subjects with abnormal findings in Reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in pottasium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in T4|Number of subjects with abnormal findings in Thyroid-Stimulating Hormone (TSH)|Number of subjects with abnormal findings in Alkaline phosphatase (ALP)|Number of subjects with abnormal findings in Alanine aminotransferase (ALT)|Number of subjects with abnormal findings in Aspartate aminotransferase (AST)|Number of subjects with abnormal findings in Gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in pulse oximetry",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5084C00004,"December 27, 2019","March 6, 2020","March 6, 2020","December 5, 2019",,"August 19, 2021","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04187456
832,NCT04187456,DB00683,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body,Completed,No Results Available,Solid Tumors,Drug: Savolitinib|Drug: Midazolam,"Midazolam: Area under the plasma concentration-time curve from time zero to infinity (AUC) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Maximum observed plasma concentration (Cmax) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Cmax|Midazolam: [AUC(0-t)]|Midazolam: Time to reach maximum observed plasma concentration (tmax)|Midazolam: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration time curve (t½,λz)|Midazolam: Terminal elimination rate constant (λz)|Midazolam and savolitinib: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)|Midazolam and savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Number of subjects with adverse events|Number of subjects with abnormal systolic blood pressure (BP)|Number of subjects with abnormal diastolic blood pressure (BP)|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in White blood cell (WBC) count|Number of subjects with abnormal findings in Red blood cell (RBC) count|Number of subjects with abnormal findings in Hemoglobin (Hb)|Number of subjects with abnormal findings in Hematocrit (HCT)|Number of subjects with abnormal findings in Mean corpuscular volume (MCV)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in Neutrophils absolute count|Number of subjects with abnormal findings in Monocytes absolute count|Number of subjects with abnormal findings in Eosinophils absolute count|Number of subjects with abnormal findings in Basophils absolute count|Number of subjects with abnormal findings in Platelets|Number of subjects with abnormal findings in Reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in pottasium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in T4|Number of subjects with abnormal findings in Thyroid-Stimulating Hormone (TSH)|Number of subjects with abnormal findings in Alkaline phosphatase (ALP)|Number of subjects with abnormal findings in Alanine aminotransferase (ALT)|Number of subjects with abnormal findings in Aspartate aminotransferase (AST)|Number of subjects with abnormal findings in Gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in pulse oximetry",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,14.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5084C00004,"December 27, 2019","March 6, 2020","March 6, 2020","December 5, 2019",,"August 19, 2021","Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT04187456
833,NCT04121910,DB12048,C[C@H](N1N=NC2=NC=C(N=C12)C1=CN(C)N=C1)C1=CN2C=CN=C2C=C1,A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole,Completed,No Results Available,Solid Tumour,Drug: Savolitinib|Drug: Itraconazole,"Savolitinib area under plasma concentration-time curve from time zero to infinity (AUC) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib maximum observed plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib:Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: Cmax|Savolitinib, M2 and M3: AUC|Savolitinib, M2 and M3: AUC(0-t)|Savolitinib, M2 and M3: tmax|Savolitinib, M2 and M3: t½,λz|Savolitinib, M2 and M3: λz|Savolitinib: CL/F|Savolitinib: Vz/F|Metabolite-to-parent ratios (MRCmax)|Metabolite-to-parent ratios (MRAUC)|Metabolite-to-parent ratios [MRAUC(0-t)]|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiogram (ECG)|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine clearence|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in alkaline phosphatase (ALP)|Number of subjects with abnormal findings in alanine aminotransferase (ALT)|Number of subjects with abnormal findings in aspartate aminotransferase (AST)|Number of subjects with abnormal findings in gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin (TBL)|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D5084C00002,"November 7, 2019","January 12, 2020","January 12, 2020","October 10, 2019",,"January 23, 2020","Research Site, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT04121910
834,NCT04121910,DB01167,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole,Completed,No Results Available,Solid Tumour,Drug: Savolitinib|Drug: Itraconazole,"Savolitinib area under plasma concentration-time curve from time zero to infinity (AUC) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib maximum observed plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib:Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: Cmax|Savolitinib, M2 and M3: AUC|Savolitinib, M2 and M3: AUC(0-t)|Savolitinib, M2 and M3: tmax|Savolitinib, M2 and M3: t½,λz|Savolitinib, M2 and M3: λz|Savolitinib: CL/F|Savolitinib: Vz/F|Metabolite-to-parent ratios (MRCmax)|Metabolite-to-parent ratios (MRAUC)|Metabolite-to-parent ratios [MRAUC(0-t)]|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiogram (ECG)|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine clearence|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in alkaline phosphatase (ALP)|Number of subjects with abnormal findings in alanine aminotransferase (ALT)|Number of subjects with abnormal findings in aspartate aminotransferase (AST)|Number of subjects with abnormal findings in gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin (TBL)|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis",AstraZeneca|Parexel,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,16.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D5084C00002,"November 7, 2019","January 12, 2020","January 12, 2020","October 10, 2019",,"January 23, 2020","Research Site, Glendale, California, United States",,https://ClinicalTrials.gov/show/NCT04121910
835,NCT04247815,DB12216,COC1=C2C=CC(=O)OC2=CC2=C1C=CO2,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
836,NCT04247815,DB01495,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
837,NCT04247815,DB14514,[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
838,NCT04247815,DB08924,CC(CC1=CC=CC=C1)\N=C\C(Cl)(Cl)Cl,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
839,NCT04247815,DB04571,CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
840,NCT04247815,DB02650,[H]C(=O)C(Cl)(Cl)Cl,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
841,NCT04247815,DB01494,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
842,NCT04247815,DB12120,COC1=CC(=C(C=C1C=C)C(=O)NC1=CC=C(C=C1)C(N)=N)C1=CC=C(N=C1C(O)=O)C(=O)NCC1CC1,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
843,NCT04247815,DB01563,OC(O)C(Cl)(Cl)Cl,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
844,NCT04247815,DB00553,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
845,NCT04247815,DB16620,CN(CC1=CN=C2N=C(N)NC(=O)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
846,NCT04247815,DB13402,OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
847,NCT04247815,DB00563,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
848,NCT04247815,DB01534,CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl,Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA,Completed,No Results Available,Rheumatoid Arthritis,Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate,The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70,"Aclaris Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ATI-450-RA-201,"March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,https://ClinicalTrials.gov/show/NCT04247815
849,NCT00553358,DB12619,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
850,NCT00553358,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
851,NCT00553358,DB12633,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
852,NCT00553358,DB05297,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
853,NCT00553358,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
854,NCT00553358,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel,Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream,Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,455.0,Industry|Other,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,EGF106903|2006-000564-81|CLAP016B2302,"January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00553358
855,NCT02260661,DB00947,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",Completed,No Results Available,"Advanced Solid Malignancies|Breast Cancer - ER+, HER2 -|Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation",Drug: AZD8835|Drug: AZD8835 in combination with fulvestrant,Determine the maximum tolerated dose (MTD) or recommended Phase II dose of oral AZD8835 as a single agent and in combination with fulvestrant|Establish the preliminary safety and tolerability profile of oral AZD8835 as a single agent and in combination with fulvestrant|To establish the pharmacokinetic profile of oral AZD8835 as a single agent and in combination with fulvestrant|To evaluate the preliminary efficacy and anti-tumor activity of oral AZD8835 as a single agent or in combination with fulvestrant|To evaluate the pharmacodynamic (PDc) effect of oral AZD8835 as a single agent and in combination with fulvestrant,AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,20.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6140C00001,November 2014,July 2016,July 2016,"October 9, 2014",,"October 10, 2016","Research Site, Denver, Colorado, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Cambridge, United Kingdom|Sarah Cannon Research Institute, United Kingdom, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02260661
857,NCT02512562,DB06290,[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C1C=CC(OC)=C2C)C1=NC(=CS1)C(C)C)C(=O)NS(=O)(=O)C1CC1,A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers,Completed,No Results Available,Chronic Hepatitis C,Drug: AL-335|Drug: ACH-3102|Drug: Simeprevir,"Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites|Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and ACH-3102 on Simeprevir|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and Simeprevir on ACH-3102",Alios Biopharma Inc.|Alexion Pharmaceuticals,All,18 Years to 60 Years   (Adult),Phase 1,32.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AL-335-602,"July 31, 2015","August 31, 2015","August 31, 2015","July 31, 2015",,"October 16, 2019","Biotrial, Rennes, France",,https://ClinicalTrials.gov/show/NCT02512562
858,NCT02341456,DB12619,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,Completed,Has Results,Advanced Solid Tumours,Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin,Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.,AstraZeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6011C00003,"January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02341456
859,NCT02341456,DB12633,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,Completed,Has Results,Advanced Solid Tumours,Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin,Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.,AstraZeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6011C00003,"January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02341456
860,NCT02341456,DB05297,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,Completed,Has Results,Advanced Solid Tumours,Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin,Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.,AstraZeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6011C00003,"January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02341456
861,NCT02341456,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,Completed,Has Results,Advanced Solid Tumours,Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin,Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.,AstraZeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6011C00003,"January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02341456
863,NCT02341456,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,Completed,Has Results,Advanced Solid Tumours,Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin,Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.,AstraZeneca,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D6011C00003,"January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02341456
864,NCT03803475,DB16019,[68Ga+3].OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC(CN(CCN(CC([O-])=O)CC2=C(O)C=CC(CCC([O-])=O)=C2)CC([O-])=O)=C(O)C=C1)C(O)=O)C(O)=O,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI),Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group|Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group,"Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,485.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,185513|NCI-2019-01394,"October 11, 2018","August 25, 2020","August 25, 2020","January 14, 2019","August 24, 2021","August 24, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03803475/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03803475
865,NCT03803475,DB09498,[Cl-].[Cl-].[89Sr++],Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI),Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group|Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group,"Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,485.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,185513|NCI-2019-01394,"October 11, 2018","August 25, 2020","August 25, 2020","January 14, 2019","August 24, 2021","August 24, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03803475/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03803475
866,NCT03803475,DB13925,[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI),Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group|Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group,"Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,485.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,185513|NCI-2019-01394,"October 11, 2018","August 25, 2020","August 25, 2020","January 14, 2019","August 24, 2021","August 24, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03803475/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03803475
867,NCT03803475,DB15494,[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1,Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients,Completed,Has Results,Prostate Cancer,Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI),Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group|Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group,"Thomas Hope|University of California, San Francisco",Male,"18 Years and older   (Adult, Older Adult)",Phase 3,485.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,185513|NCI-2019-01394,"October 11, 2018","August 25, 2020","August 25, 2020","January 14, 2019","August 24, 2021","August 24, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03803475/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03803475
868,NCT02015065,DB05294,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1,Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,Completed,Has Results,GIST,Drug: Vandetanib,Number of Participants With a Clinical Activity-radiographic Response|Count of Participants With Serious and Non-serious Adverse Events|Percentage of Participants Overall Survival|Progression Free-Survival|Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"3 Years to 99 Years   (Child, Adult, Older Adult)",Phase 2,9.0,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,130208|13-C-0208,"December 14, 2013","May 4, 2016","December 10, 2019","December 19, 2013","July 23, 2019","March 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/Prot_SAP_000.pdf|""Informed Consent Form: Standard consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_001.pdf|""Informed Consent Form: Parent QOL consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02015065
869,NCT01287598,DB08896,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
870,NCT01287598,DB00683,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
871,NCT01287598,DB08735,[H][C@@](C)(O)C[C@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
872,NCT01287598,DB08496,CC(=O)C[C@H](C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
873,NCT01287598,DB00338,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
874,NCT01287598,DB00412,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
875,NCT01287598,DB14055,CC(=O)C[C@@H](C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
876,NCT01287598,DB01418,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
877,NCT01287598,DB00736,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
878,NCT01287598,DB00682,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
879,NCT01287598,DB08736,[H][C@](C)(O)C[C@@]([H])(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O,BAY73-4506 Probe Substrate Study,Completed,No Results Available,Neoplasms,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12434,"August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01287598
880,NCT01553188,DB15639,COCCOC1=CC2=C(C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C3=CN(C)N=C3)C2=O)N=C1,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
881,NCT01553188,DB14646,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
882,NCT01553188,DB15970,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])C[C@H](Cl)C2=CC(=O)C=C[C@]12C,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
883,NCT01553188,DB12952,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
884,NCT01553188,DB06011,[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
885,NCT01553188,DB05490,ClC1=CC=C(C(Cl)=C1)S(=O)(=O)NC1=CC(Cl)=C(OC2=CN=C3C=CC=CC3=C2)C(Cl)=C1,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
886,NCT01553188,DB08079,COC1=CC2=NC=CC(OCC3=NN=C4C=CC(=NN34)C3=CC=CC=C3)=C2C=C1,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
887,NCT01553188,DB00635,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
888,NCT01553188,DB09383,[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
889,NCT01553188,DB14625,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
890,NCT01553188,DB05812,[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,AMG 386 and Abiraterone for Advanced Prostate Cancer,Completed,Has Results,"Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic",Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone,Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120079|12-C-0079,"February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01553188
891,NCT00996671,DB16106,CONC(=O)C1=CC=CC=C1NC1=CC(NC2=CC(C)=NN2C(C)C)=NC=C1Cl,"Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers",Completed,No Results Available,Cancer,Drug: GSK2256098|Drug: Placebo,"To characterize the safety of single doses of GSK2256098 in adult healthy subjects|To characterize the single dose pharmacokinetics of GSK2256098 in blood and urine in adult healthy subjects|To examine the dose proportionality of GSK2256098 pharmacokinetic parameters following single dose administration in healthy subjects|To explore dose- and concentration-effect relationships for various safety parameters, if appropriate|To estimate the effect of high fat/calorie meal on the pharmacokinetics, safety, and tolerability of a single dose of GSK2256098.|To explore and potentially identify small molecules or cytokines in plasma which may serve as biomarkers for future studies",GlaxoSmithKline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,38.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,113581,"November 6, 2009","March 17, 2010","March 17, 2010","October 16, 2009",,"June 14, 2017","GSK Investigational Site, Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT00996671
892,NCT03028103,DB00912,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,"March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103
893,NCT03028103,DB00338,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,"March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103
894,NCT03028103,DB12887,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,"March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103
895,NCT03028103,DB00736,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,"March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103
896,NCT03028103,DB00196,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",Completed,Has Results,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide,"Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,32.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZH-105,"March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028103
897,NCT00367471,DB12619,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)C(C)=C([C@@H](OC(C)=O)C1=O)C2(C)C,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
898,NCT00367471,DB01259,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
899,NCT00367471,DB12633,CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
900,NCT00367471,DB05297,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
901,NCT00367471,DB01229,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
903,NCT00367471,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",Completed,No Results Available,"Neoplasms, Breast",Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel,Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,31.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EGF103892|CLAP016A2102,"December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00367471
904,NCT05219656,DB00091,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Efficacy of Cyclosporine Rescue Therapy in Acute Ulcerative Colitis.,Completed,No Results Available,Ulcerative Colitis Acute,Drug: Cyclosporine A,Response|Remission|Adverse events|Surgical complications,Tampere University Hospital,All,"16 Years and older   (Child, Adult, Older Adult)",,182.0,Other,Observational,Observational Model: Other|Time Perspective: Other,R19617,"January 1, 2009","December 30, 2018","January 1, 2022","February 2, 2022",,"February 2, 2022",,,https://ClinicalTrials.gov/show/NCT05219656
905,NCT00550485,DB01175,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene,Completed,No Results Available,Pharmacokinetics,Drug: escitalopram,Time spent in rapid-eye-movement (REM) sleep assessed by polysomnography.|Sleep stages|Sleep continuity|ABCB1 gene expression|Metabolic changes,Max-Planck-Institute of Psychiatry,Male,20 Years to 30 Years   (Adult),Not Applicable,79.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,L3/2005,October 2007,"July 6, 2018","July 6, 2018","October 30, 2007",,"March 27, 2019","Max Planck Institute of Psychiatry, Munich, Germany",,https://ClinicalTrials.gov/show/NCT00550485
906,NCT00692159,DB00642,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,Study of TRC102 in Combination With Pemetrexed in Cancer Patients,Completed,No Results Available,Neoplasm,Drug: TRC102 + pemetrexed,"To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable.|Characterize pharmacokinetics, assess anti-tumor activity, and assess pharmacodynamics",Tracon Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,28.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,102ST101,June 2008,June 2010,September 2010,"June 6, 2008",,"September 10, 2010","Scottsdale, Arizona, United States|Santa Monica, California, United States|Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00692159
908,NCT01192165,DB01248,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",Completed,No Results Available,Cancer,Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin,"To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,169.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113486|2012-000257-32,"September 14, 2010","October 7, 2013","October 7, 2013","August 31, 2010",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Toulouse cedex, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01192165
909,NCT01192165,DB08911,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",Completed,No Results Available,Cancer,Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin,"To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,169.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113486|2012-000257-32,"September 14, 2010","October 7, 2013","October 7, 2013","August 31, 2010",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Toulouse cedex, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01192165
911,NCT01192165,DB00530,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",Completed,No Results Available,Cancer,Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin,"To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,169.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113486|2012-000257-32,"September 14, 2010","October 7, 2013","October 7, 2013","August 31, 2010",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Toulouse cedex, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01192165
912,NCT01192165,DB00642,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",Completed,No Results Available,Cancer,Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin,"To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,169.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,113486|2012-000257-32,"September 14, 2010","October 7, 2013","October 7, 2013","August 31, 2010",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Toulouse cedex, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01192165
913,NCT00902018,DB06210,CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1,Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP),Completed,Has Results,Immune Thrombocytopenia,Drug: Eltrombopag|Drug: Romiplostim|Other: healthy controls,"Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL|Number of Patients Who Received Romiplostim and Increased Their Platelet Counts to > 50,000/uL|How Many Patients Developed SAEs and/or Abnormal Liver Tests to a Level > 2 Times the Upper Limit of Normal",Weill Medical College of Cornell University|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0809009980,January 2009,"September 7, 2015","September 7, 2015","May 14, 2009","March 18, 2019","March 18, 2019","Weill Cornell Medical College, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00902018
914,NCT01453153,DB15057,C[C@H](NP(=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1,Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer,Completed,Has Results,Stage IV Pancreatic Cancer,Drug: Gemcitabine|Drug: PEGPH20|Drug: Placebo,"Number of Participants With a Dose-limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Observed Maximum Plasma Concentration (Cmax) Following Single PEGPH20 Doses|Cmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Last Measurable Observed Plasma Concentration (Cmin) Following Single PEGPH20 Doses|Cmin Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Time to Reach Cmax (Tmax) Following Single PEGPH20 Doses|Tmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Apparent Half-life (t1/2) Following Single PEGPH20 Doses|t1/2 Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Measurable Plasma Concentration (AUC0-T) Following Single PEGPH20 Doses|AUC0-T Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Plasma Hyaluronan (HA) Concentration at Baseline and After PEGPH20 Administration|H-scores, as an Assessment of HA Staining Changes in Tumor Biopsies|Percent Change in in the Maximum Standardized Uptake Value (SUVmax), as an Assessment of Total Lesion Metabolic Activity|Mean Volume Transfer Constant (Ktrans) for Scans Across Tissue Sites|Mean Extravascular-Extracellular Volume Fraction (Ve) for Scans Across Tissue Sites|Number of Participants With the Indicated Best Response, Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1|Objective Response Rate|Disease Control Rate|Progression-free Survival (PFS)|Overall Survival|Change From Baseline in Carbohydrate Antigen 19-9 or Sialylated Lewis(a) Antigen (CA19-9)|Change From Baseline in CA19-9 in Participants With a Baseline Value >=59 U/ml|Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders",Halozyme Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Halo-109-201,September 2011,February 2014,May 2015,"October 17, 2011","November 30, 2018","November 30, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|UMDNJ - New Jersey Medical School, Newark, New Jersey, United States|NSLIJ Health System, Monter Cancer Center, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Medical Radiological Research Center, Obninsk, Russian Federation|Omsk Regional Budget Medical Institution, Omsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT01453153
915,NCT01453153,DB00441,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer,Completed,Has Results,Stage IV Pancreatic Cancer,Drug: Gemcitabine|Drug: PEGPH20|Drug: Placebo,"Number of Participants With a Dose-limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Observed Maximum Plasma Concentration (Cmax) Following Single PEGPH20 Doses|Cmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Last Measurable Observed Plasma Concentration (Cmin) Following Single PEGPH20 Doses|Cmin Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Time to Reach Cmax (Tmax) Following Single PEGPH20 Doses|Tmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Apparent Half-life (t1/2) Following Single PEGPH20 Doses|t1/2 Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Measurable Plasma Concentration (AUC0-T) Following Single PEGPH20 Doses|AUC0-T Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Plasma Hyaluronan (HA) Concentration at Baseline and After PEGPH20 Administration|H-scores, as an Assessment of HA Staining Changes in Tumor Biopsies|Percent Change in in the Maximum Standardized Uptake Value (SUVmax), as an Assessment of Total Lesion Metabolic Activity|Mean Volume Transfer Constant (Ktrans) for Scans Across Tissue Sites|Mean Extravascular-Extracellular Volume Fraction (Ve) for Scans Across Tissue Sites|Number of Participants With the Indicated Best Response, Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1|Objective Response Rate|Disease Control Rate|Progression-free Survival (PFS)|Overall Survival|Change From Baseline in Carbohydrate Antigen 19-9 or Sialylated Lewis(a) Antigen (CA19-9)|Change From Baseline in CA19-9 in Participants With a Baseline Value >=59 U/ml|Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders",Halozyme Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Halo-109-201,September 2011,February 2014,May 2015,"October 17, 2011","November 30, 2018","November 30, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|UMDNJ - New Jersey Medical School, Newark, New Jersey, United States|NSLIJ Health System, Monter Cancer Center, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Medical Radiological Research Center, Obninsk, Russian Federation|Omsk Regional Budget Medical Institution, Omsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT01453153
916,NCT01453153,DB12564,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O,Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer,Completed,Has Results,Stage IV Pancreatic Cancer,Drug: Gemcitabine|Drug: PEGPH20|Drug: Placebo,"Number of Participants With a Dose-limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Observed Maximum Plasma Concentration (Cmax) Following Single PEGPH20 Doses|Cmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Last Measurable Observed Plasma Concentration (Cmin) Following Single PEGPH20 Doses|Cmin Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Time to Reach Cmax (Tmax) Following Single PEGPH20 Doses|Tmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Apparent Half-life (t1/2) Following Single PEGPH20 Doses|t1/2 Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Measurable Plasma Concentration (AUC0-T) Following Single PEGPH20 Doses|AUC0-T Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Plasma Hyaluronan (HA) Concentration at Baseline and After PEGPH20 Administration|H-scores, as an Assessment of HA Staining Changes in Tumor Biopsies|Percent Change in in the Maximum Standardized Uptake Value (SUVmax), as an Assessment of Total Lesion Metabolic Activity|Mean Volume Transfer Constant (Ktrans) for Scans Across Tissue Sites|Mean Extravascular-Extracellular Volume Fraction (Ve) for Scans Across Tissue Sites|Number of Participants With the Indicated Best Response, Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1|Objective Response Rate|Disease Control Rate|Progression-free Survival (PFS)|Overall Survival|Change From Baseline in Carbohydrate Antigen 19-9 or Sialylated Lewis(a) Antigen (CA19-9)|Change From Baseline in CA19-9 in Participants With a Baseline Value >=59 U/ml|Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders",Halozyme Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Halo-109-201,September 2011,February 2014,May 2015,"October 17, 2011","November 30, 2018","November 30, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|UMDNJ - New Jersey Medical School, Newark, New Jersey, United States|NSLIJ Health System, Monter Cancer Center, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Medical Radiological Research Center, Obninsk, Russian Federation|Omsk Regional Budget Medical Institution, Omsk, Russian Federation",,https://ClinicalTrials.gov/show/NCT01453153
917,NCT01729728,DB06204,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,"Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain",Completed,Has Results,Postoperative Pain|Acute Pain,Drug: Tapentadol,"Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Older Children (Age 6 to Less Than 12 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Older Children (Age 6 to Less Than 12 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Younger Children (Age 3 to Less Than 6 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Younger Children (Age 3 to Less Than 6 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Very Young Children (Age 2 to Less Than 3 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Very Young Children (Age 2 to Less Than 3 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter of Tapentadol Area Under the Concentration-Time Curve (AUC 0-15) After a Single Dose of Tapentadol in Adolescent Participants (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Cmax (Maximum Concentration) of Tapentadol After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Time to Maximum Concentration (Tmax) of Tapentadol After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter of Tapentadol-O-glucuronide Area Under the Concentration-Time Curve (AUC 0-15) After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Cmax (Maximum Concentration) of Tapentadol-O-glucuronide After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Time to Maximum Concentration (Tmax) of Tapentadol-O-glucuronide After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18).|Pain Intensity Assessments Using the Visual Analog Scale (VAS) in Adolescents (Age 12 to Less Than 18 Years).|Pain Intensity Assessments Using the McGrath Color Analog Scale in Adolescent Participants and Older Children (Age 6 to Less Than 18 Years).|Pain Intensity Assessments Using the Faces Pain Scale (Revised) in Children Age 3 to Less Than 12 Years.|Pain Intensity Assessment Using the Face, Legs, Activity, Cry, Consolability Scale in Young and Very Young Children (Age 2 to Less Than 6 Years).|Sum of Pain Intensity Differences Over the 4 Hours After Dosing Derived From the Different Pain Scales and for All Age Groups|Respiratory Rate Assessments|Oxygen Saturation Assessments|Systolic and Diastolic Blood Pressure Assessments|Change From Enrollment in 12-lead Electrocardiogram Parameters|Change From Enrollment in 12-lead Electrocardiogram Heart Rate Parameter|Treatment Emergent Adverse Events by Intensity|Intake of Additional Analgesic Medication During the Trial|Hematology Safety Laboratory Assessments: Hemoglobin Concentration|Hematology Safety Laboratory Assessments: Hematocrit|Hematology Safety Laboratory Assessments: Erythrocyte Mean Corpuscular Volume (Mean Corpuscular Volume)|Hematology Safety Laboratory Assessments: Platelet Count|Hematology Safety Laboratory Assessments: Leukocyte Concentration|Biochemistry Safety Laboratory Parameters: Blood Glucose Concentration|Biochemistry Safety Laboratory Parameters: Blood Sodium Concentration|Biochemistry Safety Laboratory Parameters: Blood Potassium Concentration|Biochemistry Safety Laboratory Parameters: Blood Calcium Concentration|Biochemistry Safety Laboratory Parameters: Blood Chloride Concentration|Biochemistry Safety Laboratory Parameters: Blood Phosphate Concentration|Biochemistry Safety Laboratory Parameters: Blood Urea Nitrogen (BUN) Concentration|Biochemistry Safety Laboratory Parameters: Creatinine Concentration|Biochemistry Safety Laboratory Parameters: Aspartate Aminotransferase (AST) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Triglycerides Concentration|Biochemistry Safety Laboratory Parameters: Serum Albumin Concentration|Biochemistry Safety Laboratory Parameters: Urate in the Blood|Biochemistry Safety Laboratory Parameters: Calculated Glomerular Filtration Rate|Biochemistry Safety Laboratory Parameters: Urine Specific Gravity|Biochemistry Safety Laboratory Parameters: Urine pH (Acid, Alkalinity) Test|Biochemistry Safety Laboratory Parameters: Liver Function Test - Alanine Aminotransferase (ALT) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Liver Function Test - Gamma-Glutamyl Transferase (GGT) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Liver Function Test - Bilirubin Concentration|Biochemistry Safety Laboratory Parameters: Liver Function Test - Lactate Dehydrogenase (LDH) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Blood Protein Concentration|Biochemistry Safety Laboratory Parameters: Creatine Kinase (CK) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Alkaline Phosphatase (ALP) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Triacylglycerol Lipase (TL) Enzyme Activity","Grünenthal GmbH|Janssen Research & Development, LLC",All,2 Years to 17 Years   (Child),Phase 2,86.0,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KF5503/68|2013-002016-27,November 2012,February 2014,February 2014,"November 20, 2012","November 27, 2014","November 4, 2019","Jean Brown Research, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT01729728
918,NCT01638546,DB00853,CN1N=NC2=C(N=CN2C1=O)C(N)=O,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Temozolomide|Drug: Veliparib,"Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease|Overall Response (ORR) by RECIST 1.1 Criteria|Overall Survival|Number of Participants With Adverse Events",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,97.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-01130|IRB #12-021|12-021|CDR0000737062|9026|N01CM00039|P30CA008748|U01CA070095|UM1CA186691,June 2012,January 2017,January 2017,"July 11, 2012","March 27, 2018","November 19, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01638546
919,NCT01638546,DB07232,C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,Completed,Has Results,Recurrent Small Cell Lung Carcinoma,Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Temozolomide|Drug: Veliparib,"Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease|Overall Response (ORR) by RECIST 1.1 Criteria|Overall Survival|Number of Participants With Adverse Events",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,97.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NCI-2012-01130|IRB #12-021|12-021|CDR0000737062|9026|N01CM00039|P30CA008748|U01CA070095|UM1CA186691,June 2012,January 2017,January 2017,"July 11, 2012","March 27, 2018","November 19, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01638546
920,NCT00935792,DB01590,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC,Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Completed,Has Results,Lymphocytic Leukemia,Drug: alemtuzumab|Drug: everolimus,Clinical Response (Complete or Partial Remission)|Number of Participants With Dose-Limiting Toxicities|Test the Safety and Tolerability of the Combination of Everolimus and Alemtuzumab.|Survival Time|Progression-free Survival|Duration of Response|Time to Subsequent Therapy,Mayo Clinic,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,28.0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC088C|NCI-2009-00935|08-008775,July 2009,December 2015,December 2015,"July 9, 2009","December 12, 2016","September 26, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00935792
